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Cancer is one of the leading causes of death worldwide. Treatment is 
hampered by an incomplete understanding of the mechanisms 
underlying carcinogenesis and, consequently, by the absence of 
therapies to specifically eradicate cancer cells without harming 
normal, healthy cells. Intriguingly, the avian-virus derived protein 
apoptin was found to selectively induce apoptosis in transformed and 
tumor cells, heralding the advent of a new era in cancer treatment. 
 
The aim of this thesis was to discover the path followed by apoptin to 
distinguish between normal and cancer cells, and selectively kill the 
latter, in order to a) get to the root of the problem that is cancer, and 
b) provide the knowledge which is necessary to design novel, more 
selective, more effective, safe anti-tumor therapies. To this end, we 
identified a number of apoptin-interacting proteins, and studied their 
roles in tumor-selective apoptin-induced apoptosis.  
 
Chapter 2 summarizes current knowledge on normal regulation of 
cellular proliferation and the derailments thereof leading to malignant 
transformation, as well as novel strategies in cancer treatment. Since 
the discovery of apoptin, a number of other cellular and viral proteins 
have also been shown to induce tumor-selective cytotoxicity; in 
chapter 3, an overview is presented of apoptin, and these other 
proteins killing tumor cells (PKTC).  
 
Chapter 4 introduces a novel apoptin-interacting protein, FAM96B. 
Functional analysis implicates FAM96B in the regulation of the cell 
cycle, including the processes of sensing DNA damage and 
establishing sister chromatid cohesion. In chapter 5, apoptin’s 
activities in the tumor cell nucleus are investigated, and chromatin-
bound apoptin is found to associate with various nucleolar proteins 
that are involved in the regulation of ribosome biogenesis, the DNA 
damage response and cell cycle regulation. The data suggest that 
apoptin coordinates tumor-selective apoptosis at least partially from 
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within the nucleolus. Chapter 6 analyzes the roles of the apoptin-
interacting breast cancer associated protein BCA3 and that of the 
major tumor suppressor protein phosphatase 2A (PP2A) in the 
phosphorylation of apoptin.  
 
Finally, the data are compiled in chapter 7, where novel insights into 
the cancer blueprint, the path taken by apoptin to sense it and 
effectuate cancer cell death, as well as the relevance for the design of 















Cellular proliferation and oncogenic transformation: 
uncovering the fundamental principles for specific 





The Book of Genesis gives a detailed account of how God created our 
planet in 7 days - or, rather, 6 - through a set of specific, sequential 
actions. In his On the Origin of Species, Charles Darwin postulated 
that all species of life emerged from a limited number of common 
ancestors, evolving over time through natural selection (Darwin, 
1859). However large the contradiction, both books served an identical 
purpose: to explain the origin of life. So too in medicine, it was 
believed that illnesses were the result of supernatural or divine forces, 
until Hippocrates first argued that disease was the product of 
environmental factors, diet, and living habits (Jones, 1868). Although 
many of his assumptions turned out to be erroneous, the so-called 
‘father of medicine’ did launch the idea of pathogenesis, a concept 
fundamental to modern life science research. Combining the insights 
of Hippocrates and Darwin, and of many of their colleagues in-
between and since, intense scientific effort has been directed at 
understanding the pathogenesis of one of the world’s largest 
contemporary health problems: cancer (WHO, 2008). While the 
elaborate molecular mechanisms behind tumorigenesis are being 
elucidated more and more clearly, therapy is still lacking in safety and 
effectiveness. Here, I will review the current knowledge on 
carcinogenic cell transformation, as well as therapeutic approaches 
stemming from these findings. Next, I will describe exciting new 
prospects in both research and therapy, where, finally, I will highlight 




2.1 In the beginning, there was chaos – on the origin of cancer 
Cancer is the general term for a class of diseases, characterized by 
uncontrolled cellular proliferation. Research has indicated that cancer 
development (tumorigenesis) originates with the stepwise 
accumulation of genetic changes, driving the progressive 
transformation of normal cells into highly malignant progeny (Hahn 
and Weinberg, 2002).  These genetic changes include mutations, 
deletions and amplifications, producing oncogenes with dominant gain 
of function, and tumor suppressor genes with recessive loss of 
function. The vast majority of all known tumor suppressor genes are 
involved in DNA repair and genomic regulation (Lengauer, et al., 
1998), so that tumor cells almost invariably display a large degree of 
genomic instability, resulting in further accumulation of malignant 
genetic changes.  
 
Random mutations in the approximately six billion basepairs 
comprising the human genome could theoretically give rise to a huge 
number of different combinations of genetic alterations. However, 
research indicates that the process of carcinogenesis is not a random 
one, and it has been suggested that the more than 100 different types 
of human cancer share at least six crucial characteristics, the so-
called core ‘hallmarks’ of cancer (Hanahan and Weinberg, 2000, 2011; 
Stratton, et al., 2009): 
1. self-sufficiency in growth signals 
2. insensitivity to growth-inhibitory signals 
3. evasion of programmed cell death 
4. limitless replicative potential 
5. sustained angiogenesis 
6. tissue invasion and metastasis 
 
Researchers now also propose two additional alterations, namely a 
change in cellular metabolism (Weinberg and Chandel, 2009), and 
evasion of immune destruction (Hanahan and Weinberg, 2011). As will 
Chapter 2 
18 
be discussed in following sections, each of these acquired capabilities 
represents the breach of regulatory mechanisms tightly controlling the 
cell cycle and hence normal proliferation and homeostasis, upsetting 
the balance between cell survival and proliferation, and cell death. The 
genomic instability discussed above is regarded as an enabling 
characteristic, as is the tumor micro-environment, which can secrete 
growth and inflammatory factors to promote neoplastic progression 
(see below).  
 
2.2 Normal proliferation and homeostasis: the cell cycle 
At the basis of cellular proliferation and homeostasis lies the cell 
cycle. This set of strictly organized processes dictates if, when and 
under which conditions a cell reproduces itself, and provides safe-
guarding mechanisms to dispose of aberrant cells.  
 
The most fundamental function of the cell cycle is to accurately 
duplicate the cell’s chromosomal DNA and then segregate the copies 
precisely into two genetically identical daughter cells. These processes 
define the two major phases of the cell cycle (Figure 2.1) (Heichman 
and Roberts, 1994). DNA duplication occurs during S phase (S for 
synthesis), and chromosome segregation and cell division occur in M 
phase (M for mitosis). Before each of these phases, eukaryotic cells go 
through a so-called ‘gap’ phase – G1 between M and S phase, and G2 
between S and M phase. This is partly to allow time for growth, but 
also importantly to provide time for the cell to monitor the internal 
and external environment, ensuring that conditions are suitable and 
all preparations have been completed. The G1 phase is especially 
important in this respect. Its length can vary greatly depending on 
external conditions and extracellular signals from other cells. If 
extracellular conditions are unfavorable, for example, cells delay 
progress through G1 and may even enter a specialized resting state 
known as quiescence, or G0, in which they can remain for days, 
weeks, or even years before resuming proliferation (Pardee, 1989). In 
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fact, many cells remain permanently in G0 until they or the organism 
dies. Such cells have either differentiated into specialized states, or 
have become senescent, and do not have the ability to return to G1. 
Typically, cells in G2 that do not meet the requirements for completion 
of the cell cycle, e.g. because of extensive DNA damage, are killed. 




Figure 2.1. A. The eukaryotic cell cycle is traditionally divided into four sequential 
phases: G1, S, G2, and M. G1, S, and G2 together are called interphase. B. During 
interphase, the centrioles are also replicated, forming small daughter centrioles. 
Early prophase: the centrosomes, each with a daughter centriole, begin moving 
toward opposite poles of the cell. Chromosome condensation and nuclear membrane 
disintegration are initiated. Late prophase: chromosome condensation is completed; 
each visible chromosome structure is composed of two chromatids held together at 
their centromeres. The microtubular spindle fibers begin to radiate from the regions 
just adjacent to the centrosomes, which are moving closer to their poles. Some 
spindle fibers reach from pole to pole; most go to chromatids and attach at 
kinetochores. Metaphase: the chromosomes move toward the equator of the cell, 
where they become aligned in the equatorial plane. Anaphase:  the two sister 
chromatids separate into independent chromosomes and move to one spindle pole 
each. Simultaneously, the cell elongates, and cytokinesis begins as the cleavage 
furrow starts to form. Telophase: new nuclear membranes form around the 
daughter nuclei; the chromosomes uncoil and become decondensed; and the 
nucleolus becomes visible again. Cytokinesis is nearly complete, and the spindle 
disappears as the microtubules and other fibers depolymerize. Upon the completion 
of cytokinesis, each daughter cell enters the G1 phase of the cell cycle and is ready 





Table 2-1. Specific Cyclin-Cdk complexes act to promote each phase of the cell 
cycle. 
 
Cell cycle phase Cyclin Cdk 
G1 Cyclin D Cdk4/6 
G1/S Cyclin E Cdk2 
S Cyclin A Cdk2 
M Cyclin B Cdk1 
 
Below, the four phases of the cell cycle are discussed in further detail.  
 
2.2.1 G1 
During the G1 phase of the cell cycle, cells respond to extracellular 
signals by either advancing toward another division or withdrawing 
from the cycle into G0 (Sherr, 1996). G1 progression normally relies 
on stimulation by mitogens, e.g. Ras, and can be blocked by anti-
proliferative cytokines, e.g. TNFβ.  
 
Early in G1, D-type cyclins (see Box 1) assemble into holoenzyme 
complexes with one of two catalytic subunits, Cdk4 or Cdk6 (Sherr, 
1994). Transcription of the cyclin D1 gene and assembly with Cdk4 
depend strongly on receptor-mediated Ras and PI3-K signaling (Figure 
Box 1. Cyclins and CDKs control the cell cycle 
At the heart of the cell-cycle control system is a family of protein 
kinases known as cyclin-dependent kinases (Cdks), which are 
sequentially activated to trigger the various steps of the cell cycle 
(Norbury and Nurse, 1991, 1992). Cdks are activated by the 
binding of cyclins – as indicated by their name – as well as by 
phosphorylation and dephosphorylation of the kinase. They are 
inactivated by various Cdk inhibitory proteins (CKIs), such as 
p16Ink4a, p27Kip1, and p21Cip1, and by degradation of the cyclin 
subunits at specific stages of the cell cycle (Elledge and Harper, 
1994). Each cyclin is specific for a given phase of the cell cycle, and 
the levels of the various cyclins rise and fall as the cell progresses 
through the cycle. This results directly in cyclical changes in the 
phosphorylation and (in)activation of intracellular proteins that 
initiate or regulate the major events of the cell cycle: DNA 
replication, mitosis, and cytokinesis. The major cell-cycle 




2.2A) (Marshall, 1999). Persistent mitogenic stimulation leads to 
progressive accumulation of cyclin D-dependent kinases within the 
cell nucleus; here they collaborate with cyclin E-Cdk2 to 
phosphorylate pRb and pRb family members p107 and p130, 
canceling their growth inhibitory functions by disrupting the 
interaction with E2F, resulting in activation of G1/S and S-phase 
cyclins, thereby activating the DNA replication machinery and 
facilitating S phase entry (Reed, 1992).  
Figure 2.2. Molecular pathways comprising the four phases of the cell cycle. A. In 
G1, growth stimulatory such as Ras, and growth inhibitory signals such as TGFβ, 
converge on the cyclinD1/Cdk4 complex. A net balance of positive signals lead to 
activation of cyclinD1/Cdk4, which cooperates with cyclinE/Cdk2 to phosphorylate 
pRb, thus liberating E2F and initiating DNA replication. ORC, origin recognition 
complex. B. Following DNA replication, CyclinB1/Cdk1 is activated through the 
actions of Polo like kinase. This activity is however subject to two G2/M control 
checkpoints, namely the DNA structure checkpoint, which ensures the absence of 
unreplicated or damaged DNA, and the spindle assembly checkpoint, which 
ensures the attachment of all sister chromatids to microtubules connecting them to 
opposite poles of the spindle. Successful clearance of these checkpoints results in 
activation of the APC, which results in sister chromatid separation and completion 
of cell division. See text for further details. 
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The phosphorylation and thus inactivation of pRb constitutes a so-
called restriction point (Blomen and Boonstra, 2007; Pardee, 1974); 
after this, the cells become refractory to extracellular growth 
regulatory signals, and are committed to enter S phase and complete 
the cell cycle. Beyond this point, the cell cycle can only be halted by 
activation of the cell cycle checkpoints (see Box 2).  
 
 
2.2.2 S phase 
S phase begins with the activation of the pre-replication complexes by 
cyclin A/E-Cdk2 (Wuarin and Nurse, 1996). The DNA pre-replication 
complexes are assembled on replication origins during G1, and are 
kept inactive by the binding of Cdc6. Phosphorylation of Cdc6 by S-
phase Cdk complexes not only activates initiation of DNA replication 
but also prevents re-assembly of new pre-replication complexes. 
Because of this inhibition, each chromosome is replicated just once 
during passage through the cell cycle, ensuring that the proper 
chromosome number is maintained in the daughter cells. 
Box 2. The G1/S cell cycle checkpoint 
Although cell cycle transitions depend on the underlying CDK 
cycle, superimposed checkpoint controls help ensure that certain 
processes are completed before others begin. Components of 
checkpoint control need not be essential to the workings of the 
cycle; instead, their role is to brake the cycle in the face of stress or 
damage. By allowing repair to take place, they become crucial in 
maintaining genomic stability (Sancar, et al., 2004).  
 
At the transition from G1 to S, there is an important such 
checkpoint: if the cell’s DNA is damaged, p53 (along with its family 
members p63 and p73) is activated (Bartek, 2001). One of its roles 
is to ensure that, in response to genotoxic damage, cells arrest in 
G1 and attempt to repair their DNA before it is replicated. If the 
damage is too severe to be repaired, continued activation of p53 
leads to programmed cell death (see section 2.5.1). If however, the 
damage is repaired, p53 is again inactivated, and the cell continues 




At the end of S-phase, before progression to M-phase, there are two 
checkpoints (Sancar, et al., 2004): one in early G2, to ensure all DNA 
has been replicated, and one in late G2, ensuring that the replicated 
DNA is error-free. If both checkpoints are cleared successfully, Polo-
like kinase activates Cdc25c, which itself activates cyclinB/Cdk1 by 
removing the inhibitory phosphorylations catalyzed by the Myt1 and 
Wee1 kinases.  
 
2.2.4 Mitosis 
Following its activation by Cdc25c, the cyclinB/Cdk1 complex triggers 
chromosome condensation, assembly of the mitotic spindle, nuclear 
envelope breakdown, and rearrangement of the actin cytoskeleton, 
Golgi apparatus, and ER (Figure 2.2B) (Colanzi and Corda, 2007; 
Güttinger, et al., 2009).  At the metaphase-to-anaphase transition, 
there is a final, major checkpoint: the spindle-attachment checkpoint 
(Musacchio and Salmon, 2007). At this point, the cell contains 4n 
DNA, with each replicated chromosome consisting of two identical 
sister chromatids glued together along their length by the action of 
protein complexes called cohesins. The two sister chromatids are 
attached to opposite poles of the mitotic spindle, with cohesion being 
enforced by the action of securin. Upon the initiation of anaphase, 
Cdc20 activates the anaphase promoting complex (APC), which then 
targets securin for proteolysis, freeing separase, which itself cleaves 
the cohesin complexes, allowing segregation of the sister chromatids 
(Sullivan and Morgan, 2007). 
 
The spindle-assembly checkpoint (SAC) operates to ensure that all 
chromosomes are properly attached to the spindle before sister-
chromatid segregation occurs. The SAC depends on a sensor 
mechanism that monitors the state of the kinetochore, the specialized 
region of the chromosome that attaches to microtubules of the 
spindle. The kinetochore comprises the chromosome centromere, 
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which is defined by the incorporation of specific histone variants, 
including CENP-A (Cleveland, et al., 2003), and achievement of proper 
kinetochore tension is dependent on proper formation of pericentric 
heterochromatin, which is characterized by trimethylation of histone 
H3 lysine 9 and H4 lysine 20 (Heit, et al., 2009). The generation of 
stable kinetochore-microtubule attachments depends on the B56 
regulatory subunit-containing protein phosphatase PP2A, which is 
enriched at centromeres/kinetochores of unattached chromosomes 
(Foley, et al., 2011). 
 
Any kinetochore that is not properly attached to the spindle sends out 
a negative signal to the cell-cycle control system, blocking Cdc20-APC 
activation and sister-chromatid segregation. The nature of the signal 
generated by an unattached kinetochore is not clear, although several 
proteins, including Mad2, are recruited to unattached kinetochores 
and are required for the SAC to function. Even a single unattached 
kinetochore in the cell results in Mad2 binding and the inhibition of 
Cdc20-APC activity and securin destruction. Furthermore, proteins 
such as BubR1 sense kinetochore tension, activating the SAC upon 
lack of proper, amphitelic (bi-oriented) attachment of sister 
chromatids. Thus, sister-chromatid segregation cannot occur until the 
final kinetochore has been attached, and sister chromatids are 
attached to opposite poles of the spindle. 
 
After the chromosomes have segregated to the spindle poles, the cell 
must reverse the complex changes of early mitosis. The spindle must 
be disassembled, the chromosomes decondensed, and the nuclear 
envelope reformed. Cytokinesis then ensues, the cytoplasm is pinched 
off, and two identical daughter cells are produced, completing the cell 
cycle. The exit from mitosis is triggered by the inactivation of 
cyclinB/Cdk1 (Wolf, et al., 2007). This inactivation occurs mainly by 
ubiquitin-dependent proteolysis of cyclin B, triggered by the same 
Cdc20-APC complex that promotes the destruction of securin at the 
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metaphase-to-anaphase transition. Thus, the activation of the Cdc20-
APC complex leads not only to anaphase, but also to inactivation of 
the cyclin B/Cdk1 complex — which in turn leads to all of the other 
events that take the cell out of mitosis. 
 
Recent studies have shown that the cyclin B/Cdk1 complex can also 
be inactivated by phosphorylation and inactivation of Cdk1, providing 
an important contribution to the exit from mitosis. Phosphorylation of 
Cdk1 is achieved by inactivation of Cdc25c, which again is achieved 
through the activities of PP2A, specifically PP2A complexes containing 
the B56δ subunit (Forester, et al., 2007).  
 
2.3 Mechanisms underlying uncontrolled proliferation in cancer: 
hallmarks and enabling characteristics 
As indicated before, human cancer cells have acquired certain 
capabilities, which allow them to breach the regulatory mechanisms of 
the normal cell cycle, conferring upon themselves the aforementioned 
trademark characteristics. Each trait is described below, with a few 
examples illustrating the strategies by which they are acquired in 
human cancers.  
 
Self-sufficiency in proliferative signaling 
Oncogenic processes exert their greatest effect by targeting particular 
regulators of G1 phase progression. Cancer cells commonly achieve 
autonomy from normal growth signaling through three molecular 
strategies, involving alteration of: 
- Extracellular growth signals: many cancer cells acquire the 
ability to synthesize the growth factors to which they are 
responsive, e.g. PDGF  (Ostman and Heldin, 2007; Wang, et al., 
2010), EGF and TGFα  (Kalyankrishna and Grandis, 2006). 
Alternatively, cancer cells may send signals to stimulate the 
release of growth factors by surrounding (normal) stromal cells 
(Bhowmick, et al., 2004; Cheng, et al., 2008).  
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- Transcellular transducers of those signals: growth factor 
receptors are often overexpressed or structurally altered in 
many cancers, e.g. Her2/neu in breast cancer (Freudenberg, et 
al., 2009), either allowing cells to become hyperresponsive to 
ambient levels of growth factors that normally would not trigger 
proliferation, or eliciting ligand-independent signaling, 
respectively. 
- Intracellular circuits that translate those signals into action: e.g. 
the B-Raf protein is activated in about 40% of human 
melanomas, continuously stimulating proliferation. Similarly, 
activating mutations in the catalytic subunit of PI3K are being 
detected in an array of tumor types (Jiang and Liu, 2009; Yuan 
and Cantley, 2008).  
 
Recent results have also highlighted the importance of the disruption 
of negative-feedback loops in cancer cells. In approximately 20% of 
human tumors, the Ras oncogene is activated (Davies, 2002; 
Downward, 2003; Karnoub and Weinberg, 2008). However, its 
oncogenic effects do not result from a concomitant hyperactivation of 
its downstream signaling pathways. Instead, Ras GTPase activity, 
which normally operates as an intrinsic negative-feedback mechanism 
to ensure that active signaling is transitory, is compromised.  
 
Circumventing growth-inhibitory signaling 
As discussed in paragraph 2.2.1, up to the restriction point, 
progression through the cell cycle is controlled by the effects of 
extracellular signals on pRb; beyond this point, control is executed via 
the cell cycle checkpoints. Hence, to achieve insensitivity to inhibitory 
signaling, cells must disable the TGFβ-pRb pathway, as well as the 




Disruption of the TGFβ-pRb signaling circuit, thereby acquiring 
insensitivity to anti-growth signals (Massagué, 2004), can be achieved 
in a number of ways: 
- downregulation or mutation of the TGF-β receptors (Levy and 
Hill, 2006); 
- elimination of intracellular signal transducers, e.g. by mutation 
of the gene encoding for Smad4 (Levy and Hill, 2006); 
- loss of functional pRb; in fact, the pRb gene was the first tumor 
suppressor gene to be identified (Knudson, 1971; Sherr and 
McCormick, 2002). 
 
The first and most important cell-cycle checkpoint (Box 2) involves the 
activation of another major tumor suppressor protein, p53. Whereas 
pRb acts in response to signals from the outside, p53 responds to 
signals from within the cell. If there is significant damage to the cell’s 
genome, or if the levels of growth-promoting signals, nucleotide pools, 
glucose, or oxygenation are suboptimal, p53 can halt further cell-cycle 
progression until these conditions have normalized, or, in the face of 
overwhelming or irreparable damage to such cellular subsystems, p53 
may trigger apoptosis. Accordingly, p53 function is lost in over 50% of 
human tumors, either directly as a result of mutations in the p53 
gene, or indirectly through binding to (viral) proteins, or as a result of 
alterations in genes whose products interact with p53 or transmit 
information to or from p53 (Vogelstein, et al., 2000). 
 
Evasion of cell death 
The normal cell possesses the ability to detect cellular stress, 
including abnormal mitogenic stimulation, and responds by 
preventing further division through either cell cycle arrest or 
programmed cell death (see section 2.5.1), preventing the survival and 
proliferation of cells with various disease-promoting mutations. 
Though the exact mechanisms underlying this ‘sensing’ ability remain 
to be fully elucidated, several key players have been identified.  
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For example, excessive mitogenic stimulation leads to the production 
of a cell-cycle inhibitor protein called p14ARF, which binds and 
inhibits the p53-inhibitor Mdm2, therefore causing p53 levels to 
increase, inducing either cell-cycle arrest or, if prolonged, apoptotic 
cell death (Sherr, 2001). As discussed before, p53 is also activated in 
response to DNA damage. Furthermore, insufficient survival factor 
signaling can also trigger apoptosis (section 2.5.1).  
 
Cancer cells acquire resistance to apoptosis through various 
mechanisms: 
- the p53 tumor suppressor gene is inactivated by mutation in 
approximately half of all human cancers (Brosh and Rotter, 
2009; Sherr and McCormick, 2002); 
- the anti-apoptotic Bcl-2 oncogene is often up-regulated (Reed, 
2008); 
- the Fas death-inducing signal has been shown to be titrated 
away from the Fas death receptor by upregulation of a non-
functional (decoy) Fas ligand in cancer cell lines (Pitti, et al., 
1998).  
 
Besides apoptosis, emerging evidence suggests that still other devices 
are in place to prevent abnormal cellular proliferation. These include 
autophagy, necrosis and senescence. However, it also seems that 
tumor cells might actively engage in these processes in order to 
achieve survival. Each pathway is discussed in detail in paragraph 
2.5.1, though senescence will also be discussed in the next section.  
 
Acquiring limitless replicative potential  
In principle, the combination of growth signal autonomy, insensitivity 
to anti-growth signals and resistance to apoptosis should suffice to 
enable the generation of the vast cell mass constituting a tumor. 
However, Hayflick showed that cells in culture have a finite replication 
potential and stop growing after a certain number of doublings (60-70 
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for normal human cells) – a process termed senescence (Hayflick, 
1965; Hayflick and Moorhead, 1961). Others showed that senescence 
could be circumvented by disabling the p53 and pRb tumor 
suppressor proteins, after which cells continue to multiply until they 
enter a second state, labeled crisis, which is characterized by massive 
cell death and end-to-end fusion of chromosomes (Hara, et al., 1991; 
Shay, et al., 1991).  
 
It is this latter trait that provided the clue to cellular immortalization. 
The ends of chromosomes, telomeres, are progressively shortened with 
each cycle of cell division, due to the inability of DNA polymerases to 
completely replicate the 3’ ends of the linear chromosomal DNA during 
S phase (Harley, et al., 1990; Zhao, et al., 2009). Once telomeres are 
shortened beyond a critical length, the protein complexes capping the 
ends are lost, and they are no longer able to protect the ends of 
chromosomal DNA. The unprotected chromosomal ends trigger a 
widespread DNA damage response, resulting in end-to-end fusions 
and death of the cell (Blackburn, 2000; d'Adda di Fagagna, et al., 
2003). 
 
In order to prevent telomere shortening and achieve immortalization, 
malignant cells must therefore activate a system for telomere 
maintenance (Samassekou, et al., 2010). The large majority (85-90%) 
does so by upregulating the expression of the telomerase enzyme 
(Counter, et al., 1994; Kim, et al., 1994; Shay and Bacchetti, 1997), 
which elongates telomeric DNA, while the remainder uses a 
mechanism termed “alternative lengthening of telomeres” (ALT), which 
appears to maintain telomeres through recombination-based 








In order to attain and sustain their rapid proliferation rate, tumor 
cells need to generate an ample amount of ATP for energy and de novo 
synthesis of nucleotides, lipids and proteins. This results on the one 
hand in an increased demand for oxygen cq vasculature, and on the 
other hand a fundamental switch in cellular metabolism (the ‘seventh’ 
hallmark, see below). The oxygen and nutrients supplied by the 
vasculature are crucial for cell function and survival, obligating 
virtually all cells in a tissue to reside within 100 µm of a capillary 
blood vessel. In order to progress to a larger size, tumors must 
therefore develop angiogenic ability (Bergers and Benjamin, 2003). 
This “angiogenic switch” is activated by changing the balance of 
angiogenesis inducers and countervailing inhibitors. One common 
strategy involves increased expression of vascular endothelial growth 
factor (VEGF) (Cook and Figg, 2010); VEGF gene expression can be 
up-regulated by both hypoxia and oncogene signaling (Carmeliet, 
2005; Ferrara, 2009; Mac Gabhann and Popel, 2008). Surprisingly, in 
both animal and human models, angiogenesis was found to be 
induced relatively early during the development of invasive cancers. It 
is therefore likely that the angiogenesis switch also contributes to the 
premalignant phase of neoplastic progression.  
 
Tissue invasion and metastasis 
In reality, the vast majority of human cancer deaths are not caused by 
the primary tumor, but rather by the metastases arising from it. 
Successful invasion and metastasis depend on the other hallmark 
acquired capabilities, as well as on the loss of adherence with the 
surrounding tissue. The most widely observed alteration in cell-cell 
adhesion in cancer involves E-cadherin (Berx and van Roy, 2009). 
Normally, coupling of adjacent cells by E-cadherin bridges results in 
the transmission of anti-growth and other signals via cytoplasmic 
contacts with beta-catenin to intracellular signaling circuits. Such 
“contact inhibition” is further enhanced by the actions of e.g. Merlin, 
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and LKB1. However, in the majority of epithelial cancers E-cadherin 
function is lost (e.g. by promoter hypermethylation), freeing the path 
to metastasis (Lombaerts, et al., 2006). Though it remains to be seen 
how frequently Merlin is compromised in human cancers, it is already 
known that the loss of the NF2 gene, which encodes Merlin, triggers a 
form of human neurofibromatosis. Similarly LKB1 has been identified 
as a tumor suppressor gene that is lost in certain human 
malignancies (Shaw, 2009), and suppression of LKB1 expression 
destabilizes epithelial integrity and renders epithelial cells susceptible 
to Myc-induced transformation (Hezel and Bardeesy, 2008; Partanen, 
et al., 2009).  
 
The multistep process of invasion and metastasis has been 
schematized as a sequence of discrete steps, often termed the 
invasion-metastasis cascade  (Talmadge and Fidler, 2010). This 
depiction envisions a succession of cell-biologic changes, beginning 
with local invasion, then intravasation by cancer cells into nearby 
blood and lymphatic vessels, transit of cancer cells through the 
lymphatic and hematogenous systems, followed by escape of cancer 
cells from the lumina of these vessels into the parenchyma of distant 
tissues (extravasation), the formation of small nodules of cancer cells 
(micrometastases), and finally the growth of micrometastatic lesions 
into macroscopic tumors, this last step being termed colonization. The 
epithelial-mesenchymal transition (EMT), a program normally 
occurring during embryonic development and wound healing, has 
become prominently implicated in this cascade. Several of the 
transcription factors responsible for EMT (e.g. Snail, and Slug) can 
directly repress E-cadherin gene expression, and have been shown in 
experimental models of carcinoma formation to be causally important 
for programming invasion; ectopic over-expression of some of these 
factors has even been found to elicit metastasis  (Micalizzi, et al., 
2010; Schmalhofer, et al., 2009).  It remains to be determined whether 
EMT also contributes to invasion of non-epithelial tumor types, 
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although expression of EMT-inducing transcription factors has been 
observed in some cases.  
 
Two additional, distinct modes of cancer cell invasion have been 
identified  (Friedl and Wolf, 2008). In one, termed “collective invasion”, 
nodules of cancer cells advance en masse into adjacent tissues. This 
is characteristic of e.g. squamous cell carcinomas; coincidentally, 
these cancers are rarely metastatic, suggesting that collective invasion 
lacks certain functional attributes to facilitate metastasis. The second 
mode of invasion, in which individual cancer cells gain morphological 
plasticity, enabling them to slither through existing interstices in the 
extracellular matrix, is termed “amoeboid” (Madsen and Sahai, 2010). 
It is not yet clear whether either of these modes of invasion employs 
any components of the EMT program, or whether there are still other 
cell-biologic pathways contributing to invasion and metastasis. 
 
The physical dissemination of cancer cells from the primary tumor to 
distant tissues is only one aspect of metastasis; the other major phase 
of metastasis relates to the adaptation of these cells to foreign tissue 
micro-environments, resulting in successful colonization. Little is 
known about the precise steps involved in colonization. Carcinoma 
cells that have undergone EMT during initial invasion and metastasis, 
might - when no longer under the influence of EMT-inducing signals 
from the original tumor micro-environment, - undergo a reversal 
process (termed the mesenchymal-epithelial transition, or MET), 
resulting in the formation of new tumor colonies. The explosive 
metastatic growth observed in the clinic for certain cancers, soon after 
resection of the primary tumor, suggests that the primary tumor 
might release factors that initially render micrometastases dormant. 
On the other hand, metastases that erupt decades after treatment of 
the primary tumor reflect the heterogeneity of the primary tumor (see 
below): the disseminated cells might lack certain hallmark 
capabilities, such as sustained proliferative signaling in the absence of 
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growth factors in the new micro-environment, insensitivity to growth 
signals present in this new micro-environment, or induction of 
angiogenesis. Nutrient starvation might induce intense autophagy (see 
2.5.1), causing cells to adopt a state of dormancy, which is reversed 
upon favorable changes in the new micro-environment.  
 
Alternatively, metastatic dissemination may also lead to "re-seeding" 
of cancer cells at the site of the primary lesion. It is likely that the 
micro-environment at the primary tumor site is intrinsically 
hospitable to malignant cells that ‘return home’, resulting in 
successful recolonization.  Finally, while metastatic dissemination is 
generally regarded as the final step in neoplastic progression, there 
are reports indicating that cells can disseminate remarkably early, 
dispersing from noninvasive premalignant lesions in both mice and 
humans (Coghlin and Murray, 2010; Klein, 2009). The clinical 
significance of this phenomenon is however yet to be established, as 
the ability of such premalignant cells to successfully colonize distant 
sites remains unproven.  
 
Alteration of cellular metabolism 
As briefly alluded to before, the onset of proliferation introduces 
important problems in not only the cell cycle, but in cellular 
metabolism as well, for each passage through the cycle requires a 
doubling of total biomass. Consequently, if cells are to proliferate 
rapidly and uncontrollably, as is the case in cancer, a profound 
metabolic reprogramming is required (DeBerardinis, et al., 2008). 
 
At rest, basal levels of growth-factor signaling allow cells to take up 
sufficient nutrients to provide for the low levels of ATP production and 
macromolecular synthesis needed to maintain cellular homeostasis. In 
the absence of any extrinsic signals, mammalian cells lose surface 
expression of nutrient transporters. To survive in the absence of the 
ability to take up extracellular nutrients, growth-factor-deprived cells 
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engage in autophagic degradation of macromolecules and organelles. 
This is a finite survival strategy, which can ultimately result in cell 
death. In contrast, mitogenic signaling instructs cells to begin taking 
up nutrients at a high rate and to allocate them into metabolic 
pathways that support production of ATP and macromolecules 
including proteins, lipids, and nucleic acids. The resulting increase in 
aerobic glycolysis, de novo lipid biosynthesis, and glutamine-
dependent anaplerosis, culminating in a net increase in cellular 
biomass (growth) and, ultimately, the formation of daughter cells, is 
now regarded as the seventh hallmark of tumorigenicity (Hanahan 
and Weinberg, 2011; Weinberg and Chandel, 2009).  
 
These features were first observed by Otto Warburg over 80 years ago, 
who noted that rapidly proliferating tumor cells consume glucose at a 
higher rate than normal cells, secreting most of the glucose-derived 
carbon as lactate rather than oxidizing it completely (a phenomenon 
known as the ‘Warburg effect’) (Warburg, 1925, 1956). Many reports 
have since corroborated that an increase in (aerobic) glycolysis is 
indeed a hallmark of tumorigenicity (Gatenby and Gillies, 2004), 
though aerobic glycolysis itself is not unique to tumor cells, as it also 
occurs in rapidly proliferating primary cells. The high glycolitic rate 
provides several advantages for proliferating cells. It allows cells to use 
the most abundant extracellular nutrient, glucose, to produce 
abundant ATP. Notably, the glucose transporter GLUT1 is up-
regulated in many human tumors (DeBerardinis, et al., 2008). 
Although the yield of ATP per glucose consumed is lower compared to 
oxidative phosphorylation, the rate of ATP production during 
glycolysis is higher (Pfeiffer, et al., 2001). Also, further compensating 
for the lower efficiency of aerobic glycolysis compared to oxidative 
phosphorylation, is the fact that glucose degradation provides cells 
with intermediates needed for biosynthetic pathways  (van der Heiden, 
et al., 2009). There is even advantage in the clinic, where positron 
emission tomography (PET) exploits the increased uptake and 
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utilization of glucose in cancer cells by using a radio-labeled analog of 
glucose (18F-fluorodeoxyglucose, FDG) to visualize metastatic lesions.  
 
The molecular mechanism behind the metabolic switch observed in 
tumor cells is regulated by the PI3K/AKT/mTOR pathway. PI3K 
activation can increase glucose uptake and utilization through AKT 
(Elstrom, et al., 2004; Rathmell, et al., 2003); mTOR stimulation 
activates the transcription factor HIF-1 (Majumder, et al., 2004), 
which enhances glycolysis by increasing the expression of genes that 
encode glycolytic enzymes and glucose transporters (Semenza, 2000, 
2007). Oncogenes such as Ras and Myc also stimulate glycolysis 
through induction of glycolytic enzymes and glucose transporters 
(Dang and Semenza, 1999), and activating mutations have been 
reported for the isocitrate dehydrogenase 1/2 (IDH) enzymes in certain 
types of cancer  (Yen, et al., 2010). Furthermore, the PI3K/AKT/mTOR 
pathway also stimulates ribosome biogenesis, which is fundamental to 
achieve rapid cell growth and proliferation (Dufner and Thomas, 1999; 
Gingras, et al., 2004).  
 
Evasion of immune destruction 
Yet another particular feature of cancer cells concerns their 
relationship to the immune system. Ordinarily, cells of the innate and 
adaptive immune response cooperate to protect the body against 
harmful agents, including bacteria, viruses and parasites. Evidence 
suggests, however, that these cells also function in “tumor 
surveillance”, in which cells and tissues are constantly monitored for 
nascent tumors, recognizing and eliminating incipient cancer cells. 
While this is obviously plausible for virus-induced cancers, it seems 
less so for the >80% of tumors of non-viral etiology. Still, human 
tumors frequently have defects in MHC class I antigen presentation 
(Seliger, 2008), and deficiencies in the development or function of 
cytotoxic T lymphocytes (CTLs), helper T cells or natural killer (NK) 
cells each led to demonstrable increases in cancer incidence in mouse 
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models  (Kim, et al., 2007; Teng, et al., 2008). Clinical epidemiology 
also increasingly supports the existence of anti-tumoral immune 
responses in human cancer; for example, patients with colon and 
ovarian tumors that are heavily infiltrated with CTLs and NK cells 
have a better prognosis than those lacking this abundant immune 
response (Bindea, et al., 2010). Furthermore, cancer cells may 
paralyze infiltrating CTLs and NK cells by secreting e.g. TGFβ  (Yang, 
et al., 2010), or suppress their actions by recruiting inflammatory 
cells that are actively immunosuppressive, such as regulatory T cells 
and myeloid-derived suppressor cells  (MDSC) (Mougiakakos, et al., 
2010; Ostrand-Rosenberg and Sinha, 2009).  
 
Another class of cells pertaining to the immune system comprises the 
dendritic cells (DCs). As antigen-presenting cells, DCs play a central 
role in both innate and adaptive immunity. DCs can be found in 
tumors in both humans and mice; however, cancer cells have been 
shown to suppress DCs through the expression of cytokines such as 
IL-6 and -10, and VEGF (which, coincidentally, also stimulates 
angiogenesis). Alternatively, tumors may condition DCs to form 
suppressive T cells, and studies have shown that in multiple 
myeloma, DCs even support clonogenic growth (Steinman and 
Banchereau, 2007, and references therein). Thus, much like certain 
infectious agents (e.g. HIV), cancer cells have developed strategies to 
evade, and in some instances even exploit, DCs.  
 
Taken altogether, the data imply that anti-tumor immunity might be a 
significant barrier to tumor formation and progression, imposing upon 
tumor cells the need to acquire the ability to either evade immune 
suppression, or adapt it to promote proliferation.  
 
Genomic instability 
Acquisition of the features discussed above depends in large part on a 
succession of alterations in the genomes of neoplastic cells. This 
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entails mutations, but also epigenetic modifications. Ordinarily, 
genome maintenance systems (often referred to as the caretakers of 
the genome) ensure that the rates of spontaneous mutations per cell 
cycle are very low. Additionally, as discussed above, p53, the 
“guardian of the genome”, plays a central role in the surveillance 
systems that normally monitor genomic integrity and inhibit 
proliferation of genetically damaged cells. Analysis of cancer cell 
genomes has shown that many tumor cells appear to specifically 
target the caretakers and guardians of the genome for deletions and 
inactivating mutations, further accelerating the accumulation of 
tumor-promoting genomic alterations. Conversely, other genomic 
regions, harboring genes whose expression favors neoplastic 
progression, are often amplified in cancer cells. Genomic imbalance is 
thus an enabling characteristic, exploited by cancer cells to acquire 
the hallmark capabilities required for malignant transformation.  
 
Telomerase has ambiguous roles in this regard: in the absence of 
telomerase expression, sustained proliferation results in loss of 
telomeric DNA, leading to end-to-end fusions and general karyotypic 
instability. While the resulting genetic alterations could be 
advantageous to the cancer cell, they may also induce cellular 
senescence. Increased expression of telomerase, while bypassing 
senescence, may reduce genomic instability and delay neoplastic 
progression; prolonged expression of telomerase may again lead to 
genomic imbalance due to fusion and breakage of excessively 
elongated telomeres.  
 
The immune system and other cells of the tumor micro-environment  
As discussed before, some tumors are densely infiltrated by cells of 
both the innate and adaptive arms of the immune system. What’s 
more, it’s becoming increasingly clear that practically every neoplastic 
lesion contains immune cells – ranging from subtle infiltrations to 
gross inflammations. This is largely though to reflect an attempt by 
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the immune system to eradicate cancerous cells. However, the tumor-
associated inflammatory response has been shown to have a 
paradoxical effect, enhancing tumorigenesis and progression, in fact 
helping incipient neoplasias to acquire hallmark capabilities.  
 
Inflammatory cells supply growth factors to sustain proliferative 
signaling, survival factors limiting cell death, pro-angiogenic factors, 
extracellular matrix-modifying enzymes facilitating angiogenesis, 
invasion and metastasis, and EMT-inducing signals (DeNardo, 2010; 
Grivennikov, 2010; Karnoub and Weinberg, 2006, 2007; Kessenbrock, 
et al., 2010; Qian and Pollard 2010), and have even been shown to 
release mutagenic factors, promoting genomic imbalance 
(Grivennikov, 2010). Concurrently, inflammation is in some cases 
evident at the earliest stages of neoplastic progression, and is 
demonstrably capable of fostering the development of incipient 
neoplasias into full-blown cancers (Qian and Pollard, 2010: de Visser, 
2006). The tumor-stroma interaction is not one-sided: not only do 
cancer cells secrete factors to suppress elimination by the cells of the 
immune system, but they have also been shown to stimulate these 
cells. In an experimental model of metastatic breast cancer, the cancer 
cells secreted CSF-1, stimulating tumor-associated macrophages, 
while the latter reciprocated by supplying epidermal growth factor 
(EGF) to the breast cancer cells  (Qian and Pollard, 2010).  
 
Evidently, these interactions also extend to the other cells in the 
tumor micro-environment. For contrary to earlier views, tumors are 
now regarded as complex, organized networks of heterogeneous, 
specialized cells – comparable to organs. Besides the cells of the 
immune system, these include endothelial cells and pericytes, which 
form the tumor-associated vasculature, as well as fibroblasts and 




Another important constituent of the tumor micro-environment 
concerns the so-called “cancer stem cells” (CSCs). Traditionally, 
tumors have been portrayed as reasonably homogeneous cell 
populations – principally arising from a single cell that managed to 
acquire the hallmark capabilities - until relatively late in the course of 
tumor progression, when hyperproliferation combined with increased 
genetic instability would spawn distinct clonal subpopulations. 
However, there is increasing evidence that certain cancer cells assume 
a stem cell-like character. CSCs, like their normal counterparts, may 
self-renew as well as spawn more differentiated derivatives. The 
origins of these CSCs is not entirely clear, though it is proposed that 
they arise either through de-differentiation, or through oncogenic 
transformation of normal tissue stem cells  (Cho and Clarke, 2008;  
Lobo, et al., 2007). Additionally, CSCs have been shown to express 
markers of their corresponding normal tissue stem cells  (Al-Hajj, et 
al., 2003). They were originally implicated in the pathogenesis of 
hematopoietic malignancies, but have now also been identified in e.g. 
breast carcinomas and neuroectodermal tumors. In fact, induction of 
the EMT program in certain model systems has been shown to induce 
many of the defining features of stem cells  (Mani, et al., 2008).  
 
One important implication of the above-discussed, recently acquired 
knowledge on the tumor micro-environment, is that all the core 
hallmark capabilities might not need to reside within a single cell. For 
instance, the ability to negotiate the invasion-metastasis cascade may 
be acquired in certain cancers via inflammatory cells in their micro-
environment, without the requirement that the cancer cells 
themselves undergo additional mutations beyond those that were 
needed for primary tumor formation. Another is that the dynamic 
interactions between cancer cells and their micro-environment, and 
the development of CSCs, complicates not only the elucidation of the 
mechanisms of cancer pathogenesis, but also the development of 
novel therapies to successfully target primary and metastatic tumors.   
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2.4 Oncogenic transformation: the making of a human tumor cell 
Regardless of the many remaining uncertainties, the set of cancer-
typical traits discussed above does allow for a tentative model of 
oncogenic transformation (Figure 2.3). Experiments using the viral 
oncoproteins Simian Virus 40 (SV40) large and small T antigens have 
elegantly demonstrated that full malignant transformation of human 
cells can be achieved in a limited number of steps, requiring (Hahn 
and Weinberg, 2002b): 
- Oncogenic activation of Ras, e.g. through activating mutations, 
conferring growth signal autonomy; 
- Bypassing replicative senescence and evasion of apoptosis by 
the introduction of SV40 LT, which binds to and inhibits the 
functions of pRb and p53, respectively (Ali and DeCaprio, 2001); 
- Activation of telomerase to achieve immortalization; 
- Co-expression of SV40 ST, which associates with PP2A and 
alters its cellular function (Yu, et al., 2001). Though PP2A has 
many cellular functions and has been shown to be an important 
tumor suppressor, exactly how inhibition of PP2A contributes to 
malignant transformation remains unclear (Mumby, 2007). 
 
Intriguingly, while the fifth and sixth hallmarks are not required for 
malignant transformation, but rather promote continued proliferation, 
invasion and metastasis once the tumor has been formed, the seventh 
hallmark is indeed activated by Ras. Similarly, the eighth proposed 
hallmark appears not to be required for initial malignant 
transformation, though one might speculate that the SV40 antigens 
could perhaps either trigger the activation of the immune system, 
eliciting tumor-promoting inflammation, or actively suppress antigen 
presentation, aiding in immune escape of infected cells. Furthermore, 
owing to the inhibition of pRb and p53, cells are predisposed to 
genomic instability, facilitating the acquisition of the remaining 





Figure 2.3 Experimental findings demonstrate that only a few steps are necessary 
for malignant transformation of human cells. Over-expression of Ras confers 
independence from mitogenic signaling, while inactivation of the tumor suppressors 
pRb and p53 confer immortalization, which is sustained by upregulation of 
telomerase. Ras over-expression also induces angiogenesis and the seventh 
proposed hallmark, namely the metabolic switch, which is postulated to be required 
to provide the energy and nutrients necessary for rapid cellular proliferation. PP2A 
inactivation by SV40 ST has been demonstrated to be required for full malignant 
transformation, though how this contributes to tumorigenesis has yet to be 
elucidated. Adapted from Hahn and Weinberg, 2002b. 
 
2.5 Killing tumor cells in the 21st century 
Cancer is traditionally treated by debulking through surgery, and 
killing any remaining cells by a combination of radio- and 
chemotherapy. As the conventional therapies have been designed to 
target rapidly proliferating cells in general, and do not target the 
tumor cells specifically, they are also toxic to normally rapidly 
proliferating cells, causing serious side-effects, such as anemia, and 
suppression of the immune system. Furthermore, they rely heavily on 
the induction of apoptosis, whereas, as discussed previously, cancer 
cells typically accumulate alterations to the apoptotic machinery, 
conferring on them the ability to evade apoptosis. Recent 
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understanding of the molecular pathogenesis of cancer has led to the 
development of targeted therapies, and increasing attention is being 
directed towards other types of cell death, including autophagy, 
mitotic catastrophe, necrosis and senescence. The various pathways 
leading to cell death are discussed in section 2.5.1, and the novel 
anticancer strategies designed to effectuate cancer cell death are 
presented in section 2.5.2.  
 
2.5.1 Cell death pathways and response to antitumor therapy 
The various modes of cell death have long been classified according to 
their morphological features (Kroemer, et al., 2009). Recent 
breakthroughs in cell death research have, however, allowed for the 
tentative introduction of a novel characterization based on measurable 
biochemical features (Galluzzi, et al., 2011). Both the morphological 
and biochemical features of the various cell death types are summed 
up in Table 2-2 and schematically depicted in Figure 2.4. Even though 
the various modes of cell death are discussed as separate entities, one 
must keep in mind that many interconnections exist: e.g., the 
apoptosis and autophagy pathways share a number of components 
(Maiuri, et al., 2007), while autophagy is required to mediate the 
senescence transition (Young, et al., 2009). 
 
Apoptosis 
Apoptosis is the term for programmed cell death, in which the cell 
membrane is disrupted, the cytoplasmic and nuclear skeletons are 
broken down, the nucleus is fragmented, chromosomes are degraded, 
and the shriveled cell corpse, neatly packaged, is engulfed by nearby 
cells and disappears, without eliciting an inflammatory response 
(Kroemer, et al., 2009).  
 
The apoptotic machinery, depicted in Figure 2.4A, consists of sensor 
proteins and a family of effector proteins called caspases (Kurokawa  
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Table 2-2. The morphological features of the different modes of cell death. Adapted 
from Wlodkowic, et al., 2010 and Galluzzi, et al., 2011. MAP1LC3, micro-tubule-
associated protein 1 light chain 3; SQSTM1, sequestosome 1 
 
Type of cell 
death 
Morphological features Distinctive biochemical 
features 
Apoptosis Rounding-up of the cell 
Reduction of cellular and 
nuclear volume 
Nuclear fragmentation  
Plasma membrane blebbing 
Minor modification of 
cytoplasmic organelles 
Engulfment by resident 
phagocytes in vivo 
Internucleosomal DNA 
fragmentation 








- death receptor signaling, 
caspase-8/-10 activation 
- dependence receptor 
signaling, caspase-9 
activation 




Little or no uptake by 
phagocytic cells in vivo 
Increased lysosomal activity 
Initially perceived as caspase-
independent although recent 





Necrosis Dissolution of chromatin 
Swelling of cytoplasm and 
cytoplasmic organelles 
Rupture of plasma 
membrane 





During mitosis: multiple 
micronuclei, aberrant 
mitotic spindles 
Following mitotic failure:  
formation of giant 
polykaryons 
Mitotic arrest 
Caspase-2 activation (in some 
cases) 
p53/p73 activation (in some 
cases) 






Initiated by telomere shortening 








Figure 2.4. Schematic depiction of the various modes of cell death, and a general 
overview of the most important molecular players involved, also indicating the 
cross-talks existing between the different pathways. A. Apoptosis is characterized by 
nuclear chromatin condensation and fragmentation, cell shrinkage and blebbing of 
the cytoplasmic membrane. It can be induced extrinsically by stimulation of death 
receptors, e.g. FADD and insufficient survival signaling, or intrinsically, by e.g. DNA 
damage. Both pathways converge on the activation of the executioner caspase, 
caspase-3; however, DNA damage-induced activation of caspase-2 can also result in 
cell cycle arrest and mitotic catastrophe. Release of AIF, EndoG, and HTRA2 
proteins from the mitochondria can also induce caspase-independent apoptosis. 
MOMP, mitochondrial outer membrane permeabilization. B. Autophagic cell death is 
characterized by the appearance of double-membraned autophagic vacuoles and the 
lack of chromatin condensation. Autophagy is induced by starvation and/or growth 
factor deprivation, which stimulates PI3K to induce the formation of 
autophagosomes comprising Beclin-1 and various Atg proteins. Other cellular stress 
signals, such as hypoxia and low energy also stimulate autophagy, respectively by 
removing Bcl-2 sequestration of Beclin-1, and mTOR suppression of autophagosome 
assembly. C. Necrotic cell death is characterized by chromatin dissolution, 
cytoplasmic swelling and rupture of the cell membrane. The kinase RIP1 and its 
homolog RIP3 are central players in this process, and induce necrosis in the case of 
caspase inhibition. D. Mitotic catastrophe is the result of damaged DNA and 
aberrant mitotic spindle formation. Abrupt interruption of mitosis at 
metaphase/anaphase results in the formation of multiple micronuclei. Otherwise, in 
the case of mitotic failure, the spindle is disassembled and cells enter G1 without 
having undergone cytokinesis, forming giant polykaryons (not depicted). E. DNA-
damage- and oncogene-induced senescence is characterized by the appearance of 
characteristic heterochromatic foci, cytoplasmic granules, and flattening of the 
cytoplasmic membrane. See text for further details. 
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and Kornbluth, 2009). Apoptosis can be initiated by two distinct 
pathways, respectively conveying intra- and extracellular stress 
signals. Intracellular stress signals, such as growth factor withdrawal, 
DNA damage, oxidative stress or oncogene activation, lead to release 
of cytochrome c from the intermembrane space of the mitochondria to 
the cytoplasm. This process is tightly regulated by the Bcl-2 family of 
both pro- and anti-apoptotic proteins, and results in the activation of 
caspase-9. The extrinsic pathway is activated in one of two ways: 
either by the binding of death-inducing ligands, such as Fas and 
TNFα, inducing formation of the death-inducing signaling complex 
(DISC), and activation of caspase-8 and -10, or alternatively, through 
the actions of “dependence receptors”, when the concentration of their 
specific ligands fall below a certain threshold  (Mehlen and Bredesen, 
2011). Both apoptotic pathways lead to activation of the executioner 
caspases, caspase-3, -6 and -7, which are the main proteases 
responsible for cellular degradation.  
 
In addition, experiments with caspase inhibitors, wherein cell death 
could be delayed but not inhibited, led to the proposal of a caspase-
independent mode of intrinsic apoptosis. This would entail the release 
of AIF, EndoG and HTRA2 from the mitochondria in response to 
intrinsic stress signals, leading to large-scale DNA fragmentation and 
cleaving of a wide array of proteins, including cytoskeletal proteins.  
 
The last stage of apoptosis involves the uptake of apoptotic cells by 
phagocytosis. This process is initiated by externalization of 
phosphatidylserine on the surface of apoptotic cells, facilitating 




Autophagy is characterized by the sequestration of cytoplasmic 
material (proteins and organelles) within autophagosomes for bulk 
Chapter 2 
46 
degradation by lysosomes (Kroemer, et al., 2009). Typically, 
autophagic cell death occurs in the absence of chromatin 
condensation, but is accompanied by massive autophagic 
vacuolization of the cytoplasm. These so-called “autophagosomes” 
originate from two conjugation systems, involving the autophagy-
associated Atg proteins  (de Bruin and Medema, 2008) (Figure 2.4B). 
In fact, lipidation of Atg8 (MAP1LC3) is a defining biochemical feature 
of autophagy, as is degradation of the autophagic substrate 
sequestosome 1 (SQSTM1) (Table 2-2). The autophagic pathway is 
regulated by the PI3K/AKT/mTOR pathway (Petiot, et al., 2000; Wang 
and Klionsky, 2003), which, coincidentally, is also responsible for the 
metabolic switch observed in rapidly proliferating cells (the seventh 
hallmark of cancer).  
 
Rather than being simply a cell death pathway, autophagy is actually 
quite important for cell survival, providing an alternative source of 
nutrients (Klionsky and Emr, 2000). In yeast, autophagy is induced 
under nutrient-limiting conditions as a mechanism to survive; 
however, in Drosophila melanogaster, autophagic structures are 
formed during morphogenesis, corroborating its role in cell death 
(Baehrecke, 2003). It has therefore been considered that, under 
conditions of cellular stress, autophagy might start as an adaptive 
response in order to enhance cell survival, but that, beyond a certain 
threshold, it can result in cell death. Importantly, some reports 
indicate that cells displaying features of autophagic cell death can still 
recover upon withdrawal of the death-inducing stimulus (Boya, et al., 
2005).  
 
During cellular transformation, autophagy may prevent a normal cell 
from becoming a malignant one by degrading damaged organelles and 
thereby reducing cellular stress, or by degrading specific proteins that 
enhance tumor formation (Jin and White, 2007; Mathew, et al., 2007). 
It may also limit chromosome instability and thereby tumor 
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progression (Mathew, et al., 2007). Alternatively, autophagy may 
prevent tumorigenesis by killing premalignant cells (Karantza-
Wadsworth, et al., 2007). Besides its potential tumor-suppressive 
roles in the early stages of tumorigenesis, autophagy has also been 
proposed to play a tumor-promoting role during the later stages of 
tumor growth (Amaravadi, et al., 2007; Lum, et al., 2005). In this 
case, autophagy protects cells against stressful conditions. Notably 
radio- and chemotherapy treatment can induce autophagy, leading to 
a state of reversible dormancy, enabling the resistance, persistence 
and regrowth of tumors  (Apel, et al., 2009; White and DiPaola, 2009). 
 
Necrosis 
Necrotic cell death is characterized by cellular swelling, rupture of the 
plasma membrane and subsequent loss of intracellular contents, often 
provoking an inflammatory response (Kroemer, et al., 2009). As 
opposed to apoptosis, necrosis has long been considered to be an 
uncontrolled form of cell death. However, evidence is accumulating 
that the execution of necrotic cell death may be finely regulated by 
death domain receptors and Toll-like receptors, and is dependent on 
the activity of the kinase RIP1 and its homolog RIP3  (Festjens, et al., 
2007) (Figure 2.4C). 
 
Neither the precise role of the kinase activity of RIP1 nor its 
downstream targets are known. Previously, it was shown that 
mitochondria-produced reactive oxygen species (ROS) are important 
players in the execution of necrotic cell death (Festjens, et al., 2006). 
Therefore, it is conceivable that RIP1 directly or indirectly targets 
mitochondria. Indeed, in tumor necrosis factor (TNF)-stimulated cells, 
RIP1 translocates to the mitochondria. In addition, RIP1 has also been 
shown to be essential for TNF-induced production of ceramide, the 
latter mediating TNF-induced caspase-independent cell death. As the 
phospholipase cPLA2 contributes to TNF-induced necrosis (Thon, et 
al., 2005), it is conceivable that a RIP1-cPLA2-acid sphingomyelinase 
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pathway may lead to necrotic cell death. Because inhibition of 
ceramide accumulation clearly diminished caspase-independent cell 
death but not as completely as inhibition of RIP1, ceramide obviously 
may represent a central factor, but most likely not the only one, 
transmitting the death signals generated by RIP1 in response to TNF.  
 
Notably in some studies, RIP1-dependent autophagic cell death 
instead of necrosis was observed (Yu, et al., 2006). However, the 
induction of autophagic cell death was much slower than the 
induction of death receptor-induced necrotic cell death. Thus, whether 
necrosis or autophagy ensues when apoptosis is inhibited, will surely 
depend on cells and circumstances. 
 
Necrosis can also be induced through DNA damage  (Festjens, et al., 
2006). This type of cell death is mediated by PARP-1, a protein 
involved in DNA damage repair. Activation of PARP-1 catalyzes the 
hydrolysis of NAD+ into nicotinamide and poly-ADP ribose, causing 
depletion of NAD+. This results in cellular energy failure and caspase-
independent death of different cell types. 
 
Unfortunately, the inflammatory response which accompanies 
necrotic cell death (in contrast to apoptosis and autophagy), can in 
fact promote neoplastic progression, given that the inflammatory cells 
can foster proliferation, angiogenesis and tissue invasion and 
metastasis (see paragraph 2.3). Additionally, necrotic cells can release 
factors like IL-1α, which can directly stimulate viable neighboring cells 
to proliferate, again facilitating neoplastic progression.  
 
Mitotic catastrophe 
Mitotic catastrophe is a type of cell death that follows aberrant 
mitosis, occurring either during or shortly thereafter. In mammalian 
cells, and particularly in tumor cells, mitotic catastrophe is mainly 
associated with activation of the G2/M cell cycle checkpoints for DNA 
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damage/structure and spindle assembly, and involves numerous 
players involved in these checkpoints, including Chk2, cyclinB/Cdk1, 
and members of the p53 family, including p53 and the p73 variant 
TAp73 (Figure 2.4D) (de Bruin and Medema, 2008). Following mitotic 
catastrophe, cells are ultimately killed by engaging the apoptotic or 
necrotic pathways, or by induction of cellular senescence (Figure 2.4E) 
(Galluzzi, et al., 2011).  
 
At least two subtypes of mitotic catastrophe can be distinguished 
(Castedo, et al., 2004). First, mitotic catastrophe can kill the cell 
during or close to metaphase, in a p53-independent manner involving 
the activation of caspase-2. Second, mitotic catastrophe can occur 
after failed mitosis, in a partially p53-dependent manner involving the 
activation of the polyploidy checkpoint in G1. Even though mitotic 
catastrophe is accompanied by chromatin condensation and 
mitochondrial release of apoptosis-inducing factor and cytochrome c, 
which are key features of apoptosis, there are a number of 
fundamental differences. Importantly, it has been shown that over-
expression of Bcl-2 does not block and might actually enhance mitotic 
catastrophe (Lock and Stribinskiene, 1996). Cell death occurring 
during the metaphase-to-anaphase transition is characterized by the 
activation of caspase-2, which is activated in the nucleus in response 
to DNA damage (Lassus, et al., 2002; Paroni, et al., 2002), and is a 
process that cannot be inhibited by Bcl-2 (Peart, et al., 2003; Read, et 
al., 2002; Robertson, et al., 2002).  
 
Senescence 
Analogously to the replicative senescence induced in primary cells as 
a result of shortened telomeres, treatment of malignancies may result 
in a permanently growth-arrested state (Gewirtz, et al., 2008). This is 
termed ‘accelerated senescence’, and is sensed as a permanent state 
of DNA damage, while the cell remains viable and metabolically active 
(Figure 2.4E).  DNA damage signaling activates the p53 and pRb 
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proteins (or their respective family members, as p53 and pRb function 
are often lost during tumorigenesis), which respectively results in first 
a temporary, then a prolonged arrest in G1. Senescent cells 
characteristically display senescent associated DNA damage foci (SDF) 
and senescent associated heterochromatin foci (SAHF) (Campisi and 
d'Adda di Fagagna, 2007); SAHF are often found at the promoters of 
E2F target genes where they are thought to inhibit transcription, 
thereby enforcing growth arrest (Narita, et al., 2003).  
 
2.5.2 Novel approaches to the treatment of cancer 
The success of anticancer therapies depends on their ability to 
distinguish between normal and cancer cells and specifically exert 
their toxic effect on the malignant cells. Novel anticancer strategies 
therefore involve a targeted approach, utilizing knowledge of the 
cancer hallmarks and enabling characteristics discussed above, and 
the tumor suppressor and oncogenic pathways involved. Accordingly, 
the following strategies will be discussed: 
- inhibition of growth signaling pathways 
- induction of programmed cell death 
- disruption of telomere maintenance and, hence, cellular 
immortalization 
- targeting the tumor and its micro-environment to prevent 
angiogenesis and metastasis 
- attenuation of tumor cell metabolism 
- targeting cancer cells for immune destruction 
- exploiting genomic instability 
- proteins selectively killing tumor cells 
 
Clinical experience with therapies selectively targeting only one each 
of these characteristics has shown that the effect is often transitory. 
This suggests the existence of at least some (partial) redundancy, in 
the form of multiple pathways governing each capability, and/or an 
adaptive shift from one capability to another, facilitated by genomic 
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instability and the tumor micro-environment. Hence, successful 
cancer therapies must comprise a combination of modalities.  
 
Targeting growth signaling pathways in cancer 
The first two acquired capabilities discussed in section 2.3 concerned 
self-sufficiency in growth signaling and insensitivity to growth-
inhibitory signaling. Thus, growth-signaling pathways, and especially 
the receptor proteins, are interesting targets for anticancer strategies 
(Christoffersen, et al., 2009). Therapeutic approaches involve both 
hormone therapy and monoclonal antibodies. For example, targeting 
the EGF dependent signaling pathway has been successfully applied 
in the clinic. One of the receptors in this pathway is Her2 (Her2/neu, 
ErbB2), and it has been shown to be overexpressed in 20-25% of 
breast tumors. Targeting this receptor via the antibody Herceptin 
(trastuzumab) has proven to be very effective in the treatment of this 
type of cancer (Chang, 2010).  
 
Another approach involves the development of Cdk inhibitors to halt 
the cell cycle, with several compounds already being evaluated in 
clinical trials (De Falco and De Luca, 2010). 
 
Inducing programmed cell death 
Overturning the cancer cell’s apoptosis blockade has been an 
appealing approach in the design of anti-cancer therapies. For 
example, in cells where p53 function has been lost, this might be 
substituted for by activation of the p53 family member p73, either 
alone or in combination with other anti-cancer therapies (El-Rifai and 
Zaika, 2008; Vilgelm, 2008). The same might also be achieved by 
inhibition of the negative apoptosis regulator Bcl-2 (Kang and 
Reynolds, 2009), e.g. through so-called BH3-mimicking compounds 
(Chonghaile and Letai, 2008). Another promising approach is the 
development of small therapeutic compounds, referred to as Smac 
mimetics, which are designed to block the function of members of the 
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inhibitor of apoptosis (IAP) protein family (Gyrd-Hansen and Meier, 
2010). Alterations in IAPs are found in many types of human cancer 
and are associated with chemoresistance, disease progression and 
poor prognosis (Hunter, et al., 2007; LaCasse, et al., 2008). Consistent 
with the idea that different types of cancer cells are dependent on 
(“addicted to”) IAPs for their survival, the inactivation of IAPs, 
particularly when combined with other treatments, results in the 
death of most tumour cells in vitro. Though inactivation of IAPs does 
not seem to be detrimental to normal cells, loss of IAPs is also 
associated with the development of certain types of cancer. Several 
compounds are therefore currently being assessed for safety in phase I 
clinical trials.  
 
As induction of the other modes of cell death may cause undesirable 
tumor-promoting effects, studies to define optimal strategies to 
modulate and exploit these other forms of cell death for cancer 
therapy are still ongoing. For instance, several autophagy modulators 
are currently being investigated (Chen and Karantza, 2011), and 
mechanisms being considered for the induction of senescence include 
restoration and/or promotion of p53 function, modulation of the cell 
cycle through Cdk inhibitors, and inhibition of telomerase action (see 
below) (Nardella, et al., 2011).  
 
Attacking cellular immortalization via disruption of telomere 
maintenance 
While normal human somatic cells do not or only transiently express 
telomerase and therefore shorten their telomeres with each cell 
division, most human cancer cells typically express high levels of 
telomerase and show unlimited cell proliferation (acquired capability 
4). Telomerase is thus an attractive therapeutic cancer target, and 
novel anti-cancer strategies include the direct targeting of components 
of telomerase: the protein component hTERT or RNA component hTR 
(Phatak and Burger, 2007). Examples of such agents include the small 
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molecule hTERT inhibitor BIBR1532 and Imelstat (GRN163L), a thio-
phosphoramidate oligonucleotide targeting the template region of hTR 
as a "template antagonist" (Kelland, 2007). Anti-tumor effects of both 
compounds have been observed in cell lines and, particularly for 
Imelstat, also in xenografted human tumors in mice. Imelstat 
treatment of human glioblastoma tumor-initiating cells in vitro led to 
progressive telomere shortening, reduced rates of proliferation, and 
eventually cell death (Marian, et al., 2010). In combination with 
radiation and the DNA alkylating agent temozolomide, Imelstat had a 
dramatic effect on cell survival and activated the DNA damage 
response pathway. In vivo, chronic systemic treatment produced a 
marked decrease in the rate of xenograft subcutaneous tumor growth. 
 
Effects of anti-telomerase treatment are largely dependent upon initial 
telomere length, which can result in a substantial lag before 
antitumor activity is observed in tumors possessing relatively long 
telomeres. An alternative approach is therefore to target the telomere 
itself (Telomere Targeting Agents, TTAs) (Kelland, 2005). Several 
classes of small molecules have been described that induce the G-rich 
single-stranded overhang of telomeric DNA to fold into 4-stranded G-
quadruplex structures. Such folding is incompatible with telomerase 
function and may induce rapid telomere uncapping. These molecules 
have shown potent telomerase inhibition in nanomolar concentrations 
in vitro and the rapid induction of senescence in cancer cells. The TTA 
BRACO19 has demonstrated single agent activity against human 
tumour xenografts with anti-tumour effects apparent from only 7 days 
of treatment.  
 
So far, Imelstat is the only drug of its class in clinical trials. In the 
near future, it is expected that other direct telomerase targeted agents 
as well as those targeting telomeres (e.g., AS1410 based on BRACO19) 




Targeting angiogenesis and metastasis 
As discussed above, tumor growth requires the malignant cell to be 
able to e.g. form new vasculature, as well as produce autologous 
growth factors. These characteristics need not be united in a single 
cell, as cells in the tumor micro-environment can contribute to 
neoplastic progression by providing the necessary factors, aiding not 
only in e.g. the angiogenic switch, but also in fostering tissue invasion 
and metastasis.  
 
Furthermore, the cancer stem cells (CSCs) found in many tumors 
have important properties that must be considered in the development 
of effective cancer therapies. Their relative quiescence allows them to 
escape cell death by therapies that attack only rapidly proliferating 
cells. Also, their ability for self-renewal allows them to recover from 
the anti-cancer attack, repair their DNA and again initiate the 
formation of a new tumor. Thus, even if the cancer appears to be 
cured, the CSCs survive, and in time the tumor reappears. 
Furthermore, as CSCs are able to modify the tumor 
microenvironment, providing trophic factors to support tumor growth, 
they harbor a considerable potential for recurrence, as well as 
successful colonization of distant metastases. 
 
Therapeutic strategies that could be employed to target angiogenesis 
and metastasis in general (acquired capabilities 5 and 6), and cancer 
stem cells in particular, are: 
- anti-angiogenic therapy, e.g. through inhibition of VEGF using 
the monoclonal antibody bevacizumab, to reduce the 
vasculature, thereby depleting the tumor of oxygen and 
essential nutrients (Cook and Figg, 2010) 
- blocking adhesion between cells and to the extracellular matrix 
to prevent successful colonization of metastases, e.g. by 
targeting tumor-specific cadherins and integrins (Blaschuk and 
Devemy, 2009; Desgrosellier and Cheresh, 2010)  
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- another way to prevent metastasis might be through blocking 
the EMT chemotaxis pathways that are active in the tumor and 
its micro-environment  (Nieto, 2011; Roussos, et al., 2011) 
- inducing differentiation, e.g. through BMP signaling to revert 
the capacity of CSCs to form tumors and increase their 
sensitivity to therapy (Ghotra, et al., 2009) 
- targeting self-renewal and quiescence, e.g. through PTEN or Wnt 
signaling pathways, to decrease the CSC population (Ghotra, et 
al., 2009) 
 
Targeting cancer cell metabolism 
In addition to acquiring a complex array of genetic changes, tumor 
cells develop an alteration in the metabolism of glucose and oxygen 
(acquired capability 7). As this altered metabolism does not appear to 
be subject to the high genetic variability of tumors, it may represent a 
more reliable target for cancer therapy.  
 
The altered metabolism of cancer cells is associated with increased 
glycocolytic activity and repression of oxidative phosphorylation. The 
harmful effects of the concurrent increase in H2O2 production is 
counterbalanced by the increase in glycolytic activity, creating a self-
reinforced loop. This loop can be interrupted by increasing the cellular 
levels of H2O2 (using e.g. pro-oxidant agents), or by attenuating 
glycolysis (using glycolysis inhibitors), or a combination of both 
(López-Lázaro, 2010).  
 
In fact, many anticancer agents, such as paclitaxel, doxorubicin and 
arsenic trioxide, produce H2O2  (Alexandre, et al., 2006; Jing, et al., 
1999; Ubezio and Civoli, 1994). Also, using several cancer and normal 
cell lines, Chen, et al.  (2005) observed that high concentrations of 
ascorbic acid selectively killed cancer cells and that this effect was 
mediated by H2O2. Several glycolysis inhibitors have shown anticancer 
effects (e.g. 2-deoxy-D-glucose, lonidamine, 3-bromopyruvate and 
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dichloroacetate) and some of them have already entered clinical trials  
(Chen, et al., 2007; Gatenby and Gillies, 2007; Lopez-Lazaro, 2008; 
Martin, 2006; Pelicano, 2006; Xu and Huang, 2006). For example, it 
has been shown that dichloroacetate, a known glycolysis inhibitor 
that has been used in humans for decades in the treatment of lactic 
acidosis and inherited mitochondrial diseases, induced marked 
anticancer effects in mice (Bonnet, et al., 2007). Other strategies that 
might also be used to exploit the increased glycolytic activity of cancer 
cells and selectively kill these cells, are inhibition of the Na+/K+-
ATPase pump (e.g. by cardiac glycosides), or of cellular systems 
involved in the extrusion of (acid-death inducing) protons from the 
cytosol.  
 
Because of the dual role of autophagy in cancer, it is difficult to 
predict whether inhibition or stimulation of autophagy may result in 
tumor cell death (Apel, et al., 2009). Preclinical studies with 
chloroquine, which inhibits lysosome acidification and thereby 
autophagy, in conjunction with alkylating agents, showed remarkable 
efficacy inhibiting tumour growth in mice (Amaravadi, et al., 2007). 
Alternatively, promoting autophagy might also be expected to limit 
tumor progression. Hence, before autophagy can be targeted for the 
treatment of cancer, further studies investigating the dichotomy of its 
roles in tumor prevention and promotion are warranted (Rosenfeldt 
and Ryan, 2009). 
 
Another aspect of the metabolic switch that takes place during 
neoplastic progression concerns the concurrent increase in protein 
production, and hence, ribosome biogenesis. Though this has long 
remained a largely unexploited target in cancer therapy, increasing 
attention is being paid to inhibitors of rRNA synthesis for the 
development of novel therapeutic strategies (Drygin, et al., 2010). For 
example, CX-3543, a small molecule nucleolus-targeting agent that 
selectively disrupts nucleolin/rDNA complexes in the nucleolus, 
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thereby inhibiting Pol I transcription and inducing apoptosis in cancer 
cells, is currently being evaluated for treatment of 
carcinoid/neuroendocrine tumors in a phase II clinical trial (Drygin, et 
al., 2009). Some classic anticancer therapeutics, including cisplatin 
and 5-fluorouracil, have even been shown to exert their activity, at 
least partially, through disruption of ribosome biogenesis (Ghoshal 
and Jacob, 1997; Jordan and Carmo-Fonseca, 1998).  
 
In addition, studies indicate that many common and specialized 
mRNA export factors, including CRM1 and eukaryotic translation 
initiation factor 4E (eIF4E), are disregulated in cancer, making them 
also attractive therapeutic targets (Siddiqui and Borden, 2011). 
Indeed, specific targeting of the eIF4E-dependent mRNA export 
pathway in a phase II proof-of-principle trial with ribavirin led to 
impaired eIF4E-dependent mRNA export, correlating with clinical 
responses including remissions in leukemia patients (Assouline, et al., 
2009). 
 
Immune destruction of cancer cells 
The ability of cells of the immune response system to infiltrate tumors 
presents a unique opportunity for combating cancer cells. Tumors are 
replete with potential antigens, which can become immunogenic when 
presented by DCs, activating the different arms of cell-mediated 
resistance (Steinman and Banchereau, 2007). This means that the 
resulting immune attack can encompass multiple targets, diminishing 
the cancer’s chances of immune escape. Following recognition of 
tumor-specific antigens, T lymphocytes exert their cytotoxic effects on 
tumor cells via the extrinsic apoptosis pathway, involving Fas, and via 
the secretion of perforin and serine proteases granzyme A and B 
(Pardo, et al., 2004). Perforin is a transmembrane pore-forming 
molecule, which allows granzyme A and B to enter the target cell and 
induce apoptosis. Granzyme A activates caspase-independent 
pathways by inducing single-stranded DNA damage, while granzyme B 
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directly activates caspase-3, and can also cleave Bid to induce the 
release of cytochrome c (Rousalova and Krepela, 2010). There is also 
evidence that DCs themselves can acquire killer activity and express 
granzyme and perforin.  
 
Several strategies are being employed in the field of tumor 
immunology, including the use of monoclonal antibodies against 
specific tumor-associated antigens to achieve steric inhibition and 
neutralization, complement activation, and activation of cell-mediated 
cytotoxicity, and so-called “cancer vaccines” (Dougan and Dranoff, 
2009).  
 
Vaccination against infectious diseases has proven to be one of the 
great successes of modern medicine, inducing efficient, specific 
activation of cytotoxic T lymphocytes, as well as the generation of 
memory cells, protecting against future infection. Translation of this 
knowledge for the prevention and treatment of cancer has not been 
straightforward, with, among other things, the selection of appropriate 
target antigens proving a difficult task, as well as the design and 
interpretation of clinical trials for this novel class of cancer 
therapeutics (Lesterhuis, et al., 2011; Palucka, et al., 2011). One 
example showing great promise with regard to cancer prevention is 
the development of two human papilloma virus-derived vaccines for 
the prevention of cervical cancer  (Lowy and Schiller, 2006). As for 
therapeutic vaccination, a series of clinical trials have recently yielded 
encouraging results. First, treatment of metastatic prostate cancer 
with sipuleucel-T, a cellular vaccine based on enriched blood DCs 
briefly cultured with a fusion protein of prostatic acid phosphatase 
with GM-CSF, resulted in an approximately 4-month–prolonged 
median survival in phase III trials  (Kantoff, et al., 2010). Sipuleucel-T 
has been approved by the FDA for treatment of metastatic prostate 
cancer, thereby paving the clinical development and regulatory path 
for the next generation of cellular immunotherapy products. Second, a 
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phase III trial in metastatic melanoma testing peptide vaccine in 
combination with high dose IL-2 versus IL-2 alone showed significant 
improvement in overall response rate and progression-free survival in 
patients who received the vaccine  (Schwartzentruber, et al., 2011). 
Third, a phase III trial in patients with follicular lymphoma showed 
that idiotype vaccine therapy (BiovaxID) significantly prolongs the 
duration of chemotherapy-induced remission  (Morse and Whelan, 
2010). Furthermore, a randomized phase II trial of a poxviral-based 
vaccine targeting a prostate-specific antigen (PROSTVAC) in men with 
metastatic castration-resistant prostate cancer showed an improved 
overall survival in patients when compared with patients receiving 
control vectors (an observed difference in median survival of 8.5 
months)  (Kantoff, et al., 2010b). 
 
In the sipuleucel-T example described above, DCs are generated ex 
vivo, loaded with tumor antigens, and re-injected to induce strong T-
cell and perhaps also natural killer immunity. Another, novel, 
approach to cancer vaccines is based on the delivery of antigens 
directly to dendritic cells (DCs) in vivo, using chimeric proteins made 
of anti-DC receptor antibody fused to a selected antigen (DC 
targeting). Studies in mice demonstrate that DC targeting results in 
considerable potentiation of antigen-specific T cell immunity. The 
induction of immunity is observed only when the DC maturation 
signal is provided, as, otherwise, tolerance ensues  (Bonifaz, et al., 
2002; Hawiger, et al., 2001). A major challenge of this approach will 
be to elicit T cell responses that are sufficiently robust and long 
lasting so as to be clinically active. Indeed, the efficacy of DC targeting 
in vivo needs to be established in clinical trials in patients, and early 
studies are ongoing.  
 
Besides the molecular make-up of the tumor itself, 
immunotherapeutic approaches also need to consider that of the 
tumor micro-environment, and aim to trigger a multi-facetted immune 
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response involving humoral, cellular, and innate immunity (Poschke, 
et al., 2011). Recent studies have attempted to relieve the suppression 
of immune activity in the tumor micro-environment (imposed by the 
cancer cells) by blocking inhibitory signals using monoclonal 
antibodies, showing promising results (such as blocking cytotoxic T-
lymphocyte antigen-4, CTLA-4, with the monoclonal antibody 
ipilimumab)  (Hoos, et al., 2010). Additional efforts to either directly 
target MDSC or their suppressive mechanisms should aid the 
development of successful combination-immunotherapies. Due to 
their immature nature, a potential way to remove MDSC is to force 
them to differentiate, for example, by using all-trans retinoic acid 
(ATRA) or vitamin D3, which promotes myeloid differentiation and has 
been clinically applied (Lathers, et al., 2004; Mirza, et al., 2006). 
 
Exploiting genomic instability  
The genetic instability that is characteristic of cancer cells can be both 
good and bad for anticancer therapy. Although it seems to provide an 
Achilles' heel that many conventional therapies exploit, genetic 
instability can also make eradicating cancer more difficult. Because of 
the abnormally high mutability of many cancer cells, most malignant 
tumor cell populations are heterogeneous in many respects, which 
may make them difficult to target with a single type of treatment. 
Moreover, this mutability allows many cancers to evolve resistance to 
therapeutic drugs at an alarming rate (Rajagopalan and Lengauer, 
2004). 
 
The novel “synthetic lethal” approach aims to exploit defects in DNA 
repair pathways using a new theory (Yap, et al., 2011). This theory 
proposes that targeting tumor cells, genetically defective in one given 
pathway, with a specific molecular therapy, designed to inhibit a 
“synthetic lethal” gene partner involved in a complementary pathway, 
results in selective tumor cell killing. Studies have shown that breast 
cancer cells, defective in homologous recombination due to BRCA1/2 
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defects are highly sensitive to blockade of the base excision repair 
(BER) pathway via inhibition of the poly (ADP-ribose) polymerase 
(PARP) enzyme, providing strong evidence for the clinical application of 
this approach (Bryant, et al., 2005; Farmer, et al., 2005). PARP 
inhibitors might also be used in combination with standard radio- and 
chemotherapy to sensitize cells to cytotoxic DNA damage; additionally, 
some PARP inhibitors seem to possess anti-angiogenic activity, 
making their application in the clinic even more attractive  (Mangerich 
and Bürkle, 2011).  
 
The synthetic lethal concept has also been applied for the treatment of 
p53-deficient cancers, which, as discussed before, occur rather 
frequently. Loss of p53 function renders cells dependent on the 
checkpoint kinase Chk1 for activation of cell cycle checkpoints; hence, 
inhibition of Chk1 in the presence of DNA damage or replicative stress 
should lead to mitotic catastrophe and cell death in p53-deficient 
tumors while sparing normal cells. Several Chk1 inhibitors have now 
been developed; after showing promising results in preclinical models, 
they are currently being evaluated in phase I clinical trials (Ma, et al., 
2011).  
 
Proteins selectively killing tumor cells 
In recent years, a unique set of molecules possessing a remarkable 
ability have been identified: these proteins are able to detect the 
malfunctioning of a presumably shared set of cancer-critical genes, 
and selectively kill the corresponding tumor cells, leaving the normal 
cells unharmed. Among these proteins killing tumor cells (PKTC) are 
the human cytokines TRAIL and MDA7/IL24, the frog-derived 
Brevinin-2R, the human pro-apoptotic Par-4 and Noxa proteins and 
the organic cation transporter-like 3 (ORCTL3), the alpha-lactalbumin 
and oleic acid complex HAMLET, and the viral proteins adenovirus 
E4ORF4, parvovirus NS1, and the Chicken Anemia Virus-encoded 
protein apoptin (Bruno, et al., 2009; Grimm and Noteborn, 2010; 
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Argiris, et al., 2011). As these PKTC appear to function independently 
of the type of cancer, their therapeutic potential seems 
unprecedented. Apoptin, the first of these proteins to be discovered, 




Apoptin is the protein product of the VP3 gene of the Chicken Anemia 
Virus (CAV; Noteborn, et al., 1994). The pathogenesis of CAV infection 
and discovery of apoptin will be discussed in section 2.6.1, while the 
characteristics of apoptin and perspectives for application as an anti-
cancer agent are discussed in sections 2.6.2 and 2.6.3, respectively.  
 
2.6.1 Chicken Anemia Virus 
In young chicks, CAV infection results in severe anemia and 
immunodeficiency (among other symptoms), owing to apoptosis of the 
cells in the thymus, bone marrow and spleen (Noteborn and Koch, 
1995).  Early after infection, a 2.3 kb polycistronic mRNA is 
transcribed, encoding three genes: the capsid protein VP1, the scaffold 
protein and phosphatase VP2, and VP3 (apoptin) (Noteborn, 2004). 
Later on in the infection, splicing of the CAV mRNA produces 
additional RNA products; it is however not known whether these 
result in functional proteins (Kamada, et al., 2006).  
 
Studies in transformed chicken cells in culture proved that apoptin 
was responsible for the CAV-induced apoptosis (Noteborn, et al., 
1994). Apoptin demonstrated the same apoptosis activity in human 
cancer cell lines, but, surprisingly, not in normal human cells 
(Backendorf, et al., 2008; Danen-van Oorschot, et al., 1997;  
Noteborn, et al., 2005; Tavassoli, et al., 2005). This makes apoptin 
itself an interesting protein for therapeutic treatment of cancer cells, 
but also an interesting tool to investigate the process of oncogenic 
transformation, thereby uncovering other novel targets for anticancer 
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therapies. Furthermore, apoptin may also prove useful in the 
diagnosis of cancer, e.g. based on its ability to be specifically 
phosphorylated by tumor cell lysates (see below). 
 
2.6.2 Characteristics of apoptin-induced apoptosis 
Apoptin is a small (121 aa), proline-rich protein, exhibiting little 
homology to any other known protein – including its functional 
equivalent TAIP, encoded by the TT virus (Kooistra, et al., 2004). 
Tumor-selective apoptosis induction by apoptin is preceded by a) 
phosphorylation at T108 (Rohn, et al., 2002), and b) nuclear 
translocation  (Danen-van Oorschot, et al., 2003) (Figure 2.5). These 
effects are characteristic for the transformed environment, as they are 
also elicited upon transient transformation of normal human cells by 




Figure 5. Characteristics of tumor-selective apoptosis induction by apoptin. A. In 
normal cells (left panel), apoptin is located in the cytoplasm, and can be found in 
granules extending to the cell membrane. In tumor cells (right panel), apoptin is 
located in the nucleus and induces apoptosis (arrow indicates dying cell). B. In 
tumor cells, but not in normal cells, apoptin is phosphorylated at position T108. 
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The detailed mechanisms behind both the up- and downstream 
pathways of apoptin activity in transformed and cancer cells are yet to 
be elucidated. A number of apoptin-interacting proteins have been 
identified, including Hippi, the protein interactor and apoptosis co-
mediator of the huntingtin interacting protein 1 (Cheng, et al., 2003), 
and Rybp/DEDAF, a transcription factor and proapoptotic protein 
known to associate with the death effector domain-containing DNA 
binding protein DEDD (Danen-van Oorschot, et al., 2004). 
 
Furthermore, apoptin has been shown to act through the intracellular 
apoptosis pathway, involving the translocation of Nur77 from the 
nucleus to the cytoplasm, as well as p73 and PUMA activity (Klanrit, 
et al., 2008; Maddika, et al., 2005). Apoptin expression enhances the 
level of the tumor suppressor ceramide in tumor cells, also implicating 
the involvement of sphingolipids in apoptin-induced cell death (Liu, et 
al., 2006a, b).  
 
2.6.3 Perspectives for apoptin anti-tumor therapy 
Though its pathway of action remains to be clarified, apoptin has 
demonstrated several features that make it well suited for cancer 
therapy. Besides the fact that it has been shown to selectively kill 
tumor and transformed cells, apoptin has also been shown to act 
independently of p53 (Teodoro, et al., 2004; Zhuang, et al., 1995). 
Furthermore, it is insensitive to BCR-ABL and Bcl-XL (Backendorf, et 
al., 2008; Noteborn, et al., 2005), which suggests that apoptin might 
induce apoptosis in cases where other (chemo)therapeutics might fail. 
The results of the first preclinical therapeutic studies, discussed 
below, are very promising. 
 
Apoptin cancer therapy using adenoviral vectors 
Pietersen and colleagues developed a strategy for the use of apoptin in 
cancer therapy based on adenoviral vectors (Pietersen, et al., 1999). A 
single injection of the apoptin-producing adenovirus in xenografted 
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hepatomas in nude mice resulted in a delay in tumor growth. The 
number of proliferating cells as detected by BrdU-labeling was 
dramatically decreased in the apoptin-transduced regions versus 
control-treated tumors (Van der Eb, et al., 2002). Importantly, the 
apoptin-producing adenovirus did not have appreciable toxic effects 
when injected intraperitoneally, intravenously, or subcutaneously into 
healthy rats. Further studies using these and other non-replicative 
viruses, including a fowlpox virus–based vector, used a regimen of 
multiple intratumoral injections during several days. These 
approaches resulted in a significant overall survival benefit for the 
apoptin-treated mice and, in some cases, depending on the overall 
transduction efficiency, complete regression of the established tumor 
(Noteborn, 2009).  
 
PDT4-apoptin - topical cancer treatment 
Guelen and coworkers fused apoptin to the HIV-TAT protein 
transduction domain, demonstrating efficient transduction of apoptin 
into both normal and tumor cells, while preserving its tumor-selective 
apoptotic properties (Guelen, et al., 2004). Sun and colleagues used a 
similar fusion product, employing protein transduction domain 4 
(PTD4)-mediated transduction of recombinant apoptin protein, to treat 
tumors that had been xenografted onto nude mice (Sun, et al., 2009). 
In contrast to the gene therapy-based studies discussed above, PTD4-
apoptin was administered by simple application onto the epidermis. 
Remarkably, though the protein could be detected in the epidermal 
tissue covering the subcutaneous tumor tissue and in several internal 
organs of the mice, cell death was only observed inside the tumor 
mass.  
 
Recently, Jin and colleagues (Jin, et al., 2011) reported that PTD4-
apoptin protein and dacarbazine acted synergistically to reduce tumor 
growth in a mouse melanoma model. Importantly, the combination 
with PTD4-apoptin allowed for a 50% reduction in the dosage of 
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dacarbazine, resulting in comparable reduction of tumor-growth, 
without any detectable hematological side-effect.  
 
Systemic apoptin treatment and organ-specific targeting 
Peng et al. showed that apoptin can be safely administered 
systemically, and used a specific ligand to the asialoglycoprotein 
receptor to target apoptin specifically to the liver (Peng, et al., 2007). 
Delivery of this Asor-apoptin via the tail vein into mice bearing in situ 
hepatocarcinomas resulted in specific and efficient distribution of 
apoptin in both hepatocarcinoma cells and normal liver cells. Whereas 
the former cells showed significant signs of regression, the normal 
hepatocytes were clearly not affected. 
 
Specific targeting of apoptin to the brain is currently being developed 
by de Boer and coworkers. Using the nontoxic ligand CRM197 (a 
mutant of the diphtheria toxin), the membrane-bound precursor of 
heparin-binding epidermal growth factor (HB-EGF), also known as the 
diphtheria toxin receptor (DTR), can be targeted. This receptor is 
constitutively present at the blood-brain barrier and is strongly up-
regulated in many tumors, including human glioblastoma (Mishima, 
et al., 1998). Biopharmaceutical drugs have been selectively delivered 
to the brain via this receptor (Gaillard, et al., 2005). An apoptin-
expressing plasmid coupled to CRM197 has been successfully 
delivered to human glioblastoma cells in vitro through receptor-
mediated endocytosis (Rip, et al., 2009). The combination of apoptin 
antitumor therapy and CRM197-targeting technology thus provides a 
great opportunity for development of targeted therapy for brain 
tumors.  
 
Combination therapy with apoptin and chemo- or radiotherapy 
The combination of apoptin therapy with chemotherapeutic agents 
has been reported to enhance cytotoxicity to human tumor cells in 
vitro (Olijslagers, et al., 2007). Combined treatment of recombinant 
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adenovirus expressing apoptin with different concentrations of 
etoposide clearly showed an additive cytotoxic effect in human 
osteosarcoma U2OS cells. Paclitaxel combined with apoptin acted 
additively in p53-positive human osteosarcoma U2OS and nonsmall 
cell lung carcinoma A549 cells, p53-negative osteosarcoma Saos-2 
cells, and p53-mutant prostate cancer Du145 cells. Finally, apoptin 
was proven to be coeffective when combined with the 
chemotherapeutic agent methotrexate (Zhang, et al., 2007).  
 
Recently, apoptin has also been combined with other treatments in 
vivo. As discussed above, apoptin expression modulates the ceramide-
sphingolipid pathways leading to enhanced ceramide levels (Liu, et al., 
2006). The majority of prostate tumors have elevated acid ceramidase 
levels compared with neighboring normal prostate tissue (Liu, et al., 
2006). In vitro, up-regulated acid-ceramidase protected cells from 
apoptin-induced apoptosis, whereas cotreatment with the acid-
ceramidase inhibitor LCL204 sensitized cells for apoptosis. In vivo, 
combined treatment enhanced the antitumor activity of apoptin in 
xenografted prostate tumors in mice, resulting in significantly reduced 
tumor growth and increased animal survival.  
 
Lian and colleagues combined apoptin treatment with interleukin-18 
(IL-18) and reported that combined administration results in an even 
higher induction of an effective antitumor immune response and 
tumor regression (Lian, et al., 2007). IL-18 and apoptin appear to 
affect tumors via complementary pathways. Whereas apoptin directly 
targets the tumor cells, IL-18 treatment appears to act via enhancing 
the immune response toward tumor cells. Finally, Schoop et al. 
showed that treatment of a radioresistant head- and neck cancer cell 
line with apoptin concurrently with exposure to irradiation sensitized 





Tumor-selective targeting using apoptin NLS 
Rather than using apoptin itself, or one of its cellular targets, to 
design anti-cancer therapies, Wagstaff and Jans propose the use of 
apoptin’s tumor-selective NLS (74-121) to target drugs specifically to 
the nucleus of tumor cells (Wagstaff and Jans, 2009). Delivery of 
cytotoxic agents directly to the heart of the tumor cell should result in 
efficient tumor cell killing without affecting healthy neighboring cells. 
 
2.7 Synopsis 
The new era of genomics and proteomics carries with it a great 
promise: that for every disease, the blueprint of the defective cell can 
be compared with that of a healthy one, thereby not only facilitating 
the identification of the root of the problem, but also, and more 
importantly, allow one to charter an efficient route to fix it. Drawing 
up the blueprint of a cancer cell has proven to be a difficult task. Even 
so, a complex map of intracellular pathways is starting to emerge, 
with a number of essential traits being seemingly shared by all 
transformed cells. The CAV-derived apoptin apparently senses these 
characteristics and effectively charters its own route to selectively kill 
malignant cells. The properties of apoptin and functionally related 
proteins, combined with newly developed therapeutics targeting the 
hallmark capabilities and enabling characteristics of cancer cells, 
should finally lead to the development of selective, efficient and robust 
therapies for cancer – instead of the long sought-after “magical bullet” 
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Recently, a select number of viral and cellular proteins sharing a 
unique property have been identified, namely apoptin, HAMLET, 
TRAIL, MDA7, E4ORF4, NS1 and Brevinin-2R, where all have the 
remarkable ability to selectively kill transformed and/or tumour cells, 
while causing no or only minor cytotoxicity in normal and non-
transformed cells. Research worldwide is now starting to unravel the 
molecular signalling pathways by which each of these proteins exerts 
its tumour-selective function, and the first (pre)clinical studies are 
very promising. The workshop ‘Proteins Killing Tumour Cells’ brought 
together, for the first time, researchers working on this novel class of 
intriguing proteins. Participants from 14 different countries shared 
their views on (possible common) mechanisms behind tumour-specific 
apoptosis induction and strategies to implement this knowledge in the 
clinic. 
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Cellular Transformation and Apoptosis 
The ability of certain viral and cellular proteins to induce tumour-
selective apoptosis implies the existence of a common set of 
characteristics, shared by all tumour cells, and recognized by these 
tumour-killing proteins (see Table 3-1). Mathieu Noteborn highlighted 
the delicate balance between survival and death pathways in normal 
and transformed cells, thereby effectively setting the theme of the 
meeting. Michael Green (University of Massachusetts, USA), using a 
genome-wide RNA interference screen, implicated secreted IGFBP7 
(insulin-like growth factor binding protein 7) in the induction of 
senescence and apoptosis by oncogenic Braf. Paradoxically, 
overexpressing both proteins in normal melanocytes induced 
senescence, whereas in melanoma cells this resulted in apoptosis. 
James Pipas (University of Pittsburgh, USA) discussed the role of 
different domains of the SV40 large T antigen in oncogenic 
transformation. For instance, the N-terminal J-domain, in 
combination with the LXCXE domain, induces cellular proliferation by 
inactivating Rb and liberating E2Fs from repression. Additionally, 
microarray analysis revealed a new ‘detoxification’ function for the C-
terminal domain of the large T antigen via the p450 pathway. Jason 
Arroyo from the Hahn group (Dana Farber Cancer Institute, USA) 
explained how the SV40 small T antigen contributes to the induction 
of transformation by inhibiting the protein phosphatase 2A (PP2A) 
family. Specific subunits of these heterotrimeric proteins are 
implicated in cell transformation: RNAi knockdown of the B56γ-
subunit and mutation of the Aβ-subunit both promote transformation, 
whereas deletion of the Aα-subunit results in apoptosis. A common 
target of both transforming and tumour-selective apoptosis-inducing 
viral proteins appears to be the anaphase-promoting complex (APC). 
As illustrated by Jose Teodoro (McGill University, Canada), 
knockdown of the APC1 subunit by siRNA resulted in G2M cell cycle 
arrest and apoptosis in human tumour cells. Strikingly, this effect is 
mimicked by APC inactivation through interaction with either apoptin 
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or adenovirus E4orF4, two proteins discussed during this meeting, 
thus revealing a common pathway. 
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HAMLET 
Catharina Svanborg (Lund University, Sweden) introduced HAMLET 
(Human α-lactalbumin made lethal to tumour cells), a complex 
between the milk protein α-lactalbumin and oleic acid. HAMLET kills 
tumour and immature cells but not healthy differentiated cells by a 
mechanism independent of caspase activation, Bcl-2 and p53. 
Svanborg showed that macroautophagy is involved in HAMLET-
induced cell death, as siRNA downregulation of the Beclin1 and Atg5 
markers rescued HAMLET-treated cells. In clinical trials with bladder 
cancer patients, HAMLET exerted a direct and selective cytotoxic effect 
on the cancer tissue, whereas in patients with skin papillomas it 
resulted in complete resolution of 29 out of 35 treated papillomas. 
Christel Rothe Brinkmann discussed a bovine variant of HAMLET with 
similar cytotoxicity as the human homologue. 
 
Brevinin-2R 
Brevinin-2R-triggered cell death also involves autophagy and does not 
require caspase activation. The 25-aa peptide, presented by Marek Los 
(University of Manitoba, Canada), is a non-haemolytic defensin 
isolated from the skin of the frog Rana ridibunda and induces cell 




Los also reported on the chicken anaemia virus-encoded protein 
apoptin, which induces apoptosis in numerous cancer and 
transformed cells, but leaves normal healthy cells unharmed. Los 
identified the nuclear orphan receptor Nur77 as a crucial component 
Proteins killing tumor cells 
97 
of apoptin-induced cell death. In addition, he found that apoptin 
interacts with and activates Akt kinase, leading to nuclear localization 
of Akt. 
 
Apoptin's tumour-selective cytotoxicity appears to be associated with 
nuclear localization and phosphorylation on T108. The nuclear 
targeting signal within apoptin comprises a bipartite nuclear import 
signal flanking a nuclear export signal. David Jans (Monash 
University, Australia) proposed a model where, selectively in cancer 
cells, NES function is inhibited by phosphorylation of apoptin on 
Thr108, resulting in nuclear accumulation. Dongjun Peng (Huazhong 
University, China) showed, in collaboration with the Leiden group, 
that transient expression in normal fibroblasts of the SV40 
large/small T antigens is sufficient to induce apoptin's nuclear 
localization, phosphorylation and apoptosis. Interestingly, 
suppression of PP2A activity by the small T antigen (see Arroyo, above) 
appears to play a major role in this process. Paola Bruno from the 
Tavassoli group pointed out that low levels of apoptin phosphorylation 
can be detected in normal early passage fibroblasts infected with 
adenovirus expressing apoptin fused to GFP. Apparently, apoptin 
kinase activity is present in normal cells but has very low activity, 
whereas in tumour cells it is highly activated. 
 
Rhyenne Zimmerman introduced a number of apoptin-interacting 
partners (AIPs) identified by the yeast two-hybrid technique. 
Strikingly, these AIPs are all known or putative tumour-suppressor 
genes or oncogenes, likely to be implicated in the differential 
behaviour of apoptin in normal and cancer cells. Poramaporn Klanrit 
showed for the first time (in collaboration with the Melino group 
(University of Rome, Italy) that apoptin is able to activate TAp73 and 
its downstream pro-apoptotic target PUMA, independently of p53 
function. Joseph Cheng from the Norris group (University of South 
Carolina, USA), reported on the implication of the ceramide pathway 
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in the tumour-selective activity of apoptin. In prostate cancer cells, 
apoptin expression results in ceramide upregulation and acid 
ceramidase inhibitors can significantly enhance apoptin cytotoxicity 
both in prostate cancer cell lines and tumour xenografts. 
 
Several groups discussed the use of a protein transduction strategy to 
deliver apoptin via the TAT protein transduction domain from HIV-1. 
Joop Gäken (King's College London, UK) investigated the potential of 
transduced apoptin to purge haemopoietic stem cells of malignant 
leukaemia cells, for use in autologous transplantation. His-tagged 
TAT-apoptin protein was shown to induce apoptosis in leukaemic cells 
but not in normal blood lymphocytes. Marcella Flinterman presented 
a novel mammalian secretable delivery system, using a modified TAT-
tag. Jun Sun (Huazhong University, China) reported topical 
application of PTD4-apoptin onto the tumour bearing skin of immune-
deficient mice. Apoptosis and disruption of the tumour integrity were 
apparent, whereas the surrounding normal tissue was not affected. 
 
E4orf4 
Similar to HAMLET and apoptin, over-expression of the adenoviral 
E4orf4 protein triggers p53-independent cell death in transformed and 
cancer cells, without necessitating caspase activation or mitochondrial 
dysfunction. However, as explained by Josée Lavoie (Laval University, 
Canada), E4orf4 killing requires Src tyrosine kinases and RhoGTPase-
dependent perturbations of actin dynamics on endosomes. The traffic 
of recycling endosomes to the trans-Golgi is deregulated in a Cdc42- 
and Rab11a-dependent way, contributing to cell death. Furthermore, 
E4orf4 inhibits, by direct binding, v-Src-induced morphological 
transformation. These data support a key function for Src tyrosine 
kinases and actin-regulated endosome traffic in the tumour-selective 
killing activity of E4orf4. 
 
 
Proteins killing tumor cells 
99 
TRAIL 
TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) 
selectively induces death receptor-mediated apoptosis in several 
cancer cell lines. Robbert Cool (University of Groningen, the 
Netherlands) discussed the binding of TRAIL to the death receptors 
DR4 and DR5, the decoy receptors DcR1, DcR2 and osteoprotegerin. 
To avoid sequestering by the decoy receptors, Cool developed DR5 
receptor-selective TRAIL variants with improved thermal stability. 
Henning Walczak (DKFZ Heidelberg, Germany) introduced the TRAIL 
receptor agonists currently enrolled in phase I and II clinical trials, 
including TRAIL/Apo2L and antibodies against DR4 and DR5. TRAIL 
monotherapy is rarely effective, as most primary tumours seem to be 
TRAIL resistant. Walczak discussed how this might be circumvented 
by combination therapy with either chemotherapy or ionizing 
radiation (IR). Jannie Borst showed how TRAIL, in a soluble 
isoleucine-zippered form, as produced by Walczak and coworkers, 
enhances indeed the efficacy of radiotherapy. The apoptotic pathway 
induced by IR is blocked by Bcl-2, indicating that a mitochondrial 
contribution is required for caspase activation and cell death. 
Interestingly, pretreatment of Bcl-2 overexpressing cancer cells with 
IR makes the cells more susceptible to TRAIL-induced cell death. 
 
MDA7 
Rajagopal Ramesh (University of Texas, USA) showed that expression 
of the melanoma differentiation associated gene-7 (MDA7), also known 
as interleukin-24 (IL-24), in lung cancer and melanoma is inversely 
correlated with cancer progression and patient survival. MDA7/IL-24 
selectively killed human cancer cells both in vitro and in vivo, with 
minimal effect on normal cells. In clinical phase I trials MDA7 was 
well tolerated and showed evidence of significant clinical activity 






Jean Rommelaere (DKFZ, Heidelberg, Germany) discussed the 
tumour-specific cell killing properties of parvovirus minute virus of 
mice (MVM) and its encoded protein NS1, responsible for MVM-
induced cytotoxicity. MVM can kill tumour cells resistant to standard 
cytotoxic agents such as cisplatin or TRAIL. The efficacy of MVM in a 
rat glioma model was illustrated by the complete remission of 
intracranial tumours, without side effects, and with no tumour 
relapse for over 1 year. Investigations of the molecular mechanism of 
NS1-dependent cell killing revealed that acidic vesicles accumulate in 
the cytosol of MVM-infected cells, leading to the cytosolic 
accumulation of cathepsins and activation of cathepsin B, which, in 
turn, leads to the activation of autophagy. NS1 exerts its toxicity by 
interacting with casein kinase II-α (the catalytic domain of CKII). 
 
Conclusions 
Apoptin, E4ORF4, NS1, HAMLET, TRAIL, MDA7 and Brevinin-2R are 
part of a new family of proteins, consisting of both cellular and viral 
proteins that use various mechanisms of cell death, but share one key 
feature: their killing activity is efficient in transformed and cancer 
cells and negligible in normal and healthy cells. A potential new 
member of this tumour killing protein family, IGFBP7, was introduced 
during the meeting. Besides the obvious applications for tumour 
targeting, these proteins also constitute very sensitive probes to zoom-
in onto essential molecular and cellular changes during carcinogenic 
transformation. The workshop was unanimously assessed as very 
stimulating, bringing together for the first time various research 
groups working on different proteins but all with similar potentials for 
cancer therapeutics. As one participant stated: ‘We all thought we 
were orphans, but now we know we are family’. 
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Table 3-1 Direct comparison of various properties of proteins killing tumour cells. 
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Since the first PKTC meeting, a number of other proteins exhibiting tumor-
selective toxicity have been identified. These will be discussed below.  
 
Noxa 
Noxa is a BH3-only protein with proapoptotic activity that functions 
downstream of the p53-mediated apoptotic pathway. It was recently found to 
selectively induce apoptosis in tumor cells (Suzuki, et al., 2009). Infection 
with a recombinant adenovirus, contrived to express the Noxa gene, induced 
apoptosis in several human breast cancer cell lines in vitro, but not in 
normal mammary epithelial cell lines. Furthermore, intratumoral injection of 
the Noxa-expressing adenovirus resulted in marked shrinkage of 
transplanted tumors derived from breast cancer cells, without any notable 
adverse effect on the surrounding normal tissue. In contrast, the expression 
of Puma, another BH3-only protein that also functions downstream of the 
p53 pathway, induced apoptosis in both cancer and normal cells. Thus, the 
results suggest a mechanism wherein Noxa, but not Puma, selectively 
induces apoptosis in human tumor cells. 
 
ORCTL3 
The organic-cation transporter like-3 gene (ORCTL3) was identified in a 
systematic, high-throughput screen for genes specifically inducing cell death 
in transformed tumor cells (Irshad, et al., 2009). ORCTL3 was found to be 
inactive in normal rat kidney cells (NRK), but induced apoptosis in NRK cells 
transformed by oncogenic H-ras. ORCTL3 also induced cell death in v-src-
transformed cells and in various human tumor cell lines but not in normal 
cells or untransformed cell lines. Accordingly, ORCTL3 was shown to be 
down-regulated in human kidney tumors. Though ORCTL3 is a member of 
the organic-cation transporter gene family, data indicate that it induces 
apoptosis independently of its putative transporter activity. Rather, 
experimental evidence suggest that ORCTL3-induced apoptosis is executed 
via an ER stress mediated mechanism.  
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Par-4 
The prostate apoptosis response-4 (par-4) gene was first identified as an 
immediate early apoptotic gene, which was up-regulated in response to 
elevated intracellular Ca2+ concentration in rat prostate cancer cells treated 
with ionomycin. Human Par-4, which was found to share significant 
sequence similarity with its rat counterpart, was subsequently identified in 
yeast-two hybrid studies as a partner of the atypical Protein Kinase C  (Diaz-
Meco, et al., 1996) and tumor suppressor Wilm’s tumor-1  (Johnstone, et al., 
1996). Studies conducted in cell culture models show that over-expression of 
Par-4 is sufficient to directly induce apoptosis in many cancer cell types, and 
that this ability is associated with Par-4 nuclear translocation. Moreover, the 
apoptotic action of Par-4 can overcome cell protective mechanisms, such as 
the presence of Bcl-xL, Bcl-2, or absence of wild-type p53 or PTEN function 
(Shrestha-Bhattarai and Rangnekar, 2010). Interestingly, Par-4 is retained 
in the cytoplasm of normal and immortalized cells through an as yet 
unidentified mechanism, rendering it incapable of inducing apoptosis in 
these cells.  
 
Accordingly, Par-4 was found to be down-regulated in many cancers, 
including renal cell carcinoma (Cook, et al., 1999), neuroblastoma (Kogel, et 
al., 2001), endometrial cancer (Moreno-Bueno, et al., 2007), and breast 
cancer (Zapata-Benavides, et al., 2009). Animal studies have demonstrated 
that Par-4 knockout mice are prone to spontaneous development of tumors 
in various tissues, e.g. lungs, liver, urinary bladder and endometrium, and 
Par-4 knockout mice are more susceptible to chemical- or hormone-induced 
lesions, exhibiting a significantly shorter life span compared to wild-type 
animals, due to death by spontaneous tumors (Garcia-Cao, et al., 2005). 
Par-4 is down-regulated by oncogenic Ras via the MEK-ERK pathway, and 
this is considered an important step towards Ras-induced transformation. 
Restoration of Par-4 levels, either by MEK inhibition or by stable expression 
of ectopic Par-4, abrogates cellular transformation. This tumor-suppressor 
action of Par-4 appears to be distinct from its apoptotic function (Barradas, 
et al., 1999; Pruitt, et al., 2005; Qiu, et al., 1999). In the case of prostate 
Chapter 3 
104 
cancer, Par-4 is not down-regulated, silenced or mutated, but inactivated 
due to phosphorylation by Akt1, which prevents nuclear translocation of 
Par-4, thereby retaining it in the cytoplasm and rendering it incapable of 
causing apoptosis (Goswami, et al., 2005). 
 
In contrast, phosphorylation of the threonine 155 residue of Par-4 by Protein 
Kinase A (PKA), as well as its nuclear translocation, is essential for Par-4 
apoptotic activity (Shrestha-Bhattarai and Rangnekar, 2010). The apoptotic 
effect of Par-4 involves either an activation of the cellular apoptotic 
machinery or inhibition of the cellular pro-survival mechanisms. Par-4 
induces apoptosis in hormone-independent cancer cells by activation of the 
extrinsic apoptosis cascade through FADD. Therefore, in these cancer cells, 
over-expression of Par-4 is a sufficient signal for cell death (Chakraborty, et 
al., 2001). In parallel, Par-4 translocates to the nucleus and inhibits NF-κB-
mediated cell survival mechanisms (Nalca, et al., 1999).  
 
While most studies on Par-4 focused on the apoptotic effect mediated by 
intracellular Par-4, recent findings indicate it is also secreted by both normal 
and transformed mammalian cells (Burikhanov, et al., 2009). In vitro, Par-4 
secretion could be induced by exogenous stimuli capable of causing stress in 
the endoplasmic reticulum (ER), and secreted Par-4 was shown to induce 
apoptosis via the cell-surface protein GRP78, which is coincidentally also 
found in the ER lumen. Par-4 was also found to be secreted in vivo, and 
could be detected in the serum of Par-4 transgenic mice. In addition, Par-4 
activity in the serum was able to induce apoptosis specifically in cancer 
cells.  
 
In view of these findings, both systemic (extracellular) and intracellular Par-4 
may be applied for cancer therapy. In fact, TRAIL has been shown to cause 
the nuclear translocation of Par-4, and this mechanism is purportedly 
responsible for the ionizing radiation-induced bystander effect triggered in 
response to high-dose X-rays (Shareef, et al., 2007). 
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In tumor cells apoptin is phosphorylated, locates to the nucleus and induces 
apoptosis in contrast to normal cells. The cellular mechanisms providing 
this selectivity are largely unknown. Here, we describe the identification of a 
new interacting partner for apoptin, apoptin interacting protein 3 (AIP3), also 
known as FAM96B, and examine which processes are targeted by apoptin 
via its interaction with this protein. We show that FAM96B interacts with 
apoptin independently of the latter’s tumor-selective phosphorylation. 
Interaction studies including yeast two-hybrid and co-immunoprecipitation 
experiments demonstrated that FAM96B associates with proteins involved in 
DNA transcription, replication and repair, as well as components of the actin 
cytoskeleton. Furthermore, ectopic over-expression of FAM96B alone in 
cancer cells induced apoptosis. The results indicate that, through its 
interaction with FAM96B, apoptin is linked to the fundamental cellular 
processes of DNA repair and cell division. This discovery highlights an 
important part of the mechanisms responsible for tumor-selective cell death 
induced by apoptin. 
 





Recent years have witnessed the development of a new area of cancer 
research, focusing on proteins credited with the ability to selectively kill 
tumor cells (Backendorf, et al., 2009). These proteins are expected to target 
malignant cells more specifically than the anticancer agents that are 
presently used (Los, et al., 2009). Also, whereas current therapies mostly 
result in necrosis of the cancer cells, thus entailing a considerable amount of 
inflammation, these proteins induce cell death through mechanisms such as 
apoptosis and autophagy (Bruno, et al., 2009), potentially providing 
substantial improvement to the treatment of patients.  
 
The chicken-anemia-virus derived protein apoptin has opened the field for 
this type of tumor-selective research. Apoptin has been shown to efficiently 
and safely kill tumors in various preclinical models (Grimm & Noteborn, 
2010). In tumor cells, apoptin becomes phosphorylated and is located in the 
nucleus, whereas in normal cells it is unmodified and present in the 
cytoplasm (Backendorf, et al., 2008). Studies on the underlying mechanisms 
of apoptin-induced tumor-selective cell death have revealed that apoptin 
interacts with proteins such as DEDAF (Danen-van Oorschot, et al., 2004) 
and APC/C1 (Teodoro, et al., 2004). However, the cellular mechanisms 
underlying the activation of apoptin, and its subsequent execution of cell 
death are not yet clear (Agriris, et al., 2011).  
 
Here, we describe that apoptin interacts with apoptin-interacting protein 3 
(AIP3), previously designated FAM96B. Further analysis revealed that 
FAM96B itself interacts with a number of cellular proteins, mostly known to 
be involved in either DNA repair or cytoskeletal organization, offering 
important insights into the mechanisms behind tumor-selective cell death 
induced by apoptin.  
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Materials & methods 
 
Yeast two-hybrid screens 
The Matchmaker yeast two-hybrid kit System 3 was purchased from 
Clontech (Leusden, The Netherlands), and experiments were performed 
according to manufacturer protocol, with a few slight modifications. Briefly, 
a cDNA library derived from human keratinocytes was cloned into the 
leucine-selectable pGAD10yeast expression vector, downstream of the gene 
encoding the GAL4 activation domain (AD). Full-length apoptin or FAM96B 
was cloned downstream of the gene encoding the GAL4 DNA-binding domain 
(BD) in the tryptophane-selectable plasmid pGBKC3 and used as bait in the 
yeast two-hybrid screen. After proper selection, resulting clones were 
sequenced by LGTC (Leiden, the Netherlands).  
 
Cells, plasmids & transfections 
Positive clones from the apoptin yeast two-hybrid screen were digested with 
appropriate restriction enzymes to generate cDNA fragments, which were 
subcloned into pMT2SM-myc, providing the fragments with an in-frame N-
terminal myc-tag (9E10) (Gebbink, et al., 1997) The sequence encoding myc-
tagged FAM96B was then cloned into the pcDNA 3.1 (+) vector to obtain 
pcDNA-myc-FAM96B.  
 
Positive clones from the FAM96B yeast two-hybrid screen were digested with 
appropriate restriction enzymes to generate cDNA fragments, which were 
subcloned into the pIBA105 vector, providing the fragments with an in-frame 
N-terminal strep-tag  (Schmidt and Skerra, 2007) (IBA GmbH, Mannheim, 
Germany). 
 
The DNA sequence encoding apoptin was synthesized by Base-Clear (Leiden, 
the Netherlands), according to the published apoptin sequences (Noteborn, 
et al., 1991) and cloned into the mammalian expression vector pcDNA. The 
final construct was checked by sequencing and named pcDNA-apoptin. Next, 
we generated the pcDNA-Flag-apoptin plasmid encoding apoptin fused with 
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a Flag-tag at its N-terminus. Subsequently, mutations were introduced to 
create flag-apoptinT108E, encoding a mutant apoptin mimicking constitutive 
phosphorylation, and flag-apoptin5Ala106, encoding Flag-apoptin in which 
amino acids 106-110 were replaced by alanines, resulting in a 
phosphorylation-negative mutant apoptin.  
 
The human osteosarcoma cell line Saos-2, VH10/SV40 and human foreskin 
fibroblasts were grown in DMEM, supplemented with 10% newborn bovine 
serum (NBS), and 2 mM L-glutamine.  
 
For transfection experiments, nucleofection technology was used in 
conjunction with cell type specific Nucleofector solution (AMAXA Biosystems, 
Cologne, Germany).  
 
Co-immunoprecipitation and Western blot analysis 
For co-immunoprecipitation experiments, cells were lysed 24h after 
transfection. Cells were washed with cold phosphate buffered saline and 
harvested in ice-cold mild lysis buffer (50mM Tris (pH 7.5), 5mM EDTA, 
250mM NaCl, 0.1% Triton X-100, 5 mM NaF,  1mM Na3VO4, 20mM beta-
glycerolphosphate, and Protease Inhibitor Cocktail (Roche, Almere, the 
Netherlands), followed by incubation on ice for 30 min. The lysate 
supernatant was prepared by centrifugation at 13,000 × g and 4°C for 30 
min, and incubated with indicated antibodies for 90 min, followed by 
incubation with Protein A/G Microbeads (Miltenyi Biotech, Bergisch 
Gladbach, Germany). Magnetic immunoprecipitation was performed 
according to manufacturer protocol. Samples were resolved on sodium 
dodecyl sulfate-polyacrylamide gel, followed by Western blotting analysis 
with appropriate antibodies.  
 
Bioinformatics analysis 
The STRING database was used to identify functional network connectivity 
(Jensen, et al., 2009).  
 




Yeast two-hybrid analysis reveals a novel apoptin interacting protein: 
AIP3/FAM96B   
In order to gain more insight into the mechanism by which apoptin induces 
apoptosis in human tumor cells, we performed a yeast two-hybrid screen 
using full-length apoptin as bait (Danen-van Oorschot, et al., 2004). One of 
the interacting proteins identified in this manner was AIP3. This protein of 
unknown function had previously been designated FAM96B (Finn, et al.,  
 
 
Figure 4.1 The AIP3 (also known as FAM96B) gene is conserved in chimpanzee, dog, cow, 
mouse, rat, chicken, zebrafish, fruit fly, mosquito, C.elegans, S.pombe, S.cerevisiae, 
K.lactis, E.gossypii, M.grisea, N.crassa, A.thaliana, and rice. Shown here is a ClustalW 
alignment of the amino acid sequences of human FAM96B (NP_057146.1) and its orthologs 
in the mouse Mus musculus (NP_081029.1), Drosophila melanogaster (NP_648416.1), 
Caenorhabditis elegans (NP_499777.1), and Saccharomyces cerevisiae (NP_011990.1). 
Small, hydrophobic amino acids are coloured red; acidic amino acids are blue, basic amino 
acids are magenta, and polar amino acids are shown in green. "*" means that the residues 
or nucleotides in that column are identical in all sequences in the alignment. ":" means that 
conserved substitutions have been observed, according to the colours indicated above. "." 
means that semi-conserved substitutions are observed (Chenna, et al. 2003). 
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2010).  Figure 4.1 shows the alignment of the amino acid sequence of 
human FAM96B with that of the mouse, C.elegans, Drosophila, and 
S.cerevisiae, demonstrating the conservation of this protein across a wide 
range of species. 
 
Apoptin interacts with FAM96B in normal and cancer cells, 
independently of its phosphorylation status 
Next, we examined whether FAM96B associates with phosphorylated and/or 
non-phosphorylated apoptin in Saos-2 tumor cells and in primary 
fibroblasts. The cells were co-transfected with plasmids encoding Flag-tagged 
apoptin, Flag-apoptinT108E mimicking constitutively phosphorylated 
apoptin, phosphorylation deficient-mutant Flag-apoptin5Ala106 and myc-
tagged FAM96B or an empty vector. Co-immunoprecipitation and Western 
blot analysis were carried out as described in the Materials and Methods 
section.   
 
Figure 4.2A shows the Western blots of the co-immunoprecipitation analysis 
of normal and tumor cells expressing Flag-apoptin protein with or without 
FAM96B. Immunoprecipitation with antibodies against the Flag-tag of 
apoptin resulted for both cell types in co-immunoprecipitated FAM96B 
protein product. Similar co-immunoprecipitation results were obtained with 
lysates derived from normal and tumor cells co-expressing FAM96B and 
Flag-apoptinT108E or Flag-apoptin5Ala106 mutants (Figures 4.2B and C, 
respectively). In all cases, myc-tagged FAM96B co-immunoprecipitated with 
Flag-apoptinT108E or Flag-apoptin5Ala106.  
 
These results indicate that the interaction between FAM96B and apoptin is 
independent of the phosphorylation status of apoptin, and can occur both in 
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Figure 4.2 FAM96B interacts with apoptin in human cells, independently of apoptin’s 
phosphorylation status. A. Cells were transfected with plasmids encoding flag-apoptin and 
myc-tagged FAM96B, or control plasmid (neo) in the indicated combinations. Total lysates 
(L) or protein complexes immunoprecipitated with antibody against the flag-tag were 
separated by SDS-PAGE and analyzed by Western blotting. Left panel normal human 
foreskin fibroblasts; right panel human Saos-2 tumor cells. B. As A, using flag-
apoptinT108E, which mimicks constitutively phosphorylated apoptin. C. As A, using flag-
apoptin5Ala106, in which amino acids 106-110 have been replaced with a 5-aa stretch of 
alanines, thereby abolishing the phosphorylation site at aa108. 
 
Association of FAM96B with DNA repair and the cytoskeleton 
A yeast two-hybrid screen was then performed using human FAM96B as 
bait, with the purpose of understanding the cellular processes involving 
FAM96B, and how these could be involved in the induction of apoptosis by 
apoptin. Twenty different proteins were found to associate with FAM96B 
(Table 4-1). For all but one of these interactants, the association could be 
confirmed by co-immunoprecipitation in a human cellular background 
(Figure 4.3).  




Figure 4.3 Co-immunoprecipitation of FAM96B in human cells with interaction partners 
identified by yeast two-hybrid. VH10/SV40 cells were transfected with plasmids encoding 
myc-tagged FAM96B and strep-tagged candidate interaction partners. Twenty-four hours 
post transfection, cells were lysed and protein complexes immunoprecipitated with 
antibodies recognizing either the myc- or strep-tag. MAP3K7IP2 was the only candidate 
partner out of 20 that did not interact with FAM96B in a human cell background. 
 
Bioinformatics analysis of the cellular pathways in which the newly 
identified FAM96B interactants were involved, revealed the distribution of 
these partners in two main groups of proteins, namely DNA transcription 
and repair, and cytoskeleton organization and dynamics, with many linked 
specifically to chromosome segregation (Table 4-2 and Figure 4.4). Among 
these proteins, there are clear links to tumor-related processes: the 
nucleoside diphosphate kinase NM23B, for instance, has been shown to 
suppress metastasis (Roymans, et al., 2002), while UHRF2 is a putative 
tumor suppressor gene (Bronner, et al., 2007; Sjöblom, et al., 2006), and 
CIAO1 is linked to the Wilms tumor suppressor protein 1 (WT1) (Johnstone, 
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et al,1998). FAM96B was also found to associate with protein chaperones 
such as BIP (HSPA5) and HSPE1 (Hsp10), both of which have been shown to 
be differentially expressed in cancer (Zhuang, et al., 2009; Czarnecka, et al., 
2006), Interestingly, both BIP and DEDAF, a transcriptional repressor 
involved in DNA damage-induced apoptosis, has previously also been shown 
to interact with apoptin, and over-expression of DEDAF in tumor cells has 
been shown to induce apoptosis (Danen- van Oorschot, et al., 2004; Novak 
and Phillips, 2008; Sato, et al., 2010).  
 
As depicted in figure 4.4, there are also many links between the FAM96B 
interactants themselves. From this network of proteins, it emerges that 
FAM96B might be involved in the regulation of cell division, particularly 





Figure 4.4 Schematic representation of the FAM96B interaction network, as derived from 
our yeast two-hybrid experiments (blue lines) and literature (green lines). The STRING 
database was used to identify functional network connectivity (Jensen, et al. 2009). 
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Table 4-1 Proteins associating with FAM96B. FAM96B interactants were identified through 
yeast two-hybrid analysis and confirmed as FAM96B partners in a human cellular 
background. Besides the protein name, the table also lists the proposed function (Funcbase 




Proposed function FuncBase 
annotation 
Links to cancer 
CIAO1 Cytosolic Fe–S cluster maturation, 
transcriptional regulation: Depletion 
of Cia1 impairs the export of the 
large ribosomal subunit from the 
nucleus   
Positive regulation 
of cell proliferation 
Deletion lethal in S. 
cerevisiae. Modulates the 
transactivation activity of 
Wilms tumor suppressor 
protein (WT1)   
NM23B Nucleoside diphosphate kinase  Metastasis 
suppressor 
Suppressor of metastasis  





associated with increased 
risk of pancreatic cancer. 
May also function as 
transcriptional co-
activator of estrogen 
receptor (ER)  
DEDAF 
(RYBP) 
PcG protein with transcriptional co-
repressor activity 
Induces cell-cycle arrest and is 




Decreased in human 




E3 ubiquitin protein ligase 
Induces G1 arrest and associates 
with Cdk2/cyclin E  
E3 ubiquitin ligase, 





MAPK signaling pathway (Links 
MAP3K7 with TRAF6; also interacts 
with TRAF2 























phenotype and reduces 
malignant activity of 
breast cancer 
CAP1 Directly regulates filament dynamics Cell morphology 
and motility 
Over-expression is 
involved in aggressive 
behavior of pancreatic 
cancer 
CDC42BPA Serine/threonine protein kinase Actin cytoskeleton 
reorganization 
May act as a downstream 
effector of CDC42 in 
cytoskeletal 
reorganization, 
contributes to cell 
invasion 
FN1 Cell adhesion and motility Cell adhesion and 
migration 
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Table 4-1. continued.  
 
ITGB4 Laminin receptor, structural role in 




Likely to play a pivotal 
role in the biology of 
invasive carcinoma.  
FLNA/B/C Connects cell membrane 
constituents to the actin 
cytoskeleton 
Actin cytoskeleton Aberrant FLN’s are 
involved in e.g. acute 
myelomonoblastic 
leukaemia 
KRT5 Cytokeratin Cytoskeletal keratin; 
cell migration 
 
BIP Heat shock protein; probably plays a 
role in the assembly of multimeric 
protein complexes in the ER 
Unfolded protein 
response 
Possibly involved in 
pathogenesis of renal 
cell carcinoma, 
expression appears to 
correlate with melanoma 
progression 














Table 4-2 FAM96B-associating proteins are grouped according their biological function. 
Protein names in italics are assigned to more than one group, and the asterisk (*) denotes 
the only protein identified by yeast two-hybrid, for which the interaction could not be 
confirmed through co-immunoprecipitation in a human cellular background. 
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FAM96B induces apoptosis in cancer cells  
To investigate this last hypothesis, we analyzed the effect of FAM96B over-
expression on cancer cells. As the DNA repair pathways in cancer cells are 
presumed to be faulty, we expected over-expression of FAM96B in these cells 
to halt cellular proliferation. To this end, human cancer cells were 
transfected with plasmids encoding myc-tagged FAM96B and green 
fluorescent protein (GFP) as a negative control. At twenty-four, forty-eight 
and seventy-two hours after transfection, cells were fixed and stained with 
DAPI to determine apoptosis activity. Twenty four hours after transfection, a 
small percentage of FAM96B-positive cells exhibited morphological features 
charactristic of apoptosis, steadily increasing up to approximately 40% after 
72 hours. In contrast, GFP-expressing cells did not exceed the level of 5% 
morphologically apoptotic cells. The results clearly demonstrate that 
expression of FAM96B induced apoptosis in cancer cells, whereas the 





Figure 4.5 Over-expression of FAM96B in apoptosis in human cancer cells. Human Saos-2 
tumor cells were transfected with plasmid encoding myc-tagged FAM96B or control and 
grown on coverslips. Twenty-four, forty-eight, and seventy-two hours post transfection 
coverslips were fixed and stained with appropriate antibodies for immunofluorescence 
analysis. Apoptotic cells were scored according to their nuclear morphology as determined 
by DAPI staining. Data is representative of 3 independent experiments, each in which at 
least 100 cells were scored. 
 
 




We have identified cellular factors providing insights in the action of the 
tumor-selective apoptosis inducer apoptin. Our protein-protein interaction 
studies revealed firstly the association of apoptin with human FAM96B, and 
secondly of FAM96B with proteins involved in DNA transcription, replication 
and repair as well as cytoskeleton dynamics. The fact that FAM96B interacts 
with apoptin in both its phosphorylated and non-phosphorylated state 
indicates its importance to apoptin’s activity: the interaction likely occurs in 
an already early phase, preceding apoptin’s phosphorylation and activation 
of its tumor-selective apoptosis induction.  
 
Though the exact function of FAM96B cannot yet be established, several 
clues are provided. FAM96B is highly conserved among eukaryotes, and 
contains a well conserved domain (DUF59), found in proteins serving various 
functions, including phenylacetic acid degradation, iron-sulfur cluster 
biosynthesis, and calcium-dependent protein kinase, but also nucleotide-
binding and chromosome partitioning (Finn, et al., 2010).  Studies in 
S.cerevisiae suggest that the yeast homolog of FAM96B is an essential 
protein (Davierwala, et al., 2005), and further analysis even indicates its 
requirement for the establishment of sister chromatid cohesion (Ben-Aroya, 
et al., 2008). Recently, Ito and colleagues have reported that a protein 
complex containing FAM96B is involved in chromosome segregation (Ito, et 
al., 2010).  
 
Our analyses concur with these findings, indicating a role for FAM96B in 
linking chromatin-related processes to the cytoskeleton. For example, one of 
the proteins identified as an FAM96B interactor is filamin A, a cytoskeletal 
protein, which has recently been shown to interact with the tumor 
suppressor protein BRCA1 and is required for efficient DNA repair (Velkova, 
et al., 2010). We found that FAM96B associates with MMS19, which itself is 
required for nucleotide excision repair (NER) and RNA polymerase II 
transcription (Kou, et al., 2008). Through MMS19 and DNAJB6, FAM96B is 
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also linked to PHB2 and MLF1IP, respectively, which have functions in 
protecting chromatid cohesion (Takata, et al., 2007) and centromere 
assembly (Foltz, et al., 2006). Another FAM96B-protein interactor, NM23B, 
has been identified as a constituent of the centrosome (Roymans, et al., 
2001), and connects both FAM96B interaction spheres on account of its 
roles in transcription as well as regulation of cytoskeleton dynamics and 
suppression of metastasis (Lim, et al., 1998). Importantly, FAM96B-
interactor C15orf23, or SKAP, has been shown to promote metaphase-to-
anaphase transition by mediating separase activation after spindle assembly 
checkpoint is satisfied in mitosis (Fang, et al., 2009). 
 
These findings are further supported by the fact that FAM96B is linked to 
formin, which is essential for contractile ring assembly in animal cells 
(Glotzer, 2005), as well as Cdc42, which regulates the assembly and 
organization of the actin cytoskeleton, and is required for kinetochore 
attachment as well as G1 progression and S phase entry (Hall, 2009). 
UHRF2, with which FAM96B interacts directly, is also capable of inducing 
G1 arrest, and associates with CDK2 (Li, et al., 2004). CDK2 complexed with 
cyclins A and E is essential for DNA replication and G1/S transition, 
respectively (Sherr, 1994). Intriguingly, Maddika, et al. (2009) reported 
apoptin phosphorylation and activation by CDK2.  
 
We therefore propose that FAM96B functions in the regulation of cellular 
proliferation through control of chromosome segregation, and that this 
regulation is subject to control by DNA repair pathways. Consistent with this 
proposed function, we also showed that over-expression of FAM96B in 
cancer cells induces apoptosis. This apoptotic activity is highest 72 hours 
post transfection, and thus most likely represents a late-phase response, 
presumably upon failure to activate and/or execute a proper DNA damage 
response in a tumorigenic environment. 
 
In conclusion, our protein-protein interaction analysis revealed that apoptin 
interacts with FAM96B, which appears to link the cell division process to the 
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essential process of DNA repair. Further research is underway, seeking to 
characterize and more precisely define the role of FAM96B in these 
processes, and the involvement in apoptin-induced tumor-selective cell 
death.  
 
Note added in proof: 
During preparation of this manuscript, Ito et al. described that FAM96B 
(named MIP18 by the authors) is part of a multiprotein complex involved in 
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The Chicken Anemia Virus-derived protein apoptin has been identified 
as one of a select number of proteins preferentially exhibiting toxicity 
towards cancer cells. Coupled to this tumor-selective behavior is a 
differential subcellular localization: in tumor cells, apoptin-induced 
apoptosis involves its nuclear translocation, whereas in normal cells, 
it remains cytoplasmic, where it is degraded without killing the cell. To 
obtain a comprehensive nuclear interaction map of apoptin in the 
cancer cell nucleus, and shed light on the mechanisms underlying its 
tumor cell-killing abilities, we designed a proteomic strategy based on 
chromatin immunoprecipitation (ChIP) coupled with mass 
spectrometry. We found that apoptin localizes to chromatin containing 
proteins relevant for ribosome biogenesis, RNA metabolism, DNA 
damage response and cell cycle regulation. Our data suggest that in 
transformed cells, apoptin might induce apoptosis from within the 
nucleolus, where it senses the activation of the DNA damage response 
and interferes with cellular protein synthesis.  
 





The viral protein apoptin has emerged as a promising new instrument 
in the development of effective anti-cancer therapies (Backendorf, et 
al., 2009; Li, et al., 2010; Wagstaff and Jans, 2009). Apoptin has been 
shown to induce apoptosis specifically in tumor cells, compared to 
normal tissue (Danen-van Oorschot, et al., 1997; Sun, et al., 2009). 
Apoptosis induction by apoptin is preceded by its phosphorylation and 
nuclear accumulation (Danen-van Oorschot, et al., 2003; Maddika, et 
al., 2009; Rohn, et al., 2002;). In-vitro experiments with recombinant 
MBP-apoptin have demonstrated that apoptin is able to interact with 
both single- and double-stranded DNA, with little or no sequence 
specificity (Leliveld, et al., 2004). Intriguingly, however, experiments 
using actinomycin D, an RNA synthesis inhibitor, and two protein 
synthesis inhibitors (emetine and puromycin), demonstrated that 
apoptin’s cell-killing effects did not require de novo transcription or 
translation (Danen-van Oorschot, et al., 2003).  Furthermore, apoptin 
specifically requires a tumorigenic nucleus: enforced nuclear 
localization of apoptin in normal human cells by fusion of a general 
nuclear localization signal to apoptin (Danen-van Oorschot, et al., 
2003) or by direct micro-injection of recombinant MBP-apoptin protein 
in the nucleus (Zhang, 2004a) did not result in apoptosis. In other 
experiments, apoptin remained in the cytoplasm of normal human 
cells, and only translocated to the nucleus upon cellular 
transformation by ectopic expression of the oncogenic SV40 large T 
antigen (Zhang, 2004b).  
 
In view of these properties, we aimed to further characterize the 
nuclear activities of apoptin, and how these result in apoptosis 
induction in cancer cells.  We present evidence that chromatin-bound 
apoptin complexes contain proteins involved in ribosome biogenesis 
and RNA metabolism, the DNA damage response pathway and 
regulation of the cell cycle. Taken altogether, our data indicate that 
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apoptin might coordinate its tumor-specific apoptosis-inducing 
activity from inside the nucleolus.  
 
Materials & methods 
 
Cell lines, plasmids and transfections 
The human SV40 transformed fibroblast cell line VH10/SV40 (Klein, 
et al., 1990) was grown in DMEM, supplemented with 10% newborn 
bovine serum (NBS). The human normal diploid skin fibroblast strain 
F44 (up to passage 15) was grown in 1:1 DMEM/Ham’s F12, 
supplemented with 10% fetal calf serum (FCS), and 2 mM L-
glutamine. All culture media were obtained from Invitrogen (Breda, 
The Netherlands) and contained penicillin and streptomycin.  
 
Plasmid pcDNA-Flag-apoptin containing the DNA sequences encoding 
Flag-tagged apoptin have been described elsewhere (Zimmerman, et 
al., 2011a). For transfection experiments, nucleofection technology 
was used in conjunction with cell type specific Nucleofector solution 




Cells were grown on glass cover slips. After transfection, the cover 
slips were first washed once with phosphate buffered saline, and 
subsequently fixed with methanol/acetone (50%/50%) for 10 min at 
room temperature. After air-drying, the slides were used for 
immunocytochemical staining or stored at -20°C for further analysis. 
Immunocytochemical staining was carried out as described by Danen-
Van Oorschot, et al. (1997). Antibody α-Flag (Sigma-Aldrich, 
Zwijndrecht, Netherlands), a mouse monoclonal antibody against the 
Flag-tag fused to apoptin, was used to detect the presence and cellular 
localization of apoptin. The fluorescein isothiocyanate (FITC) or 
Rhodamine conjugated goat antibodies (Jackson ImmunoResearch 
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Laboratories, Suffolk, UK) were used as secondary antibodies. At least 
100 cells were scored per sample in two independent experiments.  
 
In vivo cross-linking  
Twenty-four hours after transfection, SV40-transformed VH10 
fibroblasts were subjected to in vivo cross-linking and chromatin 
immunoprecipitation (Fousteri, et al., 2006). All procedures were 
carried out at 4°C unless otherwise stated. Briefly, 3 × 107 cells were 
cross-linked with 1% formaldehyde (HCHO) prepared from an 11% 
stock (0.05 M HEPES (pH 7.8), 0.1 M NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 11% HCHO) for 16 min. Next, 0.125 M (final concentration) of a 
glycine solution was added, and the cells were collected by scraping in 
cold PBS. All buffers used for cell extraction and ChIP contained, in 
addition to the specified components, 0.1 mM EDTA, 0.5 mM EGTA, 1 
mM PMSF, and a mixture of proteinase and phosphatase inhibitors. 
The cell pellet was resuspended in lysis (CL) buffer (50 mM HEPES 
(pH 7.8), 0.15 M NaCl, 0.5% NP-40, 0.25% Triton X-100, and 10% 
glycerol) and rotated for 10 min. After centrifugation (1300 rpm, 5 
min), the supernatant was removed. The pellet was washed with 
buffer consisting of 0.01 M Tris-HCl (pH 8.0), 0.2 M NaCl, 0.5 mM 
DTT, and resuspended in 1 × RIPA buffer (0.01 M Tris-HCl (pH 8.0), 
0.14 M NaCl, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS). The 
nuclear suspension was sonicated on ice using a Branson Sonifier 
250 (Danburry, CT, USA), yielding fragments between 200 and 1000 
bp. The supernatant containing the cross-linked chromatin was 
collected by centrifugation (13200 rpm, 10 min) and stored in aliquots 
at -80°C. 
  
Chromatin Immunoprecipitation   
For each ChIP reaction, an equal amount of cross-linked chromatin 
was immunoprecipitated with 0.5–2 µg of the specific anti-Flag 
antibody or mouse IgG (negative control) in RIPA buffer during o/n 
incubation. The immunocomplexes were collected by adsorption (3 hr) 
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to pre-cleared protein G Sepharose beads (Upstate Biotechnology, Inc., 
Lake Placid, NY, USA) in RIPA buffer containing 0.1 mg/ml sonicated 
salmon sperm DNA (ssDNA). The beads were next washed twice with 
20 vol of RIPA, once with RIPA containing ssDNA, and twice with RIPA 
containing ssDNA and 0.3 M NaCl. Finally, the beads were washed 
with 20 vol of LiCl buffer (0.02 M Tris (pH 8.0), 0.25 M LiCl, 0.5% 
Triton X-100, 0.5% Na-deoxycholate) and the immunocomplexes were 
resuspended in TE buffer.  
 
Mass Spectrometry 
The proteins obtained by ChIP analysis were identified by mass 
spectrometry (MS) analysis as follows. The ChIP samples were 
processed by chloroform-methanol precipitation (Wessel and Flugge, 
1984), then solubilized in urea and submitted to in-solution 
proteolytic digestion according to the filter-aided sample preparation 
(FASP) protocol using a 10K filter, as described by Wiśniewski, et al. 
(2009). Before proceeding with MS, samples were purified, desalted 
and concentrated using StageTips (Rappsilber, et al., 2007). The 
samples were analyzed on a LTQ-orbitrap mass spectrometer 
(Thermo-Fischer, Breda, the Netherlands) and MS and MSMS was 
run. Sequence identification was performed using Mascot Daemon 
(Matrix Science Inc, London, United Kingdom).  
 
Results and Discussion 
 
Apoptin localizes to specific regions of the cancer cell nucleus  
We set out to gain a better understanding of the mechanisms behind 
tumor-selective apoptosis induction by apoptin, starting with its 
particular nuclear localization. Earlier studies have shown that, in 
human cancer cells, apoptin forms distinct intranuclear granules, 
localizing to heterochromatin and nucleoli (Leliveld, et al., 2003). In 
order to gain further evidence for these findings, we transfected both 
normal and SV40-transformed human fibroblasts with plasmid DNA 
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encoding flag-tagged apoptin. Twenty-four hours after transfection, 
cells were fixed and the subcellular localization of apoptin was 
determined by immunofluorescence assay. As shown in figure 5.1, 
apoptin was localized in the cytoplasm of the normal cells, whereas in 
the transformed cells, apoptin exhibited its characteristic intranuclear 




Figure 5.1 Differential localization of apoptin in normal and transformed cells. 
Normal fibroblasts (upper panel) or stably SV40-transformed fibroblasts (lower 
panel) were transfected with plasmid DNA encoding flag-tagged apoptin. Twenty-four 
hours post-transfection, cells were fixed and stained for indirect immune 
fluorescence analysis as indicated in the Materials & Methods section. 
 
Chromatin Immunoprecipitation identifies the interaction of 
apoptin with various nuclear proteins 
Next, we examined whether apoptin could be found in specific protein 
complexes interacting with nuclear chromatin. To this end, we 
designed a proteomic strategy based on chromatin 
immunoprecipitation (ChIP) coupled with mass spectrometry (Figure 
5.2). SV40-immortalized fibroblasts were transfected with flag-
apoptin, and chromatin-protein complexes were precipitated using an 
antibody against the flag-tag. As a negative control, chromatin-protein 






Several proteins, which were clearly absent in the negative control, 
were found to co-precipitate with chromatin-associated apoptin 
complexes (Figure 5.3). Following in-solution digestion, the identity of 
these proteins was determined by mass spectrometry analysis. 
Proteins identified in the negative control were considered aspecific to 
the apoptin-chromatin interaction, and were excluded from further 
analysis.  The list of remaining proteins, specifically present in 
chromatin-bound apoptin complexes, is presented in Table 5-1.  
Figure 5.2 Schematic representation of the proteomics approach undertaken in our 
study to obtain a comprehensive nuclear interaction map of apoptin in the cancer cell 
nucleus. Stably SV40-transformed fibroblasts were transfected with flag-tagged apoptin. 
Twenty-four hours post transfection, proteins were cross-linked to chromatin using 1% 
formaldehyde, after which cells were lysed. Nuclei were pelleted, washed, resuspended, 
then sonicated to yield chromatin fragments between 200 and 1000 bp. Size of DNA 
fragments was checked by DNA gel electrophoresis (data not shown). Apoptin-bound 
complexes were precipitated using an anti-flag antibody* (recognizing the flag-tag fused 
to apoptin). After in-solution proteolytic digestion, proteins were identified using mass 
spectrometry analysis. *Alternatively, proteins were incubated with mouse IgG as a 
negative control.  





Figure 5.3 Interaction profile of chromatin-bound apoptin complexes, isolated from 
SV40-transformed cells, 24 hours post transfection with flag-tagged apoptin. 
Chromatin immunoprecipitation was carried out using flag-antibody (bait) or mouse 
IgG (control). Specifically interacting proteins were subsequently resolved by SDS-
PAGE and silver-stained according to manufacturer protocol (Bio-Rad, Hercules, 
California, USA). The resulting protein profile obtained with the anti-flag antibody is 
specific and composed of bands of distinct size and intensity, representing putative 
proteins interacting with chromatin-bound apoptin. The band belonging to flag-
apoptin is indicated (this was determined by western blot analysis, data not shown).  
 
The identification of histone proteins proves that we indeed 
precipitated chromatin-bound apoptin complexes, while the 
identification of nucleolar proteins is consistent with the previously 
observed nucleolar localization of apoptin in cancer cells. Additionally, 
apoptin has previously been shown to interact with importin beta-1  
(Poon, et al., 2005) and tubulin alpha and beta (Teodoro, et al. 2004), 
confirming the specificity of our analysis. Many of the identified 
proteins have been demonstrated to harbor cell cycle-related functions 
and possess either oncogenic or tumor suppressive activities. In 
addition, several of these proteins have been shown to interact with 
viral proteins, and are involved in the replication of viral genomes.
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Table 5-1 Proteins identified by mass spectrometry analysis of purified apoptin-chromatin immunocomplexes. Proteins unspecifically 
coprecipitating with the IgG negative control were subtracted from this list. 
 
     
 Human proteins    




Protein name Alternative 
names 
Function Links to cancer 
14.1 histone H2a  
Nucleosome constituent 
 
13.9 histone H2B   
15.4 histone H3.2   
16.5 40S ribosomal protein S16  
Ribosome constituent 
 
23 40S ribosomal protein S5   
14.9 40S ribosomal protein S15a   
26.8 40S ribosomal protein S3   
30.2 40S ribosomal protein S3a   
22.1 40S ribosomal protein S7   
29.8 40S ribsosomal protein S4, x    
15.4 40S ribosomal protein S24   
18 60S ribosomal protein L12   
18.6 60S ribosomal protein L21   
14.8 60S ribosomal protein L22   
17.9 60S ribosomal protein L24   
14.5 60S ribosomal protein L31   
12.6 60S ribosomal protein L35A   
34.5 60S acidic ribosomal protein P0   
29.2 60S ribosomal protein L7   
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Protein name Alternative  
names 
Function Links to cancer 
38.9 hnRNP A1  
Formation, packaging, processing, 
and nuclear-cytoplasmic transport 
of mRNA 
Over-expression is associated with non-small cell lung cancer. 
(Boukakis, et al., 2010) 
36.3 hnRNP A/B   
37.5 hnRNP A2/B1  
Over-expressed in non-small cell lung cancer (Boukakis, et al., 
2010), gastric cancer (Jing, et al., 2011), and hepatocellular 
carconoma (Cui, et al., 2010).  
33.7 hnRNP C1/C2   
46 hnRNP F  Expression is up-regulated in colon cancer (Balasubramani, et al., 2006) 
49.5 hnRNP H   
60.7 hnRNP L   
77.7 hnRNP M   
91.2 hnRNP U SAF-A  
39 PCBP2 hnRNP E2 Down-regulated in oral cancer  (Roychoudhury, et al., 2007) 
28.4 U2AF  Splicing factor  
54.3 NONO p54NRB 
RNA-binding protein, which plays 
various roles in the nucleus, 
including transcriptional 
regulation and RNA splicing, as 
well as the DNA damage response 
Highly expressed in malignant melanoma (Shiffner, et al., 
2011) 
16.7 NFAT5  
Transcription factor 
Activity promotes carcinoma invasion (Jauliac, et al., 2002) 
40.1 DBPA CSDA Up-regulated in gastric cancer (Wang, et al., 2009) 
   
Eukaryotic translation initiation 
and elongation 
Putative oncogenes (Lee and Surh, 2009; Lew, et al., 1992; 
Tang, et al., 2010). 
50.8 EEF1A2  
50.4 EEF1G  
17 EIF5A-1,2  
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Protein name Alternative  
names 
Function Links to cancer 
76.6 Nucleolin C23 Nucleolar proteins, involved in the synthesis and maturation of ribosomes, as well 
as regulation of many other cellular processes, including DNA damage repair, cell 
cycle and apoptosis. See text for further details. 32.7 Nucleophosmin B23, NPM1 
19.6 Nucleophosmin-3 NPM3 
33.5 SET TAF-I PP2A inhibitor, involved in the regulation of cell cycle progression; see text for further details.  
92.4 CDC5L  
Splicing factor and essential regulator of G2/M progression (Bernstein and 
Coughlin, 1998). Also regulates S-phase checkpoint in response to DNA damage 
(Zhang, et al., 2009).  
69.6 DDX5 p68 
DEAD-box RNA helicase implicated in 
cellular growth and division; see text 
for further details.  
Overexpressed in prostate cancer (Clark, 
et al., 2008) 
122.9 A26C1  Pro-apoptotic actin isoform (Liu, et al., 2009)  
Overexpressed in hepatocellular 
carcinoma (Chang, et al., 2006) 
28.3 Filamin A  Cytoskeletal proteins 50 Tubulin alpha, beta  
58.2 Importin subunit alpha-2  Nuclear protein import  
98.4 Importin subunit beta 1  
     






82.4 SV40 large T antigen 
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To facilitate interpretation, we grouped the proteins identified in our 
apoptin ChIP assay into the following 8 functional groups (Table 5-1, 
Figure 5.4): 1) Histones; 2) Ribosome constituents and other proteins 
involved in ribosomal biogenesis; 3) hnRNPs; 4) translation factors; 5) 
transcription factors; 6) regulatory nucleolar proteins; 7) proteins 
regulating progression through the cell cycle; 8) cytoskeletal proteins. 
 
Below, we will discuss a select number of these proteins in more 
detail, highlighting possible novel insights into the mechanisms 





Figure 5-4 The STRING database (Jensen, et al. 2009) was used to identify 
functional network connectivity among the proteins identified by apoptin chromatin 




Apoptin: functions in and out of the nucleolus 
 
Ribosome biogenesis 
The nucleolus is generally regarded as a cellular hub for ribosomal 
biogenesis, vital to cellular proliferation (Montanaro, et al., 2008). The 
identification of apoptin in chromatin containing ribosomal 
constituents confirms not only its presence at this important hub, but 
also its propensity for a transformed environment, given that the 
presence of multiple, large nucleoli has long been regarded as an 
immunohistochemical hallmark of cancer cells (Pianese, 1896). In 
fact, emerging evidence suggests that quantitative and qualitative 
changes in rRNA synthesis may be among the most important 
molecular alterations occurring in cancer cells, and several approved 
anticancer therapeutics are proposed to exert their activity at least in 
part through interference with this process (Drygin, et al., 2010). For 
instance, cisplatin, which is traditionally believed to work primarily 
through the induction of DNA damage, was shown to block rRNA 
synthesis through inhibition of the rRNA polymerase Pol-I; in contrast, 
its clinically ineffective analog transplatin, although still being able to 
damage DNA, had no effect on rRNA synthesis (Jordan and Carmo-
Fonseca, 1998). This data imply a role for apoptin interference with 
ribosome biogenesis as part of its mechanism for inducing apoptosis 
in cancer cells.  
 
Sensing cellular stress/DNA damage 
Recent research has provided evidence that, more than a mere 
ribosome factory, the nucleolus actively contributes to the regulation 
of cellular survival and proliferation, playing crucial roles in many 
fundamental cellular processes, including (regulation of) DNA repair, 
cell cycle checkpoints in mitosis, and apoptosis (Boisvert, et al., 2007; 
Boulon, et al., 2010). These pathways are mainly influenced through 
sequestration of regulators, such as p53, MDM2, and pRB (Tembe and 
Henderson, 2007). A group of ribosomal proteins (RPs), including 
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RPL5, RPL11, RPL23 and RPS7, were shown to serve as stress signal 
transmitters: following stress, they are released from the nucleolus 
and bind Mdm2, thereby activating p53 (Zhang and Lu, 2009). RPS7 
was among the many ribosomal proteins identified in our apoptin 
chromatin precipitation assay, as was nucleophosmin, a major 
nucleolar phosphoprotein that has also been shown to act as a 
nucleolar stress sensor (Yao, et al., 2010). Nucleophosmin associates 
with all three components of the p14(ARF)-p53-MDM2 cascade, 
(Bertwistle, et al., 2004; Colombo, et al., 2005; Kurki, et al., 2004), 
and is further linked to the DNA damage response through its 
interaction with the checkpoint kinase Chk1 (Chen, et al., 2009). It is 
also involved in numerous other cellular processes, including 
ribosome biogenesis (Okuwaki, et al., 2002). Nucleophosmin-regulated 
ribosome export is a fundamental process in cell growth, and 
inhibition of nucleophosmin shuttling can block cellular proliferation 
(Maggi, et al., 2008). It is plausible that the interaction with apoptin 
achieves just this, thereby contributing to tumor-selective apoptosis 
induction by apoptin.  
 
Regulation of mitosis 
Our assay also identified the nucleophosmin-interacting protein 
nucleolin, a major nucleolar phosphoprotein with important roles in 
chromatin structure, rDNA transcription, rRNA maturation, 
nucleocytoplasmic transport, and ribosome assembly (Ginisty, et al., 
1999; Liu and Yung, 1999; Srivastava and Pollard, 1999). Both 
nucleolin and nucleophosmin are highly expressed in proliferating and 
cancerous cells (Eichler and Craig, 1994; Pianta, et al., 2010).  
 
Aside from their nucleolar functions, both proteins have important 
functions in the regulation of mitosis. Nucleolin localizes to the 
chromosome periphery in mitotic cells, is associated with the spindle 
poles from prometaphase to anaphase, and is involved in chromosome 
congression and spindle formation (Ma, et al., 2007), while 
Chapter 5 
146 
nucleophosmin is present at centromeres  (Foltz, et al., 2006) and at 
spindle poles in metaphase cells, and is required for proper 
chromosome alignment on the equatorial planes during metaphase 
(Rousselet, 2009). Nucleophosmin is also required for centrosome 
duplication (Moss and Stefanovsky, 2002; Okuda, et al., 2000), the 
formation of functional and stable spindles with intact centrosomes 
and for proper kinetochore-microtubule attachments (Amin, et al., 
2008). Apoptin was previously shown to interact with FAM96B, which 
also localizes to the mitotic spindle and is required for proper sister 
chromatid cohesion and chromosome segregation (Zimmerman, et al., 
2011b; Ito, et al, 2010). The association with nucleolin and 
nucleophosmin, as well as actin, filamin and tubulin, again places 
apoptin at the mitotic spindle, further accentuating its important 
mechanistic function in apoptin-induced apoptosis.  
 
Further evidence comes from the identification of Cdc5L and SET in 
our assay. Cdc5L is the human homolog of Schizosaccharomyces 
pombe Cdc5, and like its yeast counterpart, it is an important cell 
cycle regulator of G2/M transition (Bernstein and Coughlin, 1998). It 
is also required for progression through the S-phase of the cell cycle, 
with recent studies describing a function for Cdc5L in the cellular 
response to DNA damage (Zhang, et al., 2005), demonstrating that it 
interacts physically with the cell-cycle checkpoint kinase ataxia-
telangiectasia and Rad3-related (ATR), and is required for the 
activation of downstream effectors or mediators of ATR checkpoint 
function, including Chk1 and Rad17 (Zhang, et al., 2009). SET, a 
potent inhibitor of the tumor suppressor protein phosphatase 2A 
(PP2A) (Li, et al., 1996) and an important modulator of chromatin 
remodeling and condensation, also regulates progression through the 
cell cycle (Vera, et al., 2007; Leung, et al., 2011). It binds directly to 
p21CIP1 and reverts the inhibitory effect of the latter protein on cyclin 
E-Cdk2 kinase activity, thus allowing progression through S-phase 
(Estanyol, et al., 1999). SET also regulates G2/M transition by 
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binding to cyclin B and inhibiting cyclin B-Cdk1 activity (Canela, et 
al., 2003). Hence, through its interactions with nucleophosmin, 
nucleolin, Cdc5L, and SET, and their roles in the pathways regulating 
the DNA damage response as well as progression through mitosis, we 
gain valuable new insights into apoptin’s modus operandi inside the 
cancer cell nucle(ol)us. 
 
hnRNPs and other RNA-related proteins (RNPs) 
In our chromatin immunoprecipitation experiments apoptin was also 
found to associate with a large number of heterogeneous nuclear 
ribonucleoproteins (hnRNPs).  
 
hnRNPs comprise a family of RNA-binding proteins that are 
principally involved in RNA metabolism (Han, et al., 2010). Within the 
nucleus, hnRNP proteins participate in RNA splicing, 3’-end 
processing, transcriptional regulation, and immunoglobulin gene 
recombination. hnRNP proteins are also involved in nucleo-
cytoplasmic transport of mRNAs, mRNA localization, translation and 
mRNA stability. Recently, evidence has been provided that hnRNPs are 
also associated with heterochromatin, at least in Drosophila 
(Piacentini, et al., 2009). hnRNP-U has been found to associate with 
the heterochromatin protein 1 alpha (HP1 alpha) in both the 
nucleoplasm and in chromatin (Ameyar-Zazoua, et al., 2009); hnRNP-
A2/B1 was shown to associate with DNA-bound proteins (Guha, et al., 
2009); and hnRNP-C1/C2 proteins were demonstrated to bind to 
chromatin in a DNA damage-dependent manner (Wardleworth and 
Downs, 2005). Additionally, it has been suggested that hnRNP 
proteins play critical and well-defined roles in carcinogenesis. hnRNP-
E1, -A1, and -D have been shown to form a heteromeric complex on 
telomeric repeats in vitro (Ishikawa, et al. 1993), suggesting that they 
may be involved in the maintenance of telomeric length. This notion is 
reinforced by the observation that deficient expression of hnRNPs can 
cause significant telomere shortening and oncogenic transformation 
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(LaBranche, et al. 1998). A recent study has indeed confirmed that 
hnRNP-A1 participates in telomere maintenance (Flynn, et al., 2011). 
hnRNP-A2/B1 is over-expressed in lung, breast, pancreas and liver 
cancer (Tauler, et al., 2010), and hnRNP-A1 has been identified as a 
potential biomarker for colorectal cancer (Ma, et al., 2009). Moreover, 
hnRNP-E1, hnRNP-K, and FUS (or hnRNP-P2) were identified as 
intricate constituents of spreading initiation centers, which are 
ribonucleoprotein complexes involved in the initiation of cell spreading 
during cancer metastasis (de Hoog, et al. 2004). Down-regulation of 
hnRNP-E1 stimulated cell spreading, consistent with the observation 
that shRNA-mediated silencing of hnRNP-E1 induces constitutive 
EMT, another prerequisite for metastatic progression (Chaudhury, et 
al. 2010; de Hoog, et al. 2004). Reduced hnRNP-E1 expression is also 
a prerequisite for human papillomavirus (HPV) proliferation and 
subsequent incidence of cervical carcinoma from cervical dysplasia 
(Pillai, et al. 2003). A study on the molecular mechanisms by which 
hnRNP proteins regulate cell proliferation in cancer, showed that 
hnRNP-A1 and hnRNP-A2 proteins control the alternative splicing of 
pyruvate kinase mRNA, which facilitates the metabolic shift from 
oxidative phosphorylation to aerobic glycolysis in cancer (Chen, et al., 
2010). Another study demonstrated that hnRNP-F was involved in the 
regulation of cell proliferation via the mTOR/S6 kinase 2 pathway 
(Goh, et al., 2010). Finally, importantly, hnRNP-U (SAF-A), is 
specifically phosphoryated in response to double-stranded DNA 
breaks (Berglund and Clarke, 2009), and was shown to be a novel 
spindle regulator with an essential role in kinetochore-microtubule 
attachment and mitotic spindle organization (Ma, et al., 2011). 
 
The identification of this many RNPs in our assay likely signifies an 
important association between apoptin and the regulation of RNA 
metabolism, a conclusion which is further strengthened by the above-
described, recently discovered roles of hnRNPs in carcinogenesis.  
 




As briefly alluded to before, several of the proteins identified in our 
assay have been shown to interact with viral genomes and proteins, 
and take part in the process of viral replication (see also Table 5-2).  
 
Table 5-2 Proteins involved in viral replication identified by ChIP-MS analysis of 
chromatin-bound apoptin protein complexes. 
 
Protein Relevant to viral replication of 
Nucleolin  Human papilloma virus-16 
Herpes simplex virus-1 
Cytomegalovirus 
DDX5 SARS virus 
Hepatitis C virus 
PCBP2 Hepatitis C virus 
Dengue virus 
hnRNP F Influenza A virus 
hnRNP C Poliovirus 
hnRNP A1 HLTV-1 
 
Nucleolin, for example, binds to the HPV16 genome (Sato, et al., 2009) 
and has also been suggested to play a role in replication of HSV-1 
DNA (Callé, et al., 2008). Furthermore, nucleolin is required for viral 
DNA synthesis and efficient virus production in human 
cytomegalovirus (HCMV)-infected cells (Strang, et al., 2010). The RNA 
helicase DDX5 is required for SARS coronavirus replication (Chen, et 
al., 2009), and is also involved in the replication of Hepatitis Virus C 
(HCV) (Goh, et al., 2004). The poly(rC)-binding protein (PCBP2, or 
hnRNP-E2) directs HCV RNA replication (Wang, et al., 2011), and is 
also involved in dengue virus replication (Rodenhuis-Zybert, 2010). 
Similarly, hnRNP-F, hnRNP-C and hnRNP-A1 are involved in the 
replication of the influenza A virus (Lee, et al., 2010), poliovirus 
(Brunner, et al., 2010), and HTLV-1, respectively (Kress, et al., 2005). 
As apoptin is itself a product of the Chicken Anemia Virus (CAV), the 
question arises whether these interactions might also be relevant for 
CAV replication. Coincidentally, CAV can only replicate in tumorigenic 
chicken cell lines, where it is localized in the nucleus, but does not 
replicate in normal chicken cell cultures (Noteborn, 2004).  
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Finally, the SV40 large T antigen was also identified in our analysis. 
Its presence in our experimental system is explained by the fact that 
this antigen was used to stably transform the cells used in our assay, 
as described in the Materials and Methods section. The oncogenic 
transformation potential of SV40 LT relies on its interaction with 
several tumor suppressors, including p53 and pRb (Ahuja, et al., 
2005; Cheng, et al., 2009)  and its expression has been shown to 
swiftly activate the DNA damage response (Boichuk, et al., 2010; Hein, 
et al., 2009).  We have previously demonstrated (Zimmerman, et al., 
2011a) that transient transformation of normal cells with SV40 LT is 
sufficient to activate apoptin, inducing its nuclear translocation, and 
subsequently, apoptosis. It is, however, the first time that we find an 





The results presented here attest that the previously observed 
nucleolar localization of apoptin is not a random one, and that 
interaction with nucleolar  proteins and R-chromatin is likely essential 
for apoptin’s tumor-selective apoptosis-inducing activity. Importantly, 
nucleolin and nucleophosmin link apoptin to the DNA damage 
response; CDC5L and SET1 provide a connection to the regulation of 
mitosis, while the interactions with tubulin, nucleophosmin and 
nucleolin also corroborate the association of apoptin with the mitotic 
spindle apparatus. Furthermore, the interactions with proteins 
involved in ribosome biogenesis and RNA metabolism suggest a 
mechanism whereby apoptin shuts down the cellular factory and 
orchestrates its apoptotic effects from within the nucleolus.  
 
A comparable mechanism has recently been demonstrated for the 
mouse Polo-like kinase 5, which also localizes to the nucleolus, and 
induces apoptosis in response to DNA damage (Andrysik, et al., 2010). 
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Recently, the pRb-regulated E2F family member E2F1 has been 
shown to induce DNA-damaged mediated apoptosis by transcriptional 
upregulation of the nucleolar protein RRP1B (Paik, et al., 2010). E2F1 
itself is activated by Nur77 (Mu and Chang, 2003), which has been 
shown to participate in apoptin-induced apoptosis (Maddika, et al., 
2005). Furthermore, apoptin has been shown to interact with DEDAF 
(Danen-van Oorschot, et al., 2004), which associates with DEDD in 
the nucleolus (Zheng, et al., 2001). It has indeed been reported that 
DEDD inhibits the Cdk1/cyclin B complex (Arai, et al., 2007), thereby 
arresting mitosis, and transferring the apoptotic signal to the 
nucleolus to shut off biosynthesis (Stegh, et al., 1998). Furthermore, 
apoptin has been shown to localize to the nucleus in response to DNA 
damage (Kucharski, et al., 2011), and induce G2/M arrest (Teodoro, et 
al., 2004). We therefore predict that apoptin’s tumor-selective nuclear 
localization functions in recognizing activation of the DNA damage 
response, interfering with biosynthesis and arresting the mitotic cycle 
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Apoptin harbors tumor-selective characteristics, making it a potentially safe 
and effective anticancer agent. Apoptin becomes phosphorylated and induces 
apoptosis in a large panel of human tumor but not normal cell lines. Here, 
we explored minimal cellular factors required for the activation of apoptin. 
Flag-apoptin was introduced into normal fibroblasts together with the 
transforming SV40 LT and ST antigens. We found that expression of 
nuclearly located SV40 ST in normal cells was sufficient to induce 
phosphorylation of apoptin. Mutational analysis showed that C103S 
mutation within the protein phosphatase 2A (PP2A)-binding domain of ST 
counteracted this effect. Knock-down of the ST-interacting PP2A B56γ 
subunit in normal fibroblasts mimicked the effect of nuclear ST expression, 
resulting in induction of apoptin phosphorylation. The same effect was 
observed upon down-regulation of the PP2A B56δ subunit, which is targeted 
by PKA. Apoptin interacts with the PKA-associating protein BCA3 (AKIP1), 
and inhibition of PKA in tumor cells by treatment with H89 increased the 
phosphorylation of apoptin, whereas the PKA activator cAMP partially 
reduced it. We therefore conclude that inactivation of PP2A, particularly of 
the B56γ and B56δ subunits, is a crucial step in triggering apoptin-induced 











Tumor formation occurs due to a complicated set of processes roughly based 
on enhanced survival and limited cell death activities (Wenner, 2010). 
Remarkably, a set of viral and cellular proteins has been found to selectively 
induce cell death in tumor cells (Bruno, et al., 2009).  Among these proteins 
is the avian virus protein apoptin, which has been shown to induce p53-
independent apoptosis in a broad spectrum of human transformed cells 
(Backendorf, et al., 2008). Recent preclinical studies demonstrated the 
therapeutic potential of apoptin as a safe and efficient anticancer agent 
(Grimm and Noteborn, 2010). Therefore, it is of interest to study the 
mechanisms underlying apoptin-induced apoptosis, particularly the ‘switch’ 
responsible for its activation during oncogenic transformation.  
 
SV40 T antigens are known to be involved in oncogenic transformation 
through interference with many cellular processes (Pipas, 2009). Distinct 
domains on LT that bind and inactivate tumor suppressors p53 and Rb, 
have long been known to play crucial roles in tumor formation (Eichhorn, et 
al., 2009). The SV40 ST protein enforces transformation of normal cells via 
negative effects on the protein phosphatase 2A (Sablina, et al., 2010).  
 
This feature is in accordance with the reduced PP2A levels found in various 
human tumor cell types (Sablina and Hahn, 2008), and accumulating 
evidence supporting major tumor suppressive roles for PP2A (Westermarck 
and Hahn, 2008). Another major cellular regulator implicated in 
carcinogenesis is protein kinase A (PKA) (Naviglio, et al., 2009). Its targets 
include PP2A (Usui, et al., 1998), and for instance, the PKA interacting 
protein Breast Cancer-associated gene 3 (BCA3) is known to be highly 
expressed in breast and prostate cancer cells compared to the normal 
surrounding tissue (Kitching, et al., 2003).   
 
In this study, we investigated the minimal steps leading to the activation of 
apoptin upon malignant transformation. We previously showed that 
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transient expression of the SV40 large and small T antigens in normal 
human fibroblasts results in activation of apoptin, displaying all three of its 
characteristic features, namely phosphorylation, nuclear localization, and 
apoptosis (Zhang, et al., 2004). Here, we analyzed which domains of the 
SV40 large and/or small T antigens were responsible for this activity. In 
parallel, BCA3 was identified as an apoptin-interacting protein, and the 
effects of PKA on apoptin phosphorylation were examined. Analysis of both 
transformation-related pathways revealed that inactivation of PP2A is crucial 
for the activation of apoptin. 
 
Materials and Methods 
 
Cells and Cell culture 
Human diploid foreskin F9 fibroblasts, isolated from neonatal foreskin, were 
obtained in the late 1980’s from Dr. M. Ponec (Dept. Dermatology, Leiden 
University Medical Center). Cells were batch-frozen after careful 
morphological inspection. At subsequent passages cells were regularly 
screened for their typical fibroblast-like morphological appearance. All cells 
used were below passage 15 and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% newborn calf serum, 100 U/ml penicillin 
and 100 µg/ml streptomycin (Invitrogen, Breda, the Netherlands). The 
human Saos-2 osteosarcoma and the HeLa cervical carcinoma cell lines were 
purchased from the American Type Culture Collection (ATCC) and cultured 
in the same medium as mentioned above. Cultures were regularly tested to 
ensure the absence of Mycoplasma infection. Cell morphology was regularly 
monitored to control the absence of cross-contamination. The sensitivity to 
apoptin is characteristic of the various cell types used (Danen-van Oorschot, 
et al., 1997) and is regularly assessed (see below). 
 
DNA plasmids 
The DNA sequence encoding apoptin was synthesized by BaseClear (Leiden, 
the Netherlands) according to the apoptin sequence published by Noteborn 
et al. (1991), and cloned into the mammalian expression vector pcDNA3.1(+) 
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(Invitrogen). The oligonucleotide fragment encoding the Flag-tag (Invitrogen) 
was inserted to create the pcDNA-Flag-apoptin plasmid encoding apoptin 
fused with a Flag-tag at its N-terminus.  
 
Plasmid pRSV-TN136 encoding the first 136 N-terminal amino acids of SV40 
LT, including the region coding for SV40 ST, was a kind gift from Dr. J.M. 
Pipas (Department of Biological Sciences, University of Pittsburgh, 
Pittsburgh, PA, USA). From pRSV-TN136, we generated the pcDNA-
LT136/ST plasmid, which encodes the LT136 (The N-terminally truncated LT 
fragment containing the first 1-136 aa) and full length ST. pcDNA-LT136, 
encoding LT136 only, was constructed by introducing an intron deletion 
disabling ST expression (Yamashita, et al., 1990). pcDNA expression vectors 
encoding only ST sequences were derived from pRSV-ST. pcDNA-ST encodes 
for ST; pcDNA-NLS-ST contains a ST fused to a nuclear localization signal 
(NLS-ST) and pcDNA-NLS-ST(C103S) encodes the N-terminal NLS-ST fusion 
protein containing the C103S mutation within the PP2A binding site 
(Gjoerup, et al., 2001). 
 
The sequences encoding the N-terminal 136 aa of LT together with either 
full-length ST or the C103S ST-mutant were cloned into pEXPR-IBA105 
vector to generate pEXPR-IBA105-LT136/ST and pEXPR-IBA105-
LT136/STC103S respectively. These plasmids expressed Strep-tagged 
LT136/ST or LT136/ST C103S proteins enabling interaction studies with 
PP2A (see below) (Schmidt and Skerra, 2007). pCEP-4HA-B56γ, encoding 
4HA-tagged B56γ, was a kind gift from Dr. M. Mumby (University of Texas, 
USA).  
 
Apoptin-interacting partners were obtained by yeast two-hybrid screening 
and verified by immunoprecipitation assays in mammalian cells, as 
previously described by Danen-Van Oorschot et al. (Danen-van Oorschot, et 
al., 2004). Positive clones from the yeast two-hybrid screen were digested 
with Xho-I to generate cDNA fragments, and subcloned into pMT2SM-myc to 
provide the fragments with an in-frame N-terminal myc-tag. The cDNA 
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We used transfection reagent DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate) (Danen-van Oorschot, et al., 1997) or 
AMAXA nucleofection technology in conjunction with cell type specific 
NucleofectorTM solution (Lonza, Cologne, Germany) (Rohn, et al., 2002) for 
DNA delivery into cells. When co-transfection or triple-transfection was 
performed, the ratio of each plasmid was 1:1 or 1:1:1 (in micrograms). In 
addition to the analysis by Western blot, the cells were seeded on several 
glass cover slips to allow parallel analysis at the single-cell level by 
immunofluorescence assay. 
 
Western Blot analysis 
Cells were lysed directly in Laemmli buffer (2% SDS, 10% Glycerol, 60mM 
Tris-Cl [pH6.8], 2% β-mercaptoethanol, 0.002% bromophenol blue). Cell 
lysates were separated by sodium dodecyl-sulfate-polyacrylamide gel 
electrophoresis, and electroblotted onto polyvinylidene difluoride membranes 
(Bio-Rad). Blots were then incubated with antibodies against 
phosphorylated-apoptin (α-108-P; Zhang, et al., 2004), Flag-apoptin (α-Flag 
M2, Sigma-Aldrich), SV40 LT (PAb416, Pab419, Calbiochem), SV40 ST 
(Pab280, Calbiochem), PP2A Aα (C-20, Santa Cruz), PP2A B56γ (α-B56γ, kind 
gift from Dr. Marc Mumby, Health Science Center, University of Texas, 
Texas, USA), PP2A B56δ (α-B56δ, Santa Cruz Biotechnology), myc-tagged 
BCA3 (α-myc, BD Biosciences), and actin (α-actin, Santa Cruz). Horseradish 
peroxidase-conjugated goat antibody against rabbit or mouse 
immunoglobulin G, or rabbit antibody against goat immunoglobulin G 
(Sigma-Aldrich) was used as secondary antibody for signal detection by 
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Protein interaction assays 
Detection of a possible interaction of ST or ST-C103S mutant protein with 
PP2A in human HeLa cells was performed as follows. Twenty-four hours 
after DNA transfection, cells were washed twice with phosphate buffered 
saline and harvested in ice-cold mild lysis buffer (50mM Tris [pH 7.5], 5mM 
EDTA, 250mM NaCl, 0.1% Triton X-100, 5 mM NaF,  1mM Na3VO4, 20mM 
beta-glycerolphosphate, and Protease Inhibitor Cocktail (Roche), followed by 
incubation on ice for 30 min. The supernatant of the lysates was prepared by 
centrifugation at 13,000 × g and 4°C for 30 min. Strep-tagged proteins and 
their interacting proteins were captured using the One-strep kit (IBA, 
Germany) according to the manufacturer’s protocol, and resolved on sodium 
dodecyl sulfate-polyacrylamide gel, followed by Western blotting analysis 
with appropriate antibodies.  
 
RNA interference assay 
For human PP2A B56γ, the target sequence was: 5’-
GATGAACCAACGTTAGAAG-3’; for PP2A B56δ two sequences were targeted 
(1): 5’ GTGTGTCTCTAGCCCCCAT 3’ (Arnold, et al., 2006) and (2) 5’ 
GACCATTTTGCATCGCATC 3’ (van Kanegan and Strack 2009) (data not 
shown). The pSUPER vector was designated for shRNA plasmid 
constructions (Boutros and Ahringer, 2008). The amplification and 
purification of plasmids were performed as specified by manufacturer’s 
instruction (GeneService, Cambridge, UK). Cells transfected with shRNA 
plasmids were lysed at 24-48 h after transfection, and then analyzed by 
Western blot assay as described above.  
 
Immunofluorescence assay 
Cells were grown on glass cover slips. At indicated time points after 
transfection, cover slips were first washed once with phosphate buffered 
saline, and subsequently fixed with methanol/acetone (50%/50%) for 5-10 
min at room temperature. After air-drying, the slides were used for 
immunocytochemical staining or stored at -20°C for further analysis. 
Immunocytochemical staining was carried out as described by Danen-Van 
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Oorschot et al. (2004). The following antibodies were used: α-108-P, a rabbit 
polyclonal antibody recognizing phosphorylated apoptin at T108 and α-Flag, 
a mouse monoclonal antibody recognizing Flag-apoptin. SV40 proteins were 
visualized with PAb416, a mouse monoclonal antibody recognizing the 
epitope residing in amino acids 83-128 of LT and non-reactive with ST or 
PAb280, a mouse monoclonal antibody against the C terminus of ST. The 
fluorescein isothiocyanate (FITC) or rhodamine conjugated goat antibodies 
(Jackson ImmunoResearch Laboratories) were used as secondary antibodies. 
Nuclei were stained with 2,4-Diamidino-2-phenylindole (DAPI) and apoptosis 
was assessed according to characteristic morphological changes (Danen-van 
Oorschot et al., 1997).  
 
PKA inhibition and stimulation 
Saos-2 cells were transfected with pcDNA-Flag-apoptin and incubated 24 
hours post-transfection with 10µM H89 (Millipore) for 1 hour (PKA 
inhibition), or 30 minutes with H89 followed by incubation with 1mM cAMP 
(Sigma) for another 30 minutes (PKA stimulation). Cells were then lysed in 
Laemmli buffer and the cell lysates analyzed for apoptin phosphorylation by 




Transient expression of N-terminal SV40 LT136/ST activates apoptin in 
normal human fibroblasts  
Apoptin activity can be induced in normal cells by transient expression of 
transforming SV40 antigens (Zhang, et al., 2004). Here, we examined the 
minimal SV40 domains responsible for this effect. Expression of the SV40 
LT136/ST DNA sequence results, due to alternative splicing, in 2 proteins: 
LT136, comprising the N-terminal 136 a.a. of LT, and the entire ST protein, 
consisting of 174 amino acids (Figure 6.1A) (Srinivasan, et al., 1997). LT136 
contains a DNA J domain, an Rb-binding site and a nuclear localization 
signal (NLS). ST shares its DNA J domain with LT136, but has a unique C-
terminal domain encompassing a PP2A binding site (Pipas, 2009).  




Figure 6.1 Transient expression of N-terminal determinants of SV40 T antigens activate 
apoptin. A. Schematic representation of the domains in SV40 LT136/ST. The J domain (a.a. 
1-82) is identical in both LT136 and ST. The Rb binding domain and nuclear localization 
signal (NLS) in LT136 are also shown. ST is expressed by differential splicing and has a 
unique C-terminus, which contains the PP2A binding domain. B. Human Fibroblasts (F9) 
were co-transfected with plasmids pcDNA-Flag-apoptin and pcDNA-LT136/ST (LT136/ST) 
or pcDNA-neo (neo) by AMAXA nucleofector transfection. Twenty-four hours post-
transfection, cells were lysed for Western blot analysis with the indicated antibodies. Mock-
transfected F9 cells were used as control. Antibody α-108-P specifically recognizes phospho-
apoptin at its Thr108. Flag-apoptin, LT and ST show the respective total protein amounts in 
the transfected cells. Actin was used as loading control. C-E. Cells were fixed for 
immunofluorescence analysis at each given time point after transfection and then stained 
with the indicated antibodies by indirect immunofluorescence assay. Scale bar = 20 µm. 
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In normal human foreskin fibroblasts, co-transfection of the SV40 LT136 
and ST proteins with Flag-tagged apoptin resulted in the latter’s 
phosphorylation (Figure 6.1B). Immunofluorescence analysis of F9 cells 
expressing all three proteins showed that Flag-apoptin became nuclear 
already 1 day after transfection. Nuclear Flag-apoptin was also shown to be 
phosphorylated (Figure 6.1C), and 3 and 5 days post transfection, apoptin 
was shown to induce apoptosis (Figure 6.1D, E). In contrast, F9 fibroblasts 
expressing apoptin alone contained mainly cytoplasmic Flag-apoptin, which 
was, as expected, not phosphorylated (Alvisi, et al., 2006; Rohn, et al., 2004) 
and did not induce apoptosis (Figure 6.1C-E).  
 
Our results clearly reveal that transient expression of LT136 and ST proteins 
in human F9 fibroblasts results in tumor-selective activation of apoptin, 
providing us with the possibility to explore which domains and respective 
cellular targets of LT136/ST were responsible for this activity. 
 
Nuclearly localized ST triggers apoptin activation  
Next, we examined whether expression of either LT136 or ST protein alone 
was sufficient to activate apoptin phosphorylation. F9 fibroblasts were co-
transfected with plasmids encoding Flag-tagged apoptin and either one of the 
following: a) pcDNA-LT136, encoding LT136, b) pcDNA-ST, encoding ST, c) 
pcDNA-LT136/ST, where both LT136 and ST are produced via alternative 
splicing, or d) pcDNA-neo, as a negative control. In each experiment, 
activation of apoptin was assayed by its phosphorylation at position T108, 
assessed by means of Western blotting.  Expression of LT136 alone did not 
trigger apoptin phosphorylation, whereas expression of ST clearly induced 
apoptin phosphorylation, albeit at a low level (Figure 6.2). Co-transfection of 
Flag-tagged apoptin with ST fused to an artificial nuclear location signal 

















Figure 6.2 Nuclear targeting of SV40 ST 
activates apoptin. In normal human 
fibroblasts, apoptin was co-transfected with 
vector only (Neo), LT136, ST, or both LT136 
and ST. Twenty-four hours post-transfection, 
cells were lysed for Western blot analysis with 




C103S mutation within PP2A-binding domain of ST disables activation 
of apoptin  
Besides its J domain, shared with LT136, ST contains a unique site for the 
binding and inactivation of PP2A. This domain has been shown to contribute 
to cellular transformation (Pipas, 2009). A single amino-acid mutation 
C103S within the ST protein drastically diminishes the interaction of ST with 
PP2A (Figure 6.3A) and its transforming capacity (Fahrbach, et al., 2008). 
Therefore, we studied the effect of the C103S mutation within the PP2A 
binding site on the activation of apoptin by (nuclear) ST in normal human 
cells.  
 
F9 cells were analyzed for phosphorylation of Flag-apoptin upon co-
expression with ST, NLS-ST or NLS-ST(C103S) protein. Figure 6.3B shows 
that expression of NLS-ST clearly induced apoptin phosphorylation.  
Introduction of the NLS-ST(C103S) mutation completely abolished this 
induction, although apoptin protein was expressed at a similar level. These 
results suggest that ST interaction with PP2A is crucial to apoptin activation, 
and that inactivation of PP2A by ST might be sufficient to activate apoptin.  
 




Figure 6.3 Apoptin activation via inhibition of PP2A by ST. A. PP2A binding to ST is 
abolished by C103S mutation. LT136 and ST with or without the C103S mutation 
(LT136/ST or LT136/ST(C103S) were fused with a Strep-tag at their N-terminus. Cell 
lysates were prepared at 24h post-transfection for protein-protein interaction assays as 
indicated in Material and Methods. The final elutions were analyzed by Western Blot with 
antibodies against PP2Aα subunit, LT and ST, respectively. Actin was taken as equal loading 
control. The first lane (input control) indicated total amount of endogenous proteins in direct 
cell lysates. B. pcDNA-Flag-apoptin was co-transfected with plasmids encoding the indicated 
proteins or vector DNA into F9 primary fibroblasts. Western blot assays were performed with 
the indicated antibodies at 24h post-transfection. 
 
Knock-down of PP2A B56γ via RNAi activates apoptin phosphorylation 
in normal human fibroblasts 
Two independent studies reported that ST interaction with PP2A resulted in 
the inhibition of the B56γ regulatory subunit, resulting in cellular 
transformation (Chen, et al., 2007; Cho, et al., 2007). Therefore, we 
examined whether down-regulation of B56γ via RNAi could trigger 
phosphorylation of apoptin in normal cells. Our shRNA sequence was 
verified to reduce ectopic expression of B56γ (Figure 6.4A). Normal F9 
fibroblasts co-expressing both apoptin and shRNA directed against B56γ 
mRNA manifested a clear level of phosphorylated apoptin in comparison to 
the cells transfected with apoptin and the RNAi control vector (Figure 6.4C). 
Our data thus indicate that inhibition of the PP2A B56γ subunit is a crucial 
and sufficient step for apoptin phosphorylation.  
 
 




Figure 6.4 Knock-down of PP2A B56γ and B56δ subunits triggers apoptin phosphorylation 
in normal cells. A. Down-regulation of PP2A B56γ subunit by shRNA. HeLa cells were co-
transfected with pCEP-4HA-B56γ expressing 4HA-tagged B56γ, and either shB56γ or control 
pSuper vector and lysed 48h post-transfection, followed by western blotting analysis with 
the indicated antibodies. B. Down-regulation of PP2A B56δ subunit by shRNA. F9 cells were 
transfected with pSuper vector encoding shRNA directed against PP2A B56δ or pSuper 
vector control; 24h post-transfection, cell lysates were prepared and subsequently analyzed 
by Western blot. C. F9 cells were co-transfected with Flag-apoptin and either pSuper vector 
encoding shRNA directed against PP2A B56γ, δ or control; 24-48h post-transfection, cell 
lysates were prepared and subsequently analyzed by Western blot. 
 
Over-expression of PKA-interacting protein BCA3 stimulates apoptin 
activity in tumor cells 
Analogous to the enhancing effect of ST on apoptin phosphorylation in 
normal cells, we observed an enhancement of apoptin phosphorylation in 
tumor cells by BCA3. BCA3 was identified as an apoptin-interacting protein 
by means of a yeast two-hybrid assay, and interacts with apoptin in a 
human cellular background (Figure 6.5A). Co-expression of BCA3 and Flag-
apoptin in human Saos-2 tumor cells resulted in a significant increase in the 
apoptosis activity of apoptin (Figure 6.5B). In fact, as early as 6 hours after 
transfection, phosphorylated apoptin could readily be detected in Saos-2 
cells expressing both apoptin and BCA3, whereas in cells expressing apoptin 
alone (control), apoptin phosphorylation was not yet visible at this early 
time-point (Figure 6.5C).  
 
As BCA3 (9) has been shown to interact with the catalytic subunit of PKA 
(Sastri, et al., 2005), the involvement of PKA in apoptin phosphorylation was 
investigated. Treatment of Saos-2 cells with H89, a known PKA inhibitor  
(Lochner and Moolman, 2006), enhanced apoptin phosphorylation. In 
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contrast, addition of the PKA activator cAMP (Bulun and Simpson, 2008) 
diminished apoptin phosphorylation (Figure 6.5D). These results suggest 
that interference with PKA activity favors activation of apoptin. Taking into 
account the fact that PP2A has been shown to be a target of PKA (Ahn, et al., 
2007), this provides another link pointing to the involvement of PP2A in the 
activation of apoptin.  
 
 
Figure 6.5 BCA3 interacts with 
apoptin and stimulates its activity. 
A. Apoptin interacts with BCA3 in a 
cellular background. Normal human 
foreskin fibroblasts were transfected 
with plasmids encoding myc-tagged 
BCA3 and Flag-tagged apoptin, or 
control plasmid in the indicated 
combinations. Total lysates (L) or 
protein complexes 
immunoprecipitated (IP) with 
antibody against the myc- (left panel) 
or Flag-tags (right panel) were 
separated by SDS-PAGE and 
analyzed by Western blot. B. 
Expression of myc-BCA3 together 
with Flag-apoptin results in 
increased induction of apoptosis. 
Human Saos-2 tumor cells were 
transfected with plasmids encoding 
Flag-tagged apoptin and myc-tagged 
BCA3, or vector control in the 
indicated combinations and grown 
on glass coverslips. Forty-eight hours 
post-transfection, slides were fixed 
and stained with appropriate 
antibodies for immunofluorescence 
analysis (right panel). pMaxGFP 
(Amaxa) was used as a negative 
control for apoptosis. Data are 
representative of 3 independent 
experiments, in which at least 100 
cells were scored. C. Co-expression 
of myc-BCA3 enhances apoptin 
phosphorylation. Saos-2 cells 
transfected with BCA3 and apoptin, 
or apoptin alone, were lysed 6 hours 
post-transfection and analyzed for apoptin phoshphorylation by Western blot analysis. D. 
Inhibition of PKA results in increased apoptin phosphorylation. Saos-2 cells were 
transfected with Flag-tagged apoptin, and treated with the PKA inhibitor H89 (1h, 10µM) or 
activator cAMP (30 minutes, 10µM H89, followed by 30 minutes 1mM cAMP) 24hs post-
transfection. Cells were then lysed and their contents analyzed by Western blot using 
indicated antibodies. 
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Down-regulation of PP2A B56δ subunit activates apoptin 
phosphorylation in normal cells 
Ahn et al. reported that the PP2A B56δ subunit is phosphorylated by PKA, 
thereby increasing the overall activity of PP2A. The activity of a B56δ mutant 
that cannot be phosphorylated by PKA is significantly less than its wild-type 
counterpart (Ahn, et al., 2007). Therefore, one can assume that inhibition of 
PKA results in a diminished functional PP2A B56δ subunit, and hence 
aberrant PP2A activity.  
 
We examined whether inhibition of the expression of the PP2A B56δ subunit 
in human F9 cells positively affected the phosphorylation of apoptin. Down-
regulation of B56δ protein expression through RNAi was confirmed in normal 
F9 fibroblasts (Figure 6.4B). Co-expression of shRNA targeting B56δ  mRNA 
and apoptin in normal F9 cells clearly resulted in the activation of apoptin 
phosphorylation, as compared to F9 cells transfected with apoptin and the 
RNAi control vector (Figure 6.4C).  
 
Our results imply that PP2A complexes containing the regulatory subunits 
B56 γ and δ are essential for maintaining a normal cell environment, as the 
loss of either one of these subunits results in the activation of apoptin, 




Activation of tumor-selective apoptosis-inducing proteins is an intriguing 
phenomenon, and revealing the molecular switch behind this process could 
allow important insights for developing anticancer therapies. Apoptin was 
the first protein known to harbor apoptosis activity selectively in transformed 
human cells (Danen-van Oorschot, et al., 1997). However, the molecular 
mechanisms underlying apoptin’s tumor-selective activity are largely 
unknown (Grimm and Noteborn, 2010). Here, our studies reveal that apoptin 
becomes activated by inhibition of normal PP2A function. Two independent 
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lines of research pointed to a fundamental role of PP2A in the regulation of 
apoptin activity. 
 
In one study, we examined the effect of specific domains within the 
transforming SV40 proteins LT136 and ST on the activation of apoptin. The 
C-terminal ST PP2A-binding transformation domain (Arroyo and Hahn, 
2005; Pipas, 2009), when targeted to the nucleus of normal cells, turned out 
to be crucial for the tumor-characteristic activation of apoptin. We showed 
that a C103S mutation within the ST PP2A binding site (Chen, et al., 2004) 
abrogated the phosphorylation of apoptin induced by NLS-ST in normal 
human fibroblasts. RNA interference studies confirmed that inactivation of 
the B56γ protein promotes phosphorylation of apoptin in human fibroblasts.  
 
A second line of research indicated that interference with the PP2A B56δ 
domain also led to the activation of apoptin. Over-expression of the apoptin- 
and PKA-interacting partner BCA3, or inhibition of PKA by treatment with 
H89 both resulted in enhanced phosphorylation and apoptosis activity of 
apoptin in human cancer cells. PKA is known to phosphorylate the B56δ 
subunit of PP2A leading to increased PP2A activity (Ahn, et al., 2007). RNA 
interference studies showed that inhibition of the synthesis of the PKA target 
PP2A-B56δ  indeed activated apoptin phosphorylation in normal human 
cells. 
 
Our studies, carried out from two different angles of research, reveal that 
apoptin senses PP2A inactivation during malignant cellular transformation. 
Interestingly, the delta and gamma subunits are the only nuclear PP2A B56 
subunits (Chen, et al., 2004; McCright, et al., 1996), and nuclear localization 
is important for both LT/ST-induced cell transformation and apoptin-
induced tumor-selective apoptosis. PP2A complexes containing B56δ 
domains prevent entry of cells into mitosis upon DNA damage (Virshup and 
Shenolikar, 2009), averting genetic instability that might contribute to cell 
transformation. B56γ mediates dephosphorylation and stabilization of the 
tumor suppressor protein p53 upon DNA damage, inhibiting cellular 
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proliferation and transformation (Li, et al., 2007). Studies have shown that 
derailment of B56γ results in aberrancies in functioning of e.g. cell cycle and 
tumor suppressor proteins, resulting in cell transformation (Chen, et al., 
2004; Sablina and Hahn, 2008).  
 
PP2A has also been shown to play a role in the activation of other tumor-
selective apoptosis-inducing proteins. Besides apoptin, also the adenovirus 
E4orf4 protein has been shown to selectively induce apoptosis in human 
cancer cells (Branton, et al., 2001; Kleinberger, 2000). Direct interaction of 
E4orf4 with PP2A regulatory B domains is essential for the tumor-selective 
apoptosis activity of E4orf4 (Strichman, et al., 2000). Interaction of E4orf4 
with the PP2A B55 subunit results in down-regulation of the expression of 
the Myc oncogene (Ben-Israel, et al., 2008). In addition to SV40 ST, other 
viral transforming proteins also interact with PP2A, showing its relevance in 
cellular transformation (Zhao and Elder, 2005). These findings corroborate 
earlier reports that aberrant PP2A functioning activates transforming 
processes, which then elicit the activation of tumor-selective apoptosis-
inducing proteins such as apoptin or E4orf4.    
 
Further steps within the development of tumorigenic cells seem at least not 
critical for apoptin’s tumor-selective apoptosis characteristics. These 
conclusions are in accordance with the observations by others and ourselves 
that apoptin is able to induce apoptosis in a very broad panel of tumor types 
(Backendorf, et al., 2008; Grimm and Noteborn, 2010; Maddika, et al., 2006; 
Tavassoli, et al., 2005). If one assumes that tumor cells arise by a wide 
variety of mechanisms, all the while sharing a limited number of key 
characteristics, then apoptin simply needs to recognize one (or a subset) of 
these characteristics.  
 
We have shown that inactivation of the nuclear PP2A B56 γ and/or δ 
subunits is sufficient to trigger apoptin’s tumor-selective apoptosis activity. 
PP2A provides a central phosphatase activity affecting many cellular 
signaling pathways, and derailment of PP2A activity seems to be one of the 
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fundamental events occurring during oncogenic transformation. This implies 
that apoptin might be applied for the treatment of tumors arising from a 
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Discussion, outlook and conclusions  
 
Mechanisms behind the tumor-specific apoptosis inducing 





With the discovery of apoptin’s unique capability to induce tumor-specific 
apoptosis, came the promise of the development of a potentially powerful, yet 
safe and effective, novel concept in anti-cancer therapy. Efforts to uncover 
the mechanisms underlying the differential behavior of apoptin in normal 
and transformed cells identified a number of interacting proteins – including 
Dedaf in tumor cells, and Hippi in normal cells – while a central dogma 
emerged: in tumor cells, apoptin was postulated to be phosphorylated, move 
to the nucleus and induce apoptosis, whereas in normal cells, according to 
the same dogma, apoptin would not be phosphorylated, remained in the 
cytoplasm and would eventually be eliminated from the cell. Recent research 
presented in this thesis, has provided important new clues into the workings 
of this enigmatic protein.  This chapter discusses these results against the 
backdrop of nearly two decades of apoptin research, highlighting the roles of 
new, key interacting partners of apoptin in the human cell. Novel insights 
into the pathways underlying apoptin cellular function are discussed, as well 
as how these could be used to improve cancer therapy.  
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The discovery of apoptin and its establishment as a Protein Killing 
Tumor Cells 
As introduced in chapter 2, apoptin is a small, proline-rich, protein encoded 
by the Chicken Anemia Virus (CAV; figure 7.1). Infection of young chicks 
with CAV causes anemia and immunodeficiency due to apoptosis of bone 
marrow, splenic and thymus cells, and apoptin was identified as the agent 
responsible for the induction of apoptosis (Jeurissen, et al., 1992; Noteborn, 
et al., 1994; Noteborn and Koch, 1995). Upon over-expression in human 
tumor cells, apoptin was shown to induce apoptosis in these cells as well 
(Zhuang, et al., 1995, 1995b), and even more excitingly, it did not do so 
when overexpressed in normal human cells (Danen-van Oorschot, et al., 




Figure 7.1 Schematic representation of the apoptin protein. A putative β-strand and two α-
helices, as predicted by the PSIPRED software, are indicated. The N-terminal (iso)leucine-
rich, multimerization and protein-protein interaction domain is indicated in blue, the bi-
partite NLS is indicated in yellow, surrounding the NES in green, and the T108 
phosphorylation site in red. Adapted from Backendorf, et al., 2008. 
 
Further comparison of the differential behavior of apoptin in normal and 
cancer cells revealed that apoptin had a cytoplasmic localization in the 
former, versus a nuclear localization in the latter (Danen-van Oorschot, et 
al., 1997). A bipartite nuclear localization signal (Poon, et al., 2005; Danen-
van Oorschot, et al., 2003) surrounding a nuclear export signal was 
identified between amino acids 80-121 (Poon, et al., 2005b). Located 
precisely in this region, a threonine amino acid at position 108 was identified 
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as the target of a yet unknown kinase activity, which appeared to be present 
in tumor cells but lacking in normal cells (Rohn, et al., 2002). Hence, it was 
hypothesized that apoptin was able to shuttle between the nucleus and 
cytoplasm, accumulating in the nucleus of tumor cells upon phoshorylation 
of T108, which would block the nuclear export signal (NES) while leaving the 
nuclear location signal (NLS) exposed. In normal cells, it would remain in the 
cytoplasm as a result of the exposed NES, where it would eventually be 
degraded and eliminated from the cell (Zhang, et al., 2003). Poon et al. 
(2005b) postulated that the phosphorylation of apoptin would most likely 
take place in the (tumor) cell nucleus. This was, however, challenged by the 
fact that phosphorylated apoptin could also be found in the cytoplasm of 
tumor cells (Zhang, et al., 2004; R. Zimmerman, unpublished results), 
consistent with recent findings in our laboratory that apoptin kinase activity 
can be found in both the cytoplasm and nucleus of various cancer cell lines 
(Lanz, et al., 2012). 
 
Immunoelectron microscopy determined that, within the nucleus, apoptin 
colocalized with heterochromatin and nucleoli, and apoptin was shown to 
bind DNA in vitro (Leliveld, et al., 2003, 2004). Intriguingly, however, 
experiments using actinomycin D, an RNA synthesis inhibitor, and two 
protein synthesis inhibitors (emetine and puromycin), demonstrated that 
apoptin’s cell-killing effects did not require de novo transcription or 
translation (Danen-van Oorschot, et al., 2003). Biochemical analysis further 
showed that apoptin functioned as a multimeric protein, with each multimer 
consisting of approximately 20-40 monomeric subunits (Leliveld, et al., 
2003). An N-terminal amphiphatic helix (amino acids 29-49) was identified 
as the multimerization domain; this multimerization domain was also 
postulated to be the interacting domain with other cellular proteins.  
 
Apoptin and its interacting proteins 
In an attempt to elucidate the molecular mechanisms involved in a) apoptin’s 
discrimination between normal and human cells, and b) the subsequent 
induction of apoptosis, human cellular proteins interacting with apoptin 
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were sought and identified. Below, we recapitulate the most important 
interactions found in literature, as well as the novel interacting proteins 
presented in this thesis (see Table 7-1 at the end of this chapter).  
 
PI3-K and Akt  
Class I phosphatidylinositol 3-kinases (PI3-Ks) play a central role in various 
regulatory processes, such as cell growth, survival and differentiation. As 
discussed in chapter 2, they are also involved in autophagic cell death, and 
can function both to limit and promote tumor development. The downstream 
effectors of PI3K include the Akt kinase (Marte and Downward, 1997; 
Vanhaesebroeck and Waterfield, 1999), which modulates the function of 
numerous substrates related to the regulation of cell proliferation, such as 
cyclin-dependent kinase inhibitors, p21Cip1/Waf1 (Li, et al., 2002), p27kip1, 
(Fruman, et al., 1998; Song, et al., 2005) and Nur77 (Pekarsky, et al., 2001). 
Another important function of activated PI3-K/Akt in cells is maintaining cell 
survival by inhibition of apoptosis, e.g. through Akt phosphorylation of Bad 
(Coffer, et al., 1998). 
 
Apoptin was shown to interact with the p85 regulatory subunit of PI3-K in 
both normal and cancer cells, leading to constitutive activation of PI3-K 
(Maddika, et al., 2008). Inhibition of PI3-K activation either by chemical 
inhibitors or by genetic approaches severely impaired cell death induced by 
apoptin. Downstream of PI3-K, Akt was activated and translocated to the 
nucleus together with apoptin. Direct interaction between apoptin and Akt 
was documented, and co-expression of nuclear Akt significantly potentiated 
cell death induced by apoptin (Maddika, et al., 2007). Accordingly, Nur77, 
one of the targets of activated Akt, was previously shown to translocate from 
the nucleus to mitochondria during apoptin-induced cell death (Maddika, et 
al., 2005).  
 
Hippi 
In chapter 2, we briefly alluded to the interaction between apoptin and 
Hippi. Hippi is the protein interactor and apoptosis co-mediator of 
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Huntingtin interacting protein 1 (Hip1). Diverse cellular functions have been 
described for Hippi (also known as estrogen-related receptor beta like 1 or 
intraflagellar transport 57 homolog). In Huntington’s disease, the Huntingtin 
(Htt) protein undergoes polyglutamine repeat expansion and loses its ability 
to interact with the endocytic protein Hip1. This allows Hip1/Hippi 
complexes to form and in turn trigger caspase-8-mediated apoptosis 
(Gervais, et al., 2002). Moreover, Hippi was found to be a transcriptional 
regulator of caspase expression: exogenous expression of HIPPI increases 
expression of caspases-1, -8 and -10 in HeLa and Neuro2A cells and induces 
apoptosis (Majumder, et al., 2007; 2007b). In addition to this possible 
caspase-dependent mechanism for pathological cell death in Huntington’s 
disease (Ferrier, 2002), Hippi was also reported to activate the mitochondrial 
(intrinsic) apoptotic pathway in neuronal cells through Bid cleavage 
(Majumder, et al., 2006), and to bind other apoptosis-related proteins, 
including apoptin, and the apoptin-interacting protein Rybp/DEDAF 
(Stanton, et al., 2007; see below).  
 
Mapping studies indicate that Hippi binds within the self-multimerization 
domain of apoptin, and apoptin binds to the C-terminal half of Hippi, 
including its death effector domain-like motif (Cheng, et al., 2003). 
Subcellular localization studies showed that Hippi and apoptin perfectly 
colocalized in the cytoplasm of normal human HEL cells, whereas in 
cancerous HeLa cells most apoptin and Hippi were located separately in the 
nucleus and cytoplasm, respectively. These results suggested that the 
interaction with Hippi might play a role in the suppression of apoptin-
induced apoptosis in normal cells. However, over-expression of Hippi in 
HeLa cells did not prevent apoptin nuclear accumulation, nor did it inhibit 
its apoptotic activity, indicating that there is still another factor involved in 
determining the cytoplasmic localization of apoptin and inhibition of 
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FAM96B (Chapter 4) 
Family with sequence similarity 96, member B (FAM96B) is a highly 
conserved protein, whose function was until recently unknown. Proteins 
sharing its conserved domain DUF59 serve a variety of roles, including 
phenylacetic acid degradation, iron-sulfur cluster biosynthesis, nucleotide-
binding and chromosome partitioning, and calcium-dependent protein 
phosphorylation  (Finn, et al., 2010). 
 
We found that FAM96B interacts with apoptin in both normal and tumor 
cells (chapter 4). Interestingly, this function was independent of apoptin 
phosphorylation. Proteomic analysis suggests FAM96B is involved in the 
establishment of sister chromatid cohesion and subsequent chromosome 
segregation (chapter 4; Ben Arroya, et al., 2008; Ito, et al., 2010). FAM96B 
associates with various proteins involved in DNA replication and repair, as 
well as, cytoskeletal components, effectively linking the DNA damage 
response to sister chromatid cohesion and segregation, and cell cycle 
regulation. Preliminary results indicate FAM96B is down-regulated in tumor 
cells (R. Zimmerman, J. Tian and C. Backendorf, unpublished results). 
Furthermore, studies in yeast (Ben-Aroya, et al., 2008) and preliminary 
observations in zebrafish (R. Zimmerman, unpublished results) indicate that 
FAM96B is an essential gene required for normal embryonic development. 
This implies that ectopic expression of FAM96B reimposes a cellular control 
mechanism (most likely regarding its function in linking the DNA damage 
response to control of the mitotic spindle), which is recognized by apoptin: in 
normal cells, this prevents apoptin-induced apoptosis, whereas in tumor 
cells, where this control mechanism is lacking, apoptin-induced apoptosis is 
triggered.  
 
RYBP/DEDAF and other nucleolar proteins (chapter 5) 
One of the proteins found to associate with FAM96B is Rybp/DEDAF 
(chapter 4). Coincidentally, the same protein was also found to interact with 




Rybp (RING1 and YY1 binding protein) belongs to the Rybp/Yaf2 family of 
small, basic, Npl4 zinc finger (NZF)-containing proteins that have been 
highly conserved throughout evolution. Initially, Rybp was characterized as 
an interacting partner for proteins involved in transcriptional regulation, 
such as YY1 and members of the E2F family, as well as with transcriptional 
co-repressors such as Polycomb group proteins (Bejarano, et al., 2005; 
Garcia, et al., 1999; Sawa, et al., 2002; Schlisio, et al., 2002; Trimarchi, et 
al., 2001). Importantly, Rybp is involved in the p53 response to DNA 
damage, by interacting with MDM2 and decreasing MDM2-mediated p53 
ubiquitination, leading to stabilization of p53 and cell-cycle arrest (Chen, et 
al., 2009).  
 
Beyond this, Rybp has been implicated in the promotion of apoptosis. Rybp 
binds heterotypically to several DED-containing apoptotic mediators, and 
accordingly is also known as DEDAF, for death effector domain associated 
factor (Zheng, et al., 2001). Homophilic interactions of death effector 
domains (DEDs) are crucial for the signaling pathways of death receptor-
mediated apoptosis. Rybp/DEDAF interacts with FADD, procaspase-8, and 
procaspase-10 in the cytosol, as well as with the DED-containing DNA-
binding protein (DEDD) in the nucleus. It can enhance both death receptor- 
and caspase-10 DED-mediated apoptosis in lymphoma cell lines (Zheng, et 
al., 2001). At the cell membrane, it augmented the formation of CD95-FADD-
caspase-8 complexes and enhanced death receptor- as well as DED-
mediated apoptosis. In the nucleus, Rybp/DEDAF caused the DEDD protein 
to relocalize from subnuclear structures to a diffuse distribution in the 
nucleoplasm.  
 
As mentioned before, Rybp/DEDAF also interacts with apoptin and has been 
suggested, like apoptin, to induce apoptosis preferentially in transformed cell 
lines (Danen-van Oorschot, et al., 2004; Novak and Phillips, 2008). 
Accordingly, expression of Rybp/DEDAF is decreased in human cancer 
tissues compared with adjacent normal tissues. Rybp/DEDAF is 
predominantly nuclear and partially co-localizes with apoptin in intact and 
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apoptotic tumor cells, but not in normal cells, where it is nuclear while 
apoptin remains cytoplasmic.  
 
In chapter 5, apoptin was demonstrated to interact with chromatin, and 
possibly nucleolar (R-)chromatin. Indeed, proteins co-purifying with 
chromatin-associated apoptin complexes included the nucleolar proteins 
Cdc5L, nucleophosmin and nucleolin, as well as components of the mitotic 
spindle and the PP2A inhibiting, cell cycle regulatory protein SET1. Like 
DEDAF, both Cdc5L and nucleophosmin play important roles in the 
response to DNA damage and maintenance of genomic stability; in addition, 
Cdc5L and SET1 are involved in the progression of both S-phase and the 
G2/M transition. Nucleophosmin is also involved in cellular growth through 
nucleocytoplasmic export of ribosomes, and centrosome duplication and 
mitotic spindle formation, with nucleolin sharing similar functions. Together 
with the identification of proteins involved in ribosome biogenesis and RNA 
metabolism, the data suggest that apoptin orchestrates its apoptotic effects 
from within the nucleolus, where it senses DNA damage and shuts down the 
cellular protein factory. 
 
Rsf-1  
One of the apoptin-interacting proteins found by yeast-two-hybrid assay is 
Rsf-1. We found that Rsf-1 interacted and colocalized with apoptin in the 
nucleus of human tumor cells (R. Zimmerman and A. Danen-van Oorschot, 
unpublished results). RSF is a heterodimer of the PHD-finger containing 
protein Rsf-1 and the SNF2H ATPase belonging to the ISWI family, and a 
unique chromatin remodeling factor that can assemble regularly spaced 
nucleosomal arrays without the aid of additional histone chaperones (Loyola, 
et al., 2001; 2003). Such nucleosome remodeling is essential for 
transcriptional activation or repression (Vignali, et al., 2000), DNA 
replication (Flanagan and Peterson, 1999), and cell cycle progression 
(Cosma, et al., 1999). Rsf-1 was found to play a role in silent chromatin 
formation by promoting histone H2Av replacement. H2Av is the Drosophila 
variant of mammalian H2AZ, a histone H2A variant that is essential for 
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establishing proper chromatin structure in many organisms  (Raisner and 
Madhani, 2006; Greaves, et al., 2007; Rangasamy, et al., 2004), and is 
involved in the formation of constitutive, as well as, facultative 
heterochromatin (Greaves, et al., 2006; Sarcinella, et al., 2007). Drosophila 
H2Av mutants exhibit reduced H3 lysine 9 (H3K9) methylation and HP1 
binding (Swaminathan, et al., 2005), both of which are required to recruit 
Suv420h1/2 for the establishment of heterochromatin (Schotta, et al., 2004). 
In Drosophila melanogaster, loss of RSF function reduced the levels of the 
histone variant H2Av and histone H3-K9 methylation, and suppressed 
silencing of transcription in a euchromatic region near the centromeric 
heterochromatin (Hanai, et al., 2008).  
 
RSF was also found to interact with CENP-A chromatin, a histone H3 variant 
that is crucial to the formation of centromeric chromatin (Perpelescu, et al., 
2009). Rsf-1 depletion induced loss of centromeric CENP-A, and purified RSF 
complex reconstituted and spaced CENP-A nucleosomes in vitro, further 
implicating the involvement of Rsf-1 in this process. 
 
The sequence of the gene for Rsf-1 is located on chromosome 11q13, and 
includes that for HBXAP, which was postulated to be involved in the 
transcriptional regulation of the hepatitis B virus (Shamay, et al., 2002). 
HBXAP actually contains a 252-amino-acid truncation of the amino terminus 
of Rsf-1, which lacks the ISWI-interaction domain, and therefore is not 
functional within the RSF complex. Amplification at the 11q13 locus is 
commonly observed in breast, ovarian, head and neck, oral, and esophageal 
cancer (Mao, et al., 2006; Schwab, 1998; Shih Ie, et al., 2005; Nakayama, et 
al., 2007). Patients with Rsf-1 amplification or over-expression had a 
significantly shorter overall survival than those without (Shih Ie, et al., 
2005). In vitro, over-expression of the Rsf-1 gene stimulated cell proliferation 
and transformation of nonneoplastic cells by conferring serum-independent 
and anchorage-independent growth. Furthermore, Rsf-1 gene knockdown 
inhibited cell growth in OVCAR3 cells, which harbor Rsf-1 amplification 
(Shih Ie, et al., 2005). The association of Rsf-1 amplification cq over-
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expression with worse survival in (ovarian) cancer patients, combined with 
the stimulatory effect on cell proliferation in vitro, is similar to the properties 
of known oncogenes, including HER2/neu in breast cancer (Borg, et al., 
1990; Tsuda, et al., 1989) and N-myc in neuroblastoma (Rubie, et al., 1997). 
This suggests that Rsf-1 itself has oncogenic potential; consistent with such 
a function, Rsf-1 was found to be up-regulated in paclitaxel-resistant 
ovarian cancer cell lines, and Rsf-1 gene knockdown sensitized tumor cells 
to paclitaxel (Choi, et al., 2009). Down-regulation of hSNF2H or disruption of 
hSNF2H and Rsf-1 interaction also enhanced paclitaxel sensitivity in tumor 
cells with Rsf-1 up-regulation. On the other hand, ectopic expression of Rsf-
1 significantly enhanced paclitaxel resistance in ovarian cancer cells.  
 
Preliminary observations showed that co-expression of Rsf-1 together with 
apoptin stimulates apoptin-induced apoptosis (R. Zimmerman, unpublished 
results), corroborating both the oncogenic potential of Rsf-1 and the 
preference of apoptin for a transformed environment. 
 
Suv420h1 
Suppressor of variegation 4-20 homolog 1, or Suv420h1, is a SET-domain 
containing protein, which was found to interact with apoptin in a yeast two-
hybrid assay (A. Danen-van Oorschot, unpublished results). SET domains 
are found in histone methyl transferases (HMTs) (Qian and Zhou, 2006), and 
also serve as interaction domains with dual-specificity protein phosphatases 
(dsPTPases) (Cui, et al., 1998). Intriguingly, CAV VP2 has been shown to 
encode such a dsPTPase (Peters, et al., 2002), and SET domain-dsPTPase 
interactions appear to be critically important for regulating the growth 
properties of lymphoid progenitors (De Vivo, et al., 1998), which are among 
the preferentially targeted cell types during CAV infection (Adair, 2000).  
 
Drosophila Suv4-20 is a mixed product specificity methyltransferase that 
dimethylates approximately 90% and trimethylates less than 5% of total H4 
at lysine 20 in S2 cells (Yang, et al., 2008). Similar to the Drosophila 
enzyme, human Suv4-20h1/h2 enzymes generate di- and trimethyl H4K20 
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(Schotta, et al., 2004; 2008; Yang, et al., 2008). Dimethyl H4K20 has been 
shown to recruit the p53 binding protein 53BP1 to DNA damage foci in the 
fission yeast S. pombe, and is essential for the proper execution of the DNA 
damage response (Sanders, et al., 2004; Greeson, et al., 2008). Depletion of 
Suv4-20h1/2 in human HeLa cells impaired the formation of 53BP1 foci 
(Yang, et al., 2008), suggesting that dimethyl H4K20 is also required for a 
proper DNA damage response in human cells. The proposed mechanism 
involves exposure of normally buried H4K20me2 epitopes upon DNA double 
strand breaks (Yang and Mizzen, 2009; Botuyan, et al., 2006).  
 
Histone H4 lysine 20 trimethylation (H4K20me3) has been implicated in the 
formation of constitutive heterochromatin, particularly at (peri)centromeric 
and (sub)telomeric regions (Schotta, et al., 2004; Benetti, et al., 2007; 
Kourmouli, et al., 2004; Sims, et al., 2006). This requires trimethylation of 
H3K9 by Suv39h1/2 enzymes and the subsequent binding of HP1 proteins, 
which function to recruit Suv420h1/2 (Schotta, et al., 2004). Accordingly, 
trimethylation of H4K20, but not dimethylation, is reduced in Drosophila 
larvae lacking HP1 (Yang, et al., 2008).  
 
H4K20me3 has been shown to be down-regulated in human cancer (Fraga, 
et al., 2005; Van Den Broeck, et al., 2008). This might be achieved via 
downregulation of the Suv420h1/2 enzymes (Van Den Broeck, et al., 2008; 
Pogribny, et al., 2006; Tryndyak, et al., 2006), but also by alteration of HP1 
binding dynamics (Siddiqui, et al., 2007). Loss of H4K20me3 might lead to 
activation of transcription of previously repressed genes (through alteration 
of chromatin structure), unstable kinetochore attachment sites, as well as 
uncapped telomeres (Benetti, et al., 2007a; 2007b). In a normal cell, these 
effects might lead to cell cycle arrest and/or programmed cell death; 
however, in a malignant cell, this might only serve to increase genomic 
instability, contributing to further tumorigenesis. In addition, 
downregulation of the Suv420h enzymes also impairs DNA damage signaling 
through loss of H4K20me2, further contributing to genomic instability 
(Schotta, et al., 2008; Rouse and Jackson, 2002; Zhou and Elledge, 2000).  
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We found that apoptin interacts with Suv420h1 in human tumor cells, and 
both proteins seem to cooperate to induce apoptosis in these cells (R. 
Zimmerman, unpublished results). Preliminary results suggest that 
Suv420h1 itself was also able to induce tumor-selective apoptosis, as its 
over-expression induced apoptosis in tumor cells but not in normal cells. 
Furthermore, we found that Suv420h1 interacted with HP1 beta in both 
normal and cancer cells (R. Zimmerman and H. Lanz, unpublished results). 
This concurs with reports that HP1 beta is involved in DNA damage signaling 
originating from DNA breaks in H3K9me3-containing chromatin (Ayoub, et 
al., 2008). 
 
BCA3/AKIP1 (Chapter 6) 
Another protein identified as an interacting partner of apoptin in our yeast 
two-hybrid assay is BCA3 (chapter 6). Breast cancer associated gene 3 
(BCA3) was identified as a gene that was overexpressed in breast cancer 
compared to surrounding normal stroma (Kitching, et al., 2003; Leon and 
Canaves, 2003). It has been shown to interact with a number of proteins, 
including the catalytic subunit of protein kinase A (hence the alternative 
name A-kinase interacting protein 1, or AKIP1) (Sastri, et al., 2005), the 
transcription factor KyoT2 (Qin, et al., 2004), and Rac1 (Yu, et al., 2007).  
 
Under normal cellular conditions, PKA resides in the cytoplasm as an 
inactive holoenzyme consisting of two regulatory subunits complexed with 
two catalytic subunits. A-kinase associated proteins, or AKAPs, interact with 
the regulatory subunits and control PKA activity by anchoring the 
holoenzyme complexes at specific subcellular localizations. Upon activation 
by cAMP, the regulatory subunits dissociate, freeing the catalytic subunits. 
AKIP1 binds to the latter, reportedly facilitating its translocation into the 
nucleus (Sastri, et al., 2005).  
 
Over-expression of BCA3 appeared to induce apoptosis in human tumor 
cells, and co-expression with apoptin led to an increase in tumor cell death 
(Chapter 6). The negative effect of BCA3 on cellular proliferation had been 
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observed previously in osteoclasts (Yu, et al., 2007). In these cells, it was 
shown to interact with Rac1, a small GTPase that belongs to the Ras 
superfamily and participates in a wide range of biological processes, 
including rearrangement of the actin cytoskeleton, cell motility, cell 
transformation, gene transcription, and cell cycle progression (Michiels and 
Collard, 1999; Hall, 2005). The interaction of BCA3 with Rac1 attenuated 
colony stimulating factor-1 (CSF-1) induced cell spreading.  
 
Another interaction partner of BCA3 was identified as TAp73 (Leung and 
Ngan, 2010). TAp73 is highly similar to p53, and exhibits growth-inhibitory, 
tumor-suppressive, and proapoptotic functions (Kaghad, et al., 1997; Jost, 
et al., 1997). TAp73 binds and stabilizes BCA3 in the cervical cancer cell line 
HeLa (Leung and Ngan, 2010). When coexpressed with TAp73, BCA3 
interacts and colocalizes with TAp73 at the mitochondria. Furthermore, 
BCA3 augments the transactivation activity of TAp73 on Bax promoter, 
enhancing Bax protein expression. In addition, the expression of BCA3 also 
increases the sensitivity of TAp73-transfected cells to γ-irradiation–induced 
apoptosis, inducing activation of caspase-7 and caspase-9. Interestingly, 
Klanrit et al. (2008) reported that over-expression of TAp73 was able to 
sensitize p53-negative tumor cells to apoptin-induced cell death.  
 
APC 
In transformed cells but not in normal cells, apoptin associates with APC1, 
the largest subunit of the anaphase-promoting complex/cyclosome (APC/C) 
(Teodoro, et al., 2004) and an essential component of the mitotic checkpoint 
apparatus (see chapter 2). Apoptin expression, or depletion of APC1 by RNA 
interference, inhibits APC/C function in p53 null cells, resulting in G2/M 
arrest and apoptosis. Furthermore, apoptin expression in transformed cells 
induces the formation of nuclear bodies and recruits APC/C to these 
subnuclear structures (Heilman, et al., 2006); the interaction with PML is, 
however, not required for induction of apoptosis by apoptin (Janssen, et al., 
2007).  
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Teodoro, et al. (2004) also reported the interaction of apoptin with α-tubulin, 
β-tubulin and β-actin, suggesting an association with filamentous networks. 
As subunits of the APC/C, including APC1, have been shown to localize to 
the active centromere of dicentric chromosomes (Saffery, et al., 2000), they 
proposed that the observed association of apoptin with α- and β-tubulin 
might result from interaction between apoptin and the spindle complex. The 
interaction of apoptin with FAM96B (which controls chromosome 
segregation, chapter 4) and BCA3 (which localizes to the centrosome, 
chapter 6), as well as the identification of tubulin in chromatin-bound 




Alas, the list of apoptin interacting proteins lacks one crucial protein: a 
kinase, which is able to phosphorylate apoptin at T108, and which is only 
active in transformed and tumor cells. For, though they were found to 
interact with apoptin, neither PI3K nor PKA were able to phosphorylate it.  
 
Maddika, et al. (2009) described that Cdk2 complexed with cyclin A, but not 
E, could phosphorylate apoptin at T108, yet could not prove that this 
phosphorylation was specific to the tumorigenic environment. PKCβ has also 
been implicated in apoptin phosphorylation (Jiang, et al., 2010), Recently, 
however, our laboratory showed that that immunoprecipitation of both CDK2 
and PKCβ significantly reduced the levels of these proteins in tumor cell 
lysates, without affecting the level of apoptin phosphorylation by these 
tumor cell lysates in an in vitro kinase assay (Lanz, et al., 2012). Therefore, 
at the moment no conclusive statement can be drawn about the kinase 
modifying and activating apoptin.  
 
Zhang, et al. (2004) did find that the apoptin kinase activity could be 
specifically turned on by transient transformation of normal human 
fibroblasts expressing apoptin with the SV40 large T antigen. These results 
were further investigated in chapter 6. Here, we demonstrated that upon 
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expression of the SV40 large T antigen (LT), the small T antigen (ST) was also 
expressed. In fact, co-expression of the ST was essential to induce apoptin 
phosphorylation upon cellular transformation by SV40 LT. Analysis of ST 
functional domains, through stepwise mutational inactivation, proved that 
the interaction of ST with B56 gamma-containing PP2A was required for 
apoptin activation. Simultaneously, analysis of the effect of PKA activity on 
apoptin phosphorylation pointed to its involvement in the regulation of PP2A 
B56 delta activity. Subsequently, we found that down-regulation of PP2A 
B56 gamma and B56 delta expression through RNAi in normal cells indeed 
resulted in apoptin phosphorylation. Hence, the data presented in this thesis 
argue for an apoptin normal-cell-specific phosphatase next to a tumor-
specific kinase, even not excluding the possibility that apoptin might be 
phosphorylated by more than one kinase, and that its differential activation 
between normal and tumor cells rather depends on the activity of the tumor 
suppressor phosphatase PP2A. 
 
Outlook 
Synthesis – how might the pieces of the apoptin puzzle fit together? 
The experimental results with the newly discovered apoptin-interacting 
proteins presented in this thesis, combined with knowledge from previously 
published analyses, lead to the proposal of the following model for apoptin 
behavior in the human cell (figure 7.2).  
 
In the normal human cell (figure 7.2A), upon expression of the apoptin 
protein, apoptin is at first free to move between the nucleus and cytoplasm, 
owing to its NLS and NES. Apoptin might be phosphorylated, but it is also 
dephosphorylated by PP2A, reaching an equilibrium which finds it mostly 
unphosphorylated. Apoptin is mainly located in the cytoplasm, where it 
interacts with Hippi and accumulates in cytoplasmic granules. The exact 
nature of these cytoplasmic granules is not known; immune fluorescence 
analysis has revealed partial co-localization with markers for the lysosome, 
Golgi, ER and endosomal vesicles as well (R. Zimmerman, unpublished 
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results). Whichever the mechanism, apoptin does in fact disappear from the 
normal cell, without inducing cell death.  
 
 
Figure 7.2 Model of apoptin tumor-specific cell death pathways. A. In the normal cell, 
apoptin phosphorylation is opposed by the action of PP2A B56 gamma- and delta- 
containing complexes. The presence of FAM96B safeguards the cell cycle, while H4K20 di- 
and trimethylation function to recruit DNA repair machinery and telomere-capping proteins, 
respectively, preventing genomic instability. As a result of these actions, apoptin is 
redirected to the cytoplasm, where it interacts with e.g. Bip in the ER and Hippi in Golgi 
vesicles, and is eventually eliminated from the cell without inducing apoptosis. See text for 
further details. 
 
In the transformed cell (figure 7.2B), many cellular processes have gone 
awry: the activity of (potential) tumor suppressor proteins PP2A, FAM96B 
and Suv420h1 is derailed, while the expression of (potentially) oncogenic 
proteins, Rsf-1 and BCA3 has increased. Loss of FAM96B results in a failure 
to arrest the cell cycle upon DNA damage, whereas loss of H4K20 
trimethylation results in telomere uncapping and lack of proper pericentric 
heterochromatin formation, resulting in inappropriate kinetochore 
attachment sites. Over-expression of Rsf-1 and BCA3 might also contribute 
to the formation of aberrant mitotic spindles; altogether, the resulting 
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genomic instability would constantly signal to the DNA damage response 
machinery, whereas the ability to arrest the cell cycle and/or induce 
apoptosis has been lost. Loss of PP2A activity means apoptin 
phosphorylation is no longer opposed, leading to the accumulation of 
apoptin in the tumor cell nucleus. Within the nucleus, apoptin localizes to 
the nucleoli, where it cooperates with Rybp/DEDAF and e.g. nucleophosmin 
in sensing the many DNA damage signals. Furthermore, apoptin interacts 
with Rsf-1 at chromosome centromeres, where it inhibits APC1 activity. As a 
result, the APC cyclosome cannot catalyze chromosome segregation; in 
addition, interference of apoptin and BCA3 with the mitotic spindle 
contributes to the resulting mitotic failure and the inevitable cell death 
following it (figure 7.2 C, D).  
 
 
Figure 7.2 Model of apoptin tumor-specific cell death pathways. B. In the cancer cell, 
apoptin phosphorylation is no longer opposed, and phosphorylated apoptin accumulates in 
the nucleus, colocalizing with DEDAF and other proteins in the nucleolus, while also 
colocalizing with BCA3 at the centrosome. See text for further details.
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Figure 7.2 Model of apoptin tumor-specific cell death pathways. C. Over-expression of Rsf-1 
and BCA3 contribute to the formation of faulty mitotic spindles. Lack of H4K20 methylation 
means DSBs are no longer repaired, and telomeres become uncapped. Apoptin recognizes 
the activation of the DNA damage response, and inhibits APC1 activity, halting the 
anaphase-promoting complex and inducing G2/M arrest. See text for further details.  
 
How apoptin might distinguish between normal and tumor cells 
From the proposed model, it results that apoptin’s differential recognition of 
normal and transformed cells likely depends on three key properties of 
malignant cells: (1) sustained cellular proliferation and (2) the lack of 
execution of programmed cell death in the face of (3) severe DNA damage. 
Though apoptin has been shown to possess two different death domains, one 
acting from within the cytoplasm (Danen-van Oorschot, et al., 2003), it 
seems that the crucial step in blocking apoptin-induced apoptosis in normal 
cells is inhibiting its nuclear accumulation. Still, even if apoptin is forced to 
the nucleus of normal cells, it has been confirmed that this is not enough to 
induce apoptosis (Danen-van Oorschot, et al., 2003) – probably because of 
the lack of signals that cellular proliferation has gone awry, including 
silencing of tumor suppressor genes (e.g. FAM96B, PP2A), over-expression of 
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oncogenes (e.g. Rsf-1, and possibly BCA3), and the lack of DNA damage. It is 
the combination of these events that appears to tip the equilibrium to the 
side of apoptin phosphorylation, and hence, activation. Indeed, recent 
experiments (Kucharski, et al., 2011) demonstrated that induction of DNA 
damage was sufficient to activate apoptin, resulting in its nuclear 
translocation and induction of apoptosis in primary cells.  
 
 
Figure 7.2 Model of apoptin tumor-specific cell death pathways. D. These effects, in 
addition to apoptin association with the mitotic spindle, lead to mitotic catastrophe and 
apoptotic cell death. See text for further details.  
 
Mechanism of apoptin-induced apoptosis in tumor cells 
In the model proposed above, activated apoptin induces cell death through 
several modes of action: i) it localizes to the nucleoli, where it ia) senses DNA 
damage, activating DEDAF, among other proteins, to induce apoptosis, and 
ib) interacts with ribosomal chromatin and constituents, effectively shutting 
off cellular biosynthesis; ii) it induces mitotic failure through a doubly lethal 
combination of iia) interaction cq interference with several components of the 
mitotic spindle; and iib) inhibition of APC-catalyzed segregation of 
chromosomes. Not only is the cell therefore physically unable to divide, 
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leading to mitotic catastrophe, but also, even if the cell would manage to 
survive this event, it would die as a result of the lack of cellular biosynthesis.  
 
The results described in this thesis correlate with the previous findings in 
literature, stating that apoptin-induced tumor-selective apoptosis does not 
require de novo gene transcription/translation (Danen-van Oorschot, et al., 
2003). The same is true for the independence of p53 activity (Zhuang, et al., 
1995b), and the paradoxical relation with Bcl-2. As discussed in chapter 2, 
during mitosis, DNA damage activates the ATM/ATR signaling pathways; 
DNA single strand breaks (SSBs) activate Chk1, which inhibits the action of 
Cdc25c, leading to G2/M cell cycle arrest – as previously observed for 
apoptin, and independently of p53. DNA double strand breaks (DSBs) 
activate Chk2, which activates both p53 and p73; intriguingly, p73 has 
indeed been shown to be involved in apoptin-induced apoptosis. 
Furthermore, DNA damage-induced signaling, through an as yet unclear 
mechanism, leads to the activation of caspase-2, which directly stimulates 
cytochrome c release, G2/M cell cycle arrest and mitotic catastrophe, 
independently of either p53 or Bcl-2. In fact, it has been reported that over-
expression of Bcl-2 resulted in an enhanced frequency of mitotic catastrophe 
(see chapter 2). This is consistent with reports that over-expression of Bcl-2 
does not necessarily impede apoptin-induced apoptosis, and may even have 
a stimulatory effect (Danen-Van Oorschot, et al., 1999; Danen-Van 
Oorschot, et al., 1999b).  
 
Implications for CAV pathogenesis 
One cannot help but wonder how all this applies to the natural function of 
apoptin in CAV pathogenesis. In young chicks, CAV has been shown to 
preferentially target the cells of the bone marrow and thymus (Adair, 2000); 
besides rapid proliferation, these cells are also constantly undergoing 
rearrangements of their DNA, which could be perceived by apoptin as 
damaged DNA. In addition, many viral proteins have been shown to localize 
to the nucleolus (Hiscox, 2007), where they hijack the cell’s protein factory 
and redirect it towards their own multiplication. The subsequent induction 
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of apoptosis then leads to release of the viral progeny, and, concurrently, to 
further spreading of the infection, as nearby cells engulf the apoptotic bodies 
containing newly formed viral particles.  
 
Chickens develop a resistance to CAV-induced disease by two weeks of age; 
furthermore, experiments in normal human lymphocytes have shown that 
apoptin is not toxic to these cells. In addition, systemic expression of apoptin 
in mice does not induce apoptosis in erythroid or lymphogenic cells or their 
precursors, indicating that apoptin is indeed safe for anti-tumor therapy in 
humans (Pietersen, et al., 2005; Peng, et al., 2007).  
 
Implications for anticancer therapies 
A comparison between apoptin and the other PKTC presented in chapter 3 
reveals a number of common strategies, which could be exploited in the 
design of novel anticancer therapies.  
 
Apoptin (Liu, et al., 2006a, 2006b), TRAIL (Voelkel-Johnson, et al., 2005) 
and MDA-7/IL-24 (Sauane, et al., 2010) have all been shown to up-regulate 
ceramide production, indicating that this might be a convenient strategy in 
killing cancer cells. Autophagy seems to be a common theme, with HAMLET 
(Aits, et al., 2009), NS1 (Bruno, et al., 2009), and Brevinin-2R (Ghavami, et 
al., 2008) all employing autophagic cell death to specifically kill tumor cells. 
As one of the pathways mitigating the metabolic switch (the seventh cancer 
hallmark), this indeed seems warranted. Perhaps related to this, the 
adenovirus E4orf4 protein has been demonstrated to kill tumor cells by 
perturbing the traffic of endosomal vesicles (Landry, et al., 2009). E4orf4-
induced cell death relies on Src tyrosine kinases and RhoGTPase-dependent 
perturbation of actin dynamics (Robert, et al., 2006); similarly, apoptin has 
also been shown to target the cytoskeleton and mitotic spindle (chapters 4-
6), and both apoptin (Teodoro, et al., 2004) and E4orf4 (Kornitzer, et al., 
2001) have been shown to induce G2/M cell cycle arrest by targeting the 
APC/C anaphase promoting complex. With respect to the various 
microtubule-destabilizing agents that are now being used, the APC/C 
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cyclosome might well represent a novel target for the development of cancer-
combating agents (Heilman, et al., 2005).  
 
The interaction between apoptin and Rsf-1 and Suv420h1 (A. Danen-van 
Oorschot and R. Zimmerman, unpublished results) suggests employing 
molecules that target epigenetic chromatin modifiers. Besides the inhibitors 
of histone deacetylases (HDACs), which are already being used, alteration of 
the activities of histone methylases and chromatin remodeling complexes 
could either limit genomic instability and thus tumor progression, or, 
alternatively, promote genomic instability beyond a point compatible with 
life. The over-expression of Rsf-1 in tumor cells has also made it an 
attractive target for immunotherapies. In fact, transduction of dendritic cells 
with plasmid DNA encoding the Rsf-1 gene demonstrably generated specific 
cytotoxic T lymphocytes against ovarian cancer in vitro (Sun, et al., 2010).  
 
In chapter 5, we inferred the localization of apoptin in the nucleoli of cancer 
cells, which in fact are the ribosome factories facilitating the rapid cell 
growth characteristic of tumor cells. Thus, complementary to the proteasome 
inhibitors already employed in current anticancer therapies, shutting off 
excessive ribosomal production might also prove an effective strategy in the 
fight against cancer.  
 
Conclusions 
As discussed in chapter 2, the tumor-killing potential of the apoptin protein 
has already been established in vivo, as demonstrated by experiments in our 
laboratory with apoptin-producing adenovirus (Pietersen, et al., 1999), Asor-
apoptin  (Peng, et al., 2007) and PTD4-apoptin (Sun, et al., 2009; Jin, et al., 
2011), all in which apoptin reduced tumor cell mass and prolonged survival 
of the affected organism, without harming normal cells.  
 
In this thesis, the molecular aspects of apoptin-induced tumor-selective 
apoptosis have been investigated. The basis for apoptin’s tumor-selectivity 
has been further deciphered, as well as the mechanisms leading to apoptin-
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induced apoptosis in malignant cells. These involve the recognition by 
apoptin of several of the cancer hallmarks, including: 
- genomic instability (apoptin senses DNA damage through e.g. 
Rybp/DEDAF, and telomere uncapping by loss of H4K20 
trimethylation).  
- insensitivity to inhibitory cell cycle checkpoints (lack of FAM96B, 
aberrant chromatin and spindle structures through interaction with 
overexpressed Rsf-1 and BCA3); 
- evasion of programmed cell death (apoptin-induced apoptosis is 
stimulated by over-expression of Bcl-2); 
- activation of the metabolic switch (apoptin interacts with PI3K and 
Akt) 
 
Thus, recognition of malignant transformation by apoptin occurs already in 
the early stages of transformation, before the acquisition of angiogenic, 
metastatic and immune evasive potential, and possibly even before 
activation of telomere maintenance and cellular immortalization. As 
described above, apoptin also utilizes these cancer hallmarks to attack the 
tumor cell at various points and bring about cell death.  
 
It seems that apoptin, but also the other PKTC presented in chapter 3, 
employ several different strategies to ensure death of the cancer cell. 
Considering this, as well as the fact that cancer cells, owing to their 
propensity to rapidly accumulate genetic changes, are essentially moving 
targets, it might be naïve to assume that we can win the fight against cancer 
by employing a single strategy. Thus, rather than trying to devise a magic 
bullet, we might instead compose a magical cluster bomb, containing 
subparticles aimed at each of the above-described tumor-specific targets, 
attacking cancer from every conceivable angle, and attaining cell death, 
without the harmful side-effects of radiation and conventional 
chemotherapy.  
  
Discussion, outlook and conclusions 
 215 
Table 7-1 Summary of apoptin-associating proteins. 
 




















Nuclear Increased Co-expression 
stimulates apoptosis 
See references in 
text 
FAM96B Sister chromatid 
cohesion; 





See references in 
text 
Suv420h1 Histone H4 lysine 






See references in 
text 





Perinuclear Increased Co-expression 
stimulates apoptosis 
See references in 
text 
Bip/GRP78/HSPA5 Protein chaperone; 
mediator of 
unfolded protein 




Increased Unknown Sato, et al., 2010; 









Table 7-1 continued.  
 











Increased Uknown Sun, et al., 2002; 










Golgi Unknown Possibly involved in 
apoptin elimination 
from the normal cell 














localization in cancer, 
but has no effect on 
apoptosis activity 
Huo, Yi, & Yang, 
2008 






Unknown Inhibition by apoptin 
results in G2/M 
arrest and apoptosis 














See references in 
text 
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Table 7-1 continued.  
 







PKAc Catalytic subunit of 
cAMP-dependent 
protein kinase, 

















See references in 
text 
p85 Regulatory subunit 
of PI3K, a kinase 
strongly implicated 
in tumorigenesis, 











See references in 
text 
Akt Downstream 








See references in 
text 
Cdk2/cyclin A Promotes G1/S 
transition and 
replication of DNA 





apoptin directly in 
vitro 




Table 7-1 continued.  
 























apoptin directly in 
vitro 
See references in 
text 





regulation of DNA 
damage response 
and several stages 





vated in cancer 
Dephosphorylates 
apoptin directly in 
vitro 
See references in 
text 
 
*AKAPs, A-kinase anchoring proteins.  
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The human body consists of very many cells, in the order of trillions. 
Each of these trillions of cells has its own function, and together, 
groups of cells with similar functions make up the various organs of 
which we are comprised. Remarkably enough, all of these cells, as 
different as they are, – consider the cells making up the heart muscle, 
the ones in our brain, the ones lining our stomach and intestines, 
even the ones making our bones – all originate from one single cell: 
the fertilized oocyte. The fertilized oocyte lies at the very basis of life, 
and has the potential to replicate and specialize (i.e. differentiate) into 
each of the different types of cells required in the developing embryo. 
It does so according to a strictly regulated set of rules, that dictate 
which cells are to divide, when they are to do so, when they are to 
become more specialized, even which cells must die and when – e.g., 
to create the spaces between our fingers and toes. After birth, and 
throughout life, these rules continue to govern cellular replication, 
ensuring that old, damaged and/or dead cells are replaced, and 
wounds are healed, without creating any excess tissue or disturbing 
the functions of the different organs.  
 
Cancer occurs as a violation of these rules. When the growth and 
death of a cell are no longer controlled, it can divide unlimitedly, and 
the resulting tumor could eventually invade and disrupt surrounding 
tissue, hindering organ function. If tumor cells manage to invade the 
blood stream, they could also travel to other sites in the body, where 
they can continue to replicate; this is termed metastasis. Standard 
therapy – surgery, radio- and/or chemotherapy, is not inherently 
selective for cancer cells. This results in lower efficiency and a host of 
unwanted side-effects, ranging from surgical amputation and life-
threatening bone marrow depression, to the less dangerous but often 
equally upsetting loss of hair. Thus, in order to improve on efficiency 
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and minimize side-effects, more targeted therapies are needed.  In 
order to design such therapies, we must understand how a cancer cell 
works. Otherwise stated, we must learn how it manages to extricate 
itself from the mechanisms that normally control cell division.  
 
The hallmarks of a cancer cell 
Research over the past several decades has shown that cancer cells 
share a number of features, which are characteristic of the process of 
tumorigenesis (chapter 2). First, cancer cells have the ability to 
produce their own growth factors, inducing proliferation 
independently of signals in their environment. Alternatively, they may 
stimulate surrounding cells (i.e., the cells in the tumor environment) 
to produce the growth factors for them. Second, cancer cells have 
found a way to circumvent the influence of growth inhibitory signals. 
Together with the first feature, this renders the cancer cell insensitive 
to extracellular control. This normally triggers the activation of 
internal controls, which program the cell to die. This type of cell death 
is termed apoptosis, and evasion of apoptosis is the third trait of 
malignant transformation. Yet cells still have one more method of 
intracellular control, which cancer cells must overcome in order to 
become truly immortal. With each round of cell division, the 
chromosomes, which carry the cell’s DNA, become a little bit shorter. 
After a certain number of doublings, the chromosomes have become 
too short, and cell division is halted.  Consequently, the fourth feature 
of carcinogenesis requires cancer cells to find a way to elongate the 
chromosome ends. Once cancer cells have acquired these first four 
traits, they are able to divide unlimitedly. In order to support this 
growth, they must develop the ability to create new vessels to ensure 
their blood supply (angiogenesis, the fifth cancer hallmark); the ability 
to invade these and other vessels and give rise to metastases is the 
sixth cancer hallmark. Cancer growth further requires a fundamental 




importantly, evasion of destruction by the cells of the immune system 
(the eighth hallmark).  
 
The acquisition of these cancer-typical traits is achieved by alterations 
in the cellular DNA, including mutations, deletions and amplifications. 
The majority of genes affected are those that encode the proteins 
involved in repairing damaged DNA. As a result, cancer cells 
accumulate errors in their DNA (a phenomenon termed genomic 
instability), which again enables them to acquire further cancer-
typical features.  
 
Apoptin and other proteins killing tumor cells 
A number of proteins have recently been discovered to selectively kill 
cancer cells. That is, these proteins are able to distinguish between 
the normal and tumor cells, and kill the latter, while leaving the 
normal ones unharmed. This group of proteins killing tumor cells 
(PKTC) might therefore have the potential to be used to develop the 
ideal anti-cancer therapy.  
 
The PKTC comprise proteins of various origins, including human 
proteins TRAIL, MDA7/IL24 and Par-4, the frog-derived Brevinin-2R, 
HAMLET, a complex between the milk protein alpha-lactalbumin and 
oleic acid (a component of human fat tissue, often used  in 
detergents), and the viral proteins adenovirus E4ORF4, parvovirus 
NS1, and Chicken Anemia Virus-encoded protein apoptin.  
 
While the PKTC are discussed in chapter 3, this thesis focuses on 
apoptin, which was the first of the PKTC to be discovered. Studies 
were carried out to gain more information on the mechanisms used by 
apoptin to sense oncogenic transformation and induce tumor-selective 
apoptosis. Knowledge on the proteins with which apoptin interacts 
within the human cell, and how these help apoptin to distinguish 
between normal and tumor cells, preventing its activation in normal 
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cells, and helping it to kill malignant cells, should aid in the design 
and development of novel, effective, selective, and hence more efficient 
therapies for cancer.  
 
Apoptin interacts with FAM96B 
In order to decipher the mechanisms behind apoptin’s cellular 
activities and uncover new targets for anti-cancer therapies, we 
performed an analysis of apoptin-interacting proteins. One of the 
proteins identified in this way is the protein FAM96B (chapter 4). 
Identification of the FAM96B partners implicates a role of FAM96B in 
the regulation of the cell cycle, including the processes of sensing DNA 
damage and establishing sister chromatid cohesion. Through its 
interaction with FAM96B, apoptin is very likely also linked to these 
processes.  
 
Apoptin & the nucleolus 
One of the characteristic features of apoptin is its nuclear localization 
in tumor cells, versus its cytoplasmic localization in normal cells. 
Within the tumor cell nucleus, apoptin can be found in specialized 
regions, one of which is the nucleolus (chapter 5). The nucleolus is 
the cell’s ribosome factory, which produces the ribosomes required to 
drive protein synthesis. Furthermore, the nucleolus has roles in 
coordinating the DNA damage response and inducing apoptosis. 
Apoptin is found to associate with nucleolar chromatin as well as 
various nucleolar proteins, suggesting that apoptin localizes to the 
nucleolus of tumor cells to shut off protein synthesis and induce 
apoptosis in response to DNA damage.  
 
Apoptin interacts with BCA3 and is dephosphorylated by PP2A 
Another characteristic feature of apoptin activity is its 
phosphorylation, which can be detected only in tumor cells, and is 
likely to be the trigger for apoptin nucle(ol)ar localization and 




apoptin-interacting protein, BCA3. BCA3 led us to the involvement of 
PP2A B56δ in apoptin phosphorylation, while a second line of 
investigation led us to the involvement of PP2A B56γ in the same 
process. Dephosphorylation by the major tumor suppressor protein 
phosphatase 2A (PP2A) appears to fulfill the important function of 
keeping apoptin unphosphorylated, and, hence, inactive, in normal 
cells, while the loss of PP2A activity in tumor cells results in 
phosphorylation, and hence activation of apoptin.  
 
Future perspectives 
Apoptin is a small, avian-virus derived protein that has the 
remarkable ability to sense differences between normal and tumor 
cells, and is able to kill the latter while leaving the former unharmed. 
As discussed in chapter 7, novel insights into the mechanisms 
underlying this remarkable behavior should lead not only to an 
improved understanding of fundamental cellular biology, but also, 











Het menselijk lichaam bestaat uit triljoenen cellen. Elk van deze cellen 
heeft zijn eigen functie, en groepen van cellen met een vergelijkbare 
functie vormen samen de verschillende organen in het lichaam. 
Ondanks de grote verschillen tussen de verschillende celtypen – denk 
bijvoorbeeld aan de cellen die samen de hartspier vormen, de cellen in 
onze hersenen, die van onze darmen, en de cellen die onze botten 
vormen – ontstaan al deze cellen uit één en dezelfde cel: de bevruchte 
eicel. De bevruchte eicel is een zogenaamde ‘stamcel’, en bevat de 
unieke eigenschap dat hij zich kan vermenigvuldigen, maar dat 
sommige van de nieuw ontstane cellen zich ook kunnen specialiseren 
tot een bepaald type cel (oftewel, differentiëren). Op deze wijze ontstaat 
een volledig ontwikkeld embryo, met alle benodigde organen, uit deze 
eerste stamcel.  
 
De deling en differentiatie van cellen is strikt gereguleerd, zodat elke 
cel weet of en wanneer het zich moet delen, wanneer het zich moet 
specialiseren en tot welk celtype, en zelfs wanneer het dood moet 
gaan, bijvoorbeeld om ruimte te creëren tussen de vingers en tenen. 
Ook na de geboorte, en zelfs gedurende het gehele leven, blijft deze 
regulatie van toepassing. Hierdoor kunnen oude, beschadigde, en/of 
dode cellen vervangen en wonden geheeld worden, zonder dat er ook 
maar één cel te veel of te weinig wordt aangemaakt, en weefselfunctie 
behouden blijft.  
 
Kanker ontstaat juist wanneer deze regels geschonden worden. 
Wanneer de groei en dood van een cel niet meer gecontroleerd kunnen 
worden, kan deze cel zich blijven vermenigvuldigen. De zo ontstane 
tumor kan het omringende weefsel verstoren, waarbij de functie van 
het orgaan in gedrang kan komen. Tumorcellen kunnen bijvoorbeeld 
ook in de bloedbaan terechtkomen, en naar een ander deel van het 
Appendices 
246 
lichaam reizen, waar ze een nieuwe tumor kunnen vormen: 
metastasering.  
 
De standaardbehandeling voor kanker bestaat uit chirurgie, gevolgd 
door radio- en/of chemotherapie, en is niet selectief voor kankercellen. 
Dit heeft een lagere therapie-efficiëntie tot gevolg, evenals een lange 
lijst aan ongewenste neveneffecten, variërend van  chirurgische 
amputatie en levensbedreigende beenmergsuppressie, tot het minder 
gevaarlijke maar evenwel aangrijpende haaruitval. Om tot betere 
therapieën te komen is daarom een doelgerichtere aanpak vereist, 
waarbij gebruik wordt gemaakt van kennis van de eigenschappen van 
kankercellen.  
 
De karakteristieke eigenschappen van een kankercel 
Decennialang onderzoek heeft uitgewezen dat kankercellen een aantal 
karakteristieke eigenschappen bezitten (hoofdstuk 2). Ze kunnen ten 
eerste hun eigen groeifactoren produceren, waarmee ze hun eigen 
groei in stand kunnen houden, zonder daarvoor afhankelijk te zijn van 
hun omgeving. Andersom kunnen ze de cellen in hun omgeving ook 
zodanig beïnvloeden dat zij de benodigde groeistimulerende factoren 
uitscheiden. Kankercellen kunnen ten tweede signalen omzeilen, die 
anders voor inhibitie van de celgroei zouden zorgen. Deze twee 
eigenschappen zorgen dat kankercellen in principe ongevoelig worden 
voor controle van buitenaf. Echter, ze zijn dan nog wel gevoelig voor 
intracellulaire controlemechanismen. Een dergelijk mechanisme 
bestaat uit apoptose, een vorm van geprogrammeerde celdood, die 
wordt geactiveerd wanneer cellen zich ongecontroleerd delen. Het 
onderdrukken van apoptose vormt dan ook de derde typische 
eigenschap van kankercellen. De vierde eigenschap heeft te maken 
met de lengte van de chromosomen. Chromosomen bevatten het 
cellulaire DNA, en worden bij elke celdeling een stukje korter. Worden 
ze te kort, dan treedt er een mechanisme in werking waarbij de 




kankercellen dus een manier moeten vinden om de uiteinden van de 
chromosomen weer te verlengen, bijvoorbeeld door het aanzetten van 
een bepaald eiwit, of door stukjes DNA aan elkaar te plakken en weer 
op andere plaatsen te knippen. Wanneer een kankercel deze vier 
eigenschappen bezit, is het in principe onsterfelijk geworden en kan 
het zich ongecontroleerd vermenigvuldigen. Hoe groter de tumor, hoe 
groter de behoefte aan zuurstof en voedingsstoffen; om hierin te 
kunnen voorzien zullen de kankercellen dus ook nieuwe bloedvaten 
aan moeten kunnen leggen: dit is de vijfde eigenschap. Komt een 
kankercel eenmaal in een bloed- of ander vat terecht, dan kan dit 
aanleiding geven tot metastasering (de zesde eigenschap). Om snel en 
veel te kunnen blijven groeien, ondergaan kankercellen bovendien een 
verandering in hun metabolisme (de voorgestelde zevende eigenschap); 
daarnaast zorgen kankercellen ervoor dat ze niet ontdekt en dus 
opgeruimd worden door cellen van het immuunsysteem.  
 
Kankercellen verkrijgen de bovengenoemde typische eigenschappen 
door middel van veranderingen in hun DNA, waaronder mutaties, 
deleties en amplificaties. De genen die het vaakst door deze 
veranderingen worden getroffen, coderen vaak voor eiwitten die een rol 
spelen bij het herstel van DNA schade. Hierdoor kunnen genetische 
veranderingen zich ophopen (dit fenomeen wordt genetische 
instabiliteit genoemd), waardoor het weer makkelijker wordt voor de 
kankercel om de verdere benodigde eigenschappen te verkrijgen.  
 
Apoptin en andere eiwitten die kankercellen doden 
Recentelijk zijn er een aantal eiwitten ontdekt, waarvan bewezen is dat 
zij specifiek kankercellen doden. Deze eiwitten kunnen onderscheid 
maken tussen normale en tumorcellen, en doden de tumorcellen 
zonder schade aan te richten in de gezonde cellen. Deze groep eiwitten 
(in het Engels PKTC genoemd, voor “proteins killing tumor cells”) 
zouden dus de basis kunnen vormen voor de ontwikkeling van 
misschien wel hèt ideale medicijn tegen kanker! 
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De PKTC groep bestaat uit eiwitten van diverse origine, waaronder de 
menselijke eiwitten TRAIL, MDA7/IL24 en Par-4, het kikkereiwit 
Brevinin-2R, en HAMLET, een complex bestaande uit het melkeiwit 
alfa-lactalbumine en oliezuur, het meest voorkomende vetzuur in 
menselijk vetweefsel en een veelgebruikt bestanddeel in zeep. 
Daarnaast zijn er nog een aantal virale eiwitten, zoals E4ORF4, 
afkomstig van het adenovirus, NS1, afkomstig van het parvovirus, en 
apoptin, afkomstig van het Chicken Anemia Virus.  
 
De verschillende PKTC zijn besproken in hoofdstuk 3, terwijl apoptin, 
die als eerste PKTC werd ontdekt, het hoofdonderwerp vormt van dit 
proefschrift. Er zijn experimenten uitgevoerd om informatie te 
verkrijgen over de mechanismen die door apoptin worden gebruikt om 
maligne transformatie te herkennen en tumorselectieve apoptose te 
induceren. Kennis over de cellulaire eiwitten waarmee apoptin een 
interactie aangaat, alsmede de manier waarop deze eiwitten bijdragen 
aan het onderscheid door apoptin tussen normale en tumorcellen, het 
aanzetten tot celdood in tumorcellen, en het voorkomen van activatie 
in normale cellen, zou belangrijke aanknopingspunten moeten 
opleveren voor de ontwikkeling van nieuwe, effectieve, selectieve en 
dus efficiëntere vormen van behandeling voor kanker.  
 
Apoptin bindt aan FAM96B 
Om aanknopingspunten te vinden voor het ontrafelen van de 
mechanismen achter het karakteristieke gedrag van apoptin en de 
ontwikkeling van nieuwe antikanker medicijnen, zijn we op zoek 
gegaan naar eiwitten die in de cel aan apoptin binden. Een van de 
eiwitten die we op deze manier gevonden hebben, was het tot dan toe 
nog relatief onbekende eiwit FAM96B (hoofdstuk 4). Analyses naar 
eiwitten die met FAM96B een interactie aangaan, hebben laten zien 
dat FAM96B betrokken is bij de regulatie van de celdeling, o.a. bij het 
herkennen van de aanwezigheid van genetische schade, en de 




deling. Vanwege de associatie met FAM96B, lijkt het aannemelijk dat 
apoptin ook bij deze processen is betrokken.  
 
Apoptin & de nucleolus 
Een van de karakteristieke eigenschappen van apoptin betreft zijn 
kernlokalisatie in tumorcellen, in tegenstelling tot zijn lokalisatie in 
normale cellen, waar apoptin in het cytoplasma verblijft. Binnen de 
kern van de tumorcel houdt apoptin zich in specifieke gebieden op, 
waaronder de nucleolus (hoofdstuk 5). De nucleolus is de plek waar 
alle ribosomen worden gemaakt; deze zijn op hun beurt weer nodig 
zijn voor de eiwitsynthese in de cel. Daarnaast is het betrokken bij het 
coördineren van herstel van DNA schade en de inductie van apoptose. 
Apoptin bindt aan nucleolair chromatine (chromatine is het complex 
van DNA plus de eiwitten die ervoor zorgen dat het netjes in de 
celkern is opgevouwen) en wordt geassocieerd met verscheidene 
nucleolaire eiwitten, wat suggereert dat apoptin zich naar de 
nucleolus van kankercellen begeeft om eiwitsynthese (en dus 
celdeling) stop te zetten en apoptose te induceren in reactie op de 
aanwezigheid van DNA schade, hetgeen zoals eerder besproken 
veelvuldig voorkomt in tumorcellen.  
 
Apoptin bindt aan BCA3 en wordt door PP2A gedefosforyleerd 
Een andere typische eigenschap van apoptin, betreft zijn fosforylering: 
deze is alleen in kankercellen aan te tonen, en is waarschijnlijk de 
aanzet tot transport naar de kern/nucleolus en inductie van apoptose. 
Hoofdstuk 6 beschrijft de identificatie van nog een interactiepartner 
van apoptin, namelijk BCA3. Via BCA3 en een ander, parallel lopend 
onderzoek, kwamen we op het spoor van het eiwit PP2A, welke een 
belangrijke rol lijkt te spelen in de fosforylering van apoptin. PP2A is 
een eiwit dat fosforylering kan verwijderen, en het lijkt erop dat het 
zorgt dat apoptin in de normale cel ongefosforyleerd blijft, terwijl in 
tumorcellen, waar PP2A ontbreekt, apoptin door toedoen van een nog 
onbekende kinase gefosforyleerd wordt en blijft.  
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Vooruitzichten voor de toekomst 
Apoptin is een klein, vogelvirus eiwit dat de bijzondere eigenschap 
heeft dat het onderscheid kan maken tussen normale en tumorcellen, 
en de laatste categorie cellen kan doden, terwijl het de eerste categorie 
cellen ongemoeid laat. Zoals besproken in hoofdstuk 7, zouden nieuw 
opgedane inzichten in de werkingsmechanismen van dit bijzondere 
eiwit niet alleen moeten leiden tot een beter fundamenteel begrip van 
celbiologie, maar ook, zeer belangrijk, tot de ontwikkeling van nieuwe, 
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Tradusí ku yudansa di S.F. de Lima-Willems 
 
E kurpa humano ta konsistí di miónes di sèl. Kada unu di e sèlnan tin 
su propio funshon i grupo di sèlnan ku funshonnan similar ta forma e 
diferente órganonan. Apesar di e gran diferensianan entre e diferente 
tipo di sèlnan, konsiderá por ehèmpel e sèlnan ku ta forma e múskulo 
di kurason, e sèlnan den nos serebro, esnan di nos intestino i e 
sèlnan ku ta forma nos wesunan, tur esakinan ta originá for di un 
solo sèl: e óvulo fekundá. E óvulo fekundá ta e asina yamá “sélula 
madre”: e ta kontené e karakterístika úniko ku e por multipliká su 
mes, i tambe ku kada un di e sèlnan resien formá por spesialisá nan 
mes den un partikular tipo di sèl (mihó bisá diferensiá), asina ku e por 
yega na forma kada un di e tipo di sèlnan nesesario pa forma un ser 
humano.  
 
E divishon i diferensiashon aki di e sèlnan ta estriktamente regulá, pa 
asina kada sèl sa si i ki ora e mester dividí, ki ora e mester spesialisá i 
den kua tipo di sèl, i asta ki ora e mester muri, por ehèmpel pa krea 
espasio entre nos dede i tenchinan. E regulashon aki ta keda na vigor 
despues di nasementu i asta durante henter nos bida. Dor di esaki 
sèlnan bieu, gastá, i/òf morto por ser remplasá i heridanan por kura, 
turestén sin ku ni sikiera un sèl di mas òf di ménos wòrdu formá, 
manteniendo e funshon di e tehido. 
 
Kanser ta surgi presisamente ora e reglanan aki ser violá. Ora ku e 
kresementu i morto di un sèl no por ser kontrolá mas, e sèl aki por 
keda multipliká su mes. E tumor ku ta surgi por perhudiká e tehido 
rondó di dje, lokual tin komo konsekuensia ku e funshon di e órgano 
por ser afektá. Sèlnan di e tumor por drenta tambe den e sirkulashon 
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di sanger i biaha pa otro partinan di kurpa, kaminda nan por forma 
un tumor nobo, esta metástasis. 
  
E tratamentu standardisá pa kanser ta konsistí di sirugia, siguí pa 
radio i/o chemoterapia, i no nesesariamente ta selektivo pa sèlnan 
maligno. Esaki tin komo konsekuensia un efisiensia abou di terapia, 
meskos ku un lista largu di efektonan sekundario indeseabel, ku ta 
varia for di amputashon kirúrgiko i depreshon di medula ku por ta 
mortal, te e esun ménos peligroso pero si mas konosí i sigur hopi 
konmovedor, ku ta kaida di kabei. Pa yega na terapianan mihó, ta 
nesesario un aserkamentu mas efikas, kaminda ta hasi uso di 
konosementu di karakterístikanan di sèlnan di kanser. 
 
E kualidatnan karakterístiko di un sèl di kanser 
Investigashon di desena di aña a saka na kla ku sèlnan di kanser ta 
poseé algun kualidatnan karakterístiko pa medio di kual nan ta 
manten’é nan mes kresementu, sin ku nan ta dependé den esei di nan 
ambiente. Kontrali na esaki nan por influensiá e sèlnan den nan 
ambiente tambe asina ku nan por ekspresá e faktornan di kresementu 
nesesario. Na di dos lugá, sèlnan kanseroso por aludí siñalnan ku di 
otro manera por a sòru pa inhibishon di e kresementu di sèlnan. E 
dos kualidatnan aki ta sòru ku sèlnan kanseroso en prinsipio ta bira 
insensibel pa kontròl di pafó. Sinembargo nan ta ketu bai sensibel p’e 
mekanismo di kontròl entre e sèlnan. Un mekanismo asina ta konsistí 
di apóptosis, un forma di morto selular programá ku ta ser aktivá ora 
sèlnan dividí fuera di kontròl. Pa e motibu ei, supreshon di apóptosis 
ta forma e di tres kualidat típiko di sèlnan kanseroso. E di kuater 
kualidat tin di haber ku e largura di e kromosómonan. 
Kromosómonan ta konten’é DNA di e sèl i ta bira mas kòrtiku kada 
bes ku esaki dividí. E momento ku nan bira muchu kòrtiku, un 
mekanismo ta drenta den akshon ku ta para e divishon di e sèl. Pa 
por sigui krese, e sèlnan kanseroso mester haña un manera pa alargá 
e puntanan di e kromosómonan, por ehèmpel dor di konvertí un 
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proteina determiná, òf dor di plak pida pida DNA na otro. E momentu 
ku un sèl di kanser ta poseé e kuater kualidatnan aki, en prinsipio el 
a bira inmortal i e por sigui multipliká su mes na un manera 
inkontrolabel. Mas grandi e tumor bira, mas grandi e nesesidat na 
oksígeno i nutrishon; pa por proporshoná den esaki, e sèlnan 
kanseroso tambe lo mester forma tubu di sanger nobo: esaki ta e di 
sinku kualidat. Si un sèl kanseroso resultá den un tubu di sanger òf 
kualkier otro tubu esaki por tin metastatis komo konsekuensia (e di 
seis kualidat). Pa por sigui krese rápidamente, sèlnan kanseroso ta 
pasa den un kambio di metabolismo (e di shete kualidat); banda di 
esei, sèlnan kanseroso ta sòru pa nan no ser deskubrí i pikí dor di e 
sèlnan di e sistema inmune. 
 
Sèlnan di kanser ta atkerí tur e kualidatnan típiko aki pa medio di 
kambionan den nan DNA, manera mutashon, eliminashon, i 
amplifikashon. E gènnan ku mas ta ser afektá dor di e kambionan 
aki, ta kodifiká hopi bes pa proteinanan ku ta hunga un ròl den 
reparashon di DNA. Pa e motibu aki kambionan genétiko ta akumulá 
(e fenómeno aki ta ser yamá instabilidat genétiko), fasilitando e 
rekuperashon di e sobra kualidatnan nesesario pa yega na un estado 
maligno.  
 
Apòptin i otro proteina ku ta mata sèlnan kanseroso 
Resientemente a deskubrí algun proteina, di kual a proba ku nan ta 
mata sèlnan kanseroso spesífikamente. E proteinanan aki por 
distinguí entre sèlnan normal i esnan maligno, i ta mata e sèlnan 
kanseroso sin daña esnan salú. E proteinanan aki (yamá na ingles 
“PKTC”, esta “Proteins Killing Tumor Cells”) kisas por bai forma e base 
pa desaroyo di e medisina ideal kontra kanser! 
 
E grupo di PKTC ta konsistí di proteina di diferente orígen, bou di 
kual e proteinanan humano TRAIL, MDA7/IL24 i Par-4, e proteina 
sapu Brevinin-2R, i HAMLET, un kompleho konsistiendo di e proteina 
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di lechi alfa-lactalbumina i ásido di zeta, e ásido di vèt ku mas ta 
paresé den tehido di vèt humano i ku a la bes ta un ingrediente hopi 
uzá den habon. Banda di esei tin un kantidat di proteina viral, 
manera E4ORF4, prosedente for di e vírus di adeno, NS1 prosedente 
for di e vírùs di parvo, i apòptin prosedente for di e vírus di anemia di 
galiña. 
 
E diferente PKTC a ser tratá den kapítulo 3, miéntras ku apòptin, 
kual a ser deskubrí komo e promé PKTC, ta forma e tema prinsipal di 
e tésis aki. Eksperimentunan a ser kondusí pa haña informashon 
tokante di e mekanismonan ku apòptin ta uza pa rekonos’é 
transformashon maligno i introdusí apóptosis selektivo di e sèlnan 
tumorigeniko. 
 
Konosementu di e diferente proteinanan selular ku kual apòptin ta 
drenta den interakshon, i tambe e manera ku e proteinanan aki ta 
aportá na e distinshon dor di apòptin entre sèlnan normal i esnan 
kanseroso, i e sistema pa aktivá apóptosis den esnan kanseroso, 
mientras evitando aktivashon den e sèlnan normal, mester bira e 
puntonan importante pa desaroyo di formanan di tratamentu di 
kanser nobo, kual lo ta mas efektivo, selektivo, i efisiente. 
 
Apòptin ta uni su mes na FAM96B 
Pa buska punto di salida pa esklaresimentu di e mekanismonan tras 
di komportashon karakterístiko di apòptin i e desaroyo di remedi nobo 
anti-kanseroso, nos a kuminsá buska proteina ku ta uni nan mes na 
apòptin den e sèl humano. Un di e proteinanan ku nos a haña na e 
manera aki ta FAM96B, kual ta un proteina ku te na e momento ei 
tabata relativamente deskonosí (kapítulo 4). Un análisis di e 
proteinanan ku ta den interakshon ku FAM96B a mustra ku esaki ta 
involukrá den regulashon di e divishon selular, inkluso e 
rekonosimentu di presensia di daño genétiko i distribushon di e 
kromosómonan durante e divishon. Debido na e asosashon ku 
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FAM96B, ta parse akseptabel ku apòptin tambe ta involukrá den e 
proseso aki. 
 
 Apòptin i e núkleo 
Un di e kualidatnan karakterístiko di apòptin ta su lokalisashon den e 
núkleo di sèlnan di tumorigeniko, esaki kontrali na su lokalisashon 
den sèlnan normal, kaminda apòptin ta situá pafó di e núkleo, den e 
sitoplasma. Den e núkleo di e sèl maligno, apòptin ta ubiká den 
áreanan spesífiko por ehèmpel den e nukléulo. (kapítulo 5). E 
nukléulo ta e lugá kaminda tur ribosomanan ta ser formá: esakinan 
na nan turno ta nesesario pa e síntesis di proteinanan den e sèl. 
Ademas e nukléulo ta partisipá den e kordinashon di rekuperashon di 
daño den DNA i indukshon di apóptosis. A deskubri ku apòptin ta 
asosiá ku tantu kromatin komo ku vários proteina di e nukléulo, 
sugeriendo ku apòptin ta dirigí su mes pa nukléulo di sèlnan maligno 
pa para e síntesis di proteina i indusi apóptosis den reakshon riba 
presensia di daño di DNA, ku manera ya menshoná ta surgi 
frekuentamentu den e sèlnan kanseroso. 
 
Apotin ta uni ku BCA3 anto ta ser dephoshorilatá dor di PP2A 
Un otro kualidat típiko di apòptin ta e echo ku e por ser fosforilatá: 
esaki por ser demonstrá solamente den e sèlnan kanseroso, i 
probablemente e ta e empuhe pa transporte di apòptin pa e núkleo i 
nukléulo, i indukshon di apóptosis. Kapitulo 6 ta dskribí e 
identifikashon di un otro partner di interakshon di apòptin, esta 
BCA3. Pa medio di BCA3 i un otro investigashon ku a kore paralelo, 
nos a bin kontra e proteina PP2A, ku a resultá di tin un papel 
prinsipal den e proseso di fosforilá apòptin. PP2A ta un proteina ku 
por kita fosforilashon, i ta parse ku e ta sòru pa apòptin keda no 
fosforilá den e sèl normal, miéntras ku den e sèlnan di tumor, 





Perspektivanan pa futuro 
Apòptin ta originá di un vírùs di para chikitu, i tin e karakterístika 
partikular ku e por hasi distinshon entre sèlnan normal i sèlnan di 
tumor, i por mata e último kategoria di sèl , miéntras e ta laga e 
promé kategoria ileso. Manera ta bini dilanti den kapítulo 7, 
konosementu nobo di e mekanismonan di e proteina partikular aki no 
solamente mester kondusí pa un mihó komprendementu fundamental 
di biologia selular, pero tambe hopi importante, pa un desaroyo di 
medionan nobo i mihó kontra kanser. 
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